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Abstract 
This dissertation describes investigations into aspects of neoplastic initiation and 
progression in the gut, in the context of inherited and sporadic gastrointestinal 
cancer. 
In familial adenomatous polyposis, there is marked locoregional variation in 
polyp density. This work investigated the relationship between gut location and 
somatic inactivation of APC. It demonstrated that the frequency of APC loss 
of heterozygosity (LOR) varied along the colon, suggesting a colonic gradient 
in "just right" signalling. It investigated adenomas of the ileoanal pouch, where 
small bowel functions as rectum. A longitudinal study revealed the largely in-
dolent natural history of these polyps, while mutational analysis demonstrated 
that they differed from polyps arising in colon, by usually retaining 2-3 remain-
ing 20-amino-acid repeats. A comparison of pouch and rectal polyps showed 
differences in their histogenesis. 
Neoplastic initiation was investigated arising in the context of a f!t' new pheno-
type of young-onset colorectal cancer, with multiple adenomas and neurological 
deficit. A novel homozygous mutation involving PMS2 and FSCJV was found. 
Although neoplastic lesions showed nuclear beta-catenin expression, no mutated 
wnt pathway genes were identified. No evidence was found that PMS2 or FSCN 
mutation was causative in other patients with related multiple adenoma or neu-
rological phenotypes. 
Key stepwise events in the adenoma-carcinoma sequence were investigated in 
sporadically occurring adenomas with contiguous carcinoma. Laser microdis-
section allowed crypt-by-crypt analysis of APC, TP53, KRAS2, and LOR at 
17p and 18q, in order to establish the presence of cryptal heterogeneity and 
the inferred order of genetic alterations. Using similar contiguous paired le-
sions, a further study investigated neoplastic aneuploidy using image cytometry~ 
genome-wide LOR analysis and individual SNP analysis for LOR 5q, 17p, and 
18q. Aneuploidy did not cluster as tetraploidy. The degree of aneuploidy cor-
related well with the degree of LOR ascertained by genome-wide analysis, with 
LOR at 17p and 18q (but not 5q), and with nuclear beta-catenin accumulation. 
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Abbreviations 
20AARs 20-amino-acid repeats 
aCGR array comparative genomic hybridization 
APC adenomatous polyposis coli gene 
ATZ anal transition zone 
bp IKb 1Mb base pairs Ikilo base pairs I mega base pairs 
cd codon 
cDNA complementary DNA 
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CT computed tomography 
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ex exon 
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FSCN fascin gene 
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MLHl 
MMR 
MSH2 
MSI 
MutL human homolog 1 gene 
mismatch repair 
MutS human homolog 2 gene 
microsatellite instability 
NSAIDs non-steroidal anti-inflammatory drugs 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PMS2 post-meiotic segregation increased human homolog 2 gene 
RPC restorative proctocolectomy 
RTqPCR real-time quantitative PCR 
SEM standard error of the mean 
TP53 
SNP 
tumour protein 53 gene 
single nucleotide polymorphism 
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Chapter 1 
Introduction 
1.1 The Clinical Context of Molecular Colorectal 
Cancer Research 
Colorectal cancer is a common disease which causes 16000 deaths per year in the 
United Kingdom [UK Office for National Statistics, 2007]. However, it is also a 
disease where there is considerable scope for successful intervention. Colorectal 
cancer evolves from visible cancer precursors - adenomatous polyps, described 
in Section 1.2.1 - in a process described as the adenoma-carcinoma sequence 
[Morson, 1978]. 
Since adenomatous polyps can be removed during colonoscopic screening (see 
Figure 1.1), this can prevent the development of cancer. Bowel surveillance can 
also detect early cancers confined to the bowel wall, which are surgically curable. 
However, since most adenomas and early cancers are asymptomatic, these inter-
ventions rely on screening healthy individuals. Symptoms of colorectal cancer 
(typically diarrhoea, bleeding, and weight loss) often occur only in advanced 
lesions, and cure may no longer be possible once they are evident. In the United 
16 
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Figure 1.1: Endoscopic snare removal of a colonic polyp 
Image from www.brighamandwomens.org/ generalsurg/ Images 
17 
Kingdom, more than 90% of cases of colorectal cancer are diagnosed after spread 
beyond the bowel wall has occurred, resulting in correspondingly poor 5 year 
survival rates as shown in Table l.1 [Rhodes , 2000]. 
5 Year 
Modified Dukes ' Stage TNM Stage* Sur-
vival 
A - confined to the bowel 
I (TI or T2 , NO , MO) 83% 
wall 
B - spread through bowel 
2a (T3, NO, MO) or 2b (T4, NO , MO) 64% 
wall 
C - lymph node spread 3a (TI or T2 , NI , MO) , 3b (T3 or T4 , 38% 
NI, MO), 3c (any T , N2 , MO) 
D - distant organ 
4 (any T, any N, MI) 3% 
metastasis 
*TI=mucosa, T2= musculans propna, T3=serosa, T4=adjacent organ or tissue; N2=four 
or more lymph nodes 
Table 1.1: Staging of colorectal cancer, with five year survival [Rhodes , 2000] 
Colorectal tumorigenesis may be triggered by a combination of hereditary and 
environmental factors , and each case lies somewhere on a spectrum where these 
factors are relatively more or less important. At one end of the spectrum about 
5% of colorectal cancer cases are linked to the inheritance of highly penetrant 
genetic mutations, resulting in cancer in the majority of carriers. These cancers 
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are predominantly early-onset, and patients in this group also carry an increased 
risk of extra-intestinal cancer. For this group of individuals, cancer screening 
can be prompted by a strong family history of young-onset colorectal cancer. 
However, in the remainder of colorectal cancer cases, the influence of other less 
penetrant genes and environmental factors may result in cancer, typically after 
the age of 50, and there may be no family history of the disease. 
Research into rare, strongly inherited syndromes has led to the identification of 
many genes that can trigger neoplasia, and improved understanding of the ac-
cumulating genetic changes resulting in neoplastic invasion, both in the context 
of "inherited" and "sporadic" colorectal cancer. Further characterisation of these 
pathways may allow future pharmacological therapy aimed at delaying trigger-
ing genetic changes, or halting subsequent events responsible for invasion. This 
will lead to a wider range of options for prevention and treatment of all types 
of colorectal cancer. 
The most common inherited colorectal cancer syndromes are familial adenoma-
tous polyposis (FAP) , Lynch syndrome and MYH-associated polyposis (MAP). 
Their major clinical characteristics are summarised in Table 1.2. FAP and Lynch 
Syndrome are further discussed in Sections 1.3 and 1.4. 
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Clinical FAP Lynch MAP 
Manifestation Syndrome 
Colonic polyps typically usually scanty very variable 
thousands ( <15) 
Upper GI polyps often numerous none sometimes 
Skin/Mesodermal epidermoid cyst, cafe-au-lait As yet 
osteoma, macules in undetermined 
CHRPE, homozygotes. 
desmoid, dental sebaceous 
abnormali ties adenoma, kera-
toacanthoma, 
basal call 
carCInoma 
Common duodenal, endometrium, breast [Nielsen 
extra-colonic hepato blastoma, ovary, et al., 2005] 
cancers thyroid urothelium, 
stomach, brain 
Average age 40 50 50 
colorectal cancer 
Heterozygous 100% 70% probably slight 
risk of colorectal [Balaguer et al., 
cancer 2007]; 
homozygous risk 
may be 100% 
Population 1:10 000 1:1000 1:100 
incidence of 
heterozygotes 
Table 1.2: Major phenotypic differences between FAP, Lynch Syndrome and 
MAP 
1.2 The Adenoma-Carcinoma Sequence 
1.2.1 Adenomatous Polyps 
Polyps as a whole may be classified as shown in Table 1.3. While foci of dysplasia 
can develop in other types of polyps, adenomatous polyps are characterised 
by dysplastic epithelium bounded below by the mucosal basement membrane. 
Adenomas >2cm in size, and those with a villous rather than tubular morphology 
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have the highest risk of malignancy [Cummings, 2000]. 
I Type of Polyp I Associated Syndromes and Conditions 
Adenomatous (tubular , FAP, Lynch syndrome, MAP 
tubulovillous, villous) 
Hamartomatous Peutz-Jeghers , Juvenile Polyposis 
Inflammatory Ulcerative Colitis 
Metaplastic/ Hyperplastic Hyperplastic Polyposis 
Table 1.3: Histological classification of polyps 
In normal colonic mucosa, stem cells lie in the lower third of the crypt which 
divide to form enterocytes. As these mature, they move towards the mucosal 
surface from whence they are sloughed (see Figure 1.2). 
A B 
Tennlnally Terminally 
dtfferentia ed olfferentiated 
cells cells 
Proliferative Inoex ProIiferawe Index 
Paneth cells Stem cells 
Figure 1.2: Crypts in the small intestine and colon 
Figure reproduced from McDonald et al. [2006]. The small intestine has villous 
projections rising on each side of the crypt, while colonic crypts open onto the 
lumenal surface. Paneth cells are rare in the colon. They secrete defensins, 
lysozyme and phopholipase A2, and have antimicrobial activity. 
Transformation of crypt stem cells is the likely precursor of neoplasia [Barker 
et al., 2008], resulting in clones of cells whose growth exceeds normal colono-
cytes. U nicryptal adenomas then grow by undergoing crypt fission [Wong et al., 
2002], discussed further in Chapter 7. Aberrant crypt foci (also sometimes called 
microadenomas, which are collections of around 20 dysplastic crypts visible un-
der endoscopic magnification) ) grow to form macroscopically visible adenomas. 
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However, some adenomatous polyps are sessile rather than exophytic , and are 
thus harder to detect at endoscopic examination. 
Serrated polyps of the large intestine are a heterogeneous group which include 
traditional hyperplastic polyps, serrated adenomas, and sessile serrated adeno-
mas [Snover et al., 2005]. The sessile serrated adenoma might be the precursor 
lesion for some cases of microsatellite unstable colorectal carcinoma, and are now 
considered to be biologically distinct from other adenomatous polyps in terms 
of histology and molecular features [Harvey and Ruszkiewicz, 2007] (see Section 
1.2.3) . 
1.2.2 Genetic Events in Neoplastic Progression 
The genetic changes underlying the evolution of a cancer from an adenoma 
Normal Early 
adenoma 
APe, 
Beta-
catenin 
Intermediate 
adenoma 
Late 
adenoma 
KRAS2, 
BRAF 
TGFBR2, 
SMAD2, 
SMAD4, 
18q LOH 
TP53 
Figure 1.3: The adenoma-carcinoma sequence 
Cancer 
are referred to as the adenoma-carcinoma sequence, shown in Figure 1.3. Many 
of the important molecular alterations occurring in this sequence have been 
identified [Jones et al., 2008, Fearon and Vogelstein , 1990]. Broadly described , 
the first step is usually bi-allelic inactivation of APe [Miyoshi et al. , 1992] , with 
subsequent mutational changes (including KRAS2 and TP53 ) occurring with 
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increasing polyp dysplasia, culminating in malignancy. Each mutation confers 
a growth advantage, resulting in clonal outgrowth. 
1.2.2.1 Genetic Instability 
The rate of mutational events (and hence neoplastic progression) may be in-
creased by the presence of genetic instability. Whether genetic instability is a 
prerequisite for neoplastic progression, and whether it occurs early or late in 
the neoplastic process, is a longstanding debate in the field of cancer genetics 
[Nowak et al., 2002]. The two mutually exclusive varieties of genetic instabil-
ity are chromosomal instability (CIN) and microsatellite instability (MSI). A 
tumour may also have epigenetic instability (the CpG island methylator pheno-
type, or CIMP). 
Aneuploidy and Chromosomal Instability 
Cancer cells often have between 60 and 90 chromosomes, frequently with struc-
tural aberrations [Rajagopalan and Lengauer, 2004]. This abnormality in chro-
mosomal number and structure is referred to as aneuploidy, defined as occurring 
when the chromosomal number is not a multiple of the haploid number of that 
species. Polyploidy refers to the presence of one or more extra sets of chromo-
somes (for example, triploidy or tetraploidy). 
Chromosomal instability (CIN) refers to the presence of an increased rate of 
chromosomal rearrangement, loss or gain. This results in loss of cell diploidy. 
Most sporadic cancers are aneuploid [Barber et al., 2008]; however the presence 
of aneuploidy, which refers to an abnormal DNA content in a cell, may not 
necessarily imply chromosomal instability, since aneuploidy may arise in the 
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absence of an increased rate of chromosomal rearrangement [Jones et aL 2008~ 
Sieber et al., 2005]. 
Polyploidy may develop in normal cells in specialised circumstances (for exam-
ple, stem cells fuse and megakaryocytes undergo endoreplication). However, 
aberrations of the cell cycle may cause polyploidy and aneuploidy in cancer cells 
[Storchova and Pellman, 2004]. 
Normal cell division should result in progeny with the same chromosomal con-
tent as the progenitor cell. This process relies on balanced chromosomal seg-
regation between daughter cells, shown in Figure 1.4. When stimulated to di-
vide, homologous chromosomes replicate to form sister chromatids. The chro-
matids have kinetochores which anchor them to microtubules, which on cell 
division, guide the chromatids to opposite spindles located at the cellular poles. 
During metaphase, the chromatids align and attach to their respective micro-
tubules. Once this has occurred, mitotic spindle checkpoints are inactivated 
and anaphase occurs, with migration of chromosomal material to each spin-
dle. During telophase, the cytoplasm divides and the process of cell division in 
completed. 
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Metaphase 
Anaphase 
Telophase 
Figure 1.4: Chromosome segregation in cell division 
Kinetochores are represented as red spots seen aligning with microtubules 
during metaphase. In anaphase, the sister chromatids are released from one 
another in a enzymatically controlled step , allowing migration to the mitotic 
spindles. In telophase, cell cytokinesis occurs. Figure modified from Cimini 
and Degrassi [2005]. 
Aneuploidy may result if anaphase occurs before proper kinetochore-microtubule 
attachment has occurred, or if chromatids attach incorrectly to microtubules 
(for example, if each chromatid becomes attached to microtubules leading to 
the same mitotic spindle). Theories of how cell cycle aberrations may result in 
aneuploidy are further discussed in Chapter 10. 
Microsatellite Instability 
l'vlicrosatellites , or simple sequence repeats , are sequences of DNA 1-6 base pairs 
in length, which often vary between individuals. For a given microsatellite lo-
cus, a normal individual has two set lengths of repeated sequence (which may 
be identical) - one on each allele. However, if DNA repair genes become mu-
tated, these sequences may become longer or shorter - a feature referred to as 
microsatellite instability (MSI). MSI is the hallmark of mismatch repair protein 
loss (discussed in Section 1.4). 
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Specific mutational events occur with different frequencies in adenomas with CIN 
or MSI. For example, TGFf3R2 (discussed below) is mutated more frequently 
in the setting of MSI [Salahshor et al., 1999]. Axinl and TCF4, components 
of the Wnt pathway described below, have been found to be mutated in some 
microsatellite-unstable tumours; they are discussed further in Chapter 8. 
Epigenetic Instability 
Epigenetic instability refers to altered gene expression mediated by DNA methy-
lation occurring at regions of genes (for example, CpG island promotor regions) 
that regulate important cell functions including transcription [Baylin and Ohm, 
2006]. Clinically, this phenotype has become known as CIMP (CpG island 
methylator phenotype) [Boland and Goel, 2005]. For example, promotor hyper-
methylation may silence a mismatch repair gene, causing secondary microsatel-
lite instability. 
1.2.2.2 Genes Commonly Mutated in Colorectal Neoplasia 
While the sequential model of the adenoma-carcinoma sequence shown in Figure 
1.3 above is convenient and easy to visualise, conflicting experimental evidence 
suggests that not all tumours progress in this predictable stepwise manner. This 
may indicate that cancer precursors are heterogeneous. For example, some ade-
nomas harbour identifiable APe or KRAS2 mutations, and others have both 
or neither [Liichtenborg et al., 2005]. 
KRAS2 is an important oncogene of the MAPK (mitogene activated protein ki-
nase) signalling pathway. KRAS2 auto-hydrolyses GTP to become inactive; the 
mutational hotspots at codons 12 and 13 are GTP /GDP binding sites. KRAS2 
and BRAF mutations are generally mutually exclusive, and these genes are 
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thought to have similar functions [Rajagopalan et al., 2002]. KRAS2 muta-
tion has been variously described as a mutation which occurs early in neoplasia 
(before APe in sporadic aberrant crypt foci [Takayama et al., 2001]); as associ-
ated with larger adenomas [Rajagopalan et al., 2002]; with progression to ane-
uploidy [Rapallo et al., 1999]; and with cancer invasion and metastasis [Pollock 
et al., 2005]. In fact, the evidence concerning KRAS2 illustrates that, while 
commonly mutated genes important for tumorigenesis have successfully been 
identified, confusion remains in classifying mutations as causal, permissive, or 
neutral "hitchhikers" [Maley et al., 2004]. 
TP53 is a tumour suppressor gene located on 17p, postulated to have a causal 
role in malignant change [Baker et al., 1990]. It has DNA-binding domains and 
functions as transcriptional regulator of other DNA repair genes. In addition, 
it can hold the cell in G 1 or S phase to allow DNA repair to occur. If damage 
is irreparable, TP53 can initiate cell apoptosis [Vogelstein and Kinzler, 2004]. 
Its functional importance as "guardian of the genome" is seen in patients with 
Li-Fraumeni syndrome, who inherit a germline mutation of TP53, and suffer 
from multiple diverse young-onset tumours. The frequent finding of 17p LOR 
in carcinomas seems to correlate with mutation of TP53 [Baker et al., 1990]. 
Another change thought to occur late in the adenoma-carcinoma sequence is 
that of 18q loss of heterozygosity (LOR) [Thiagalingam et al., 1996]. Genes 
in this region likely to be involved in subsequent neoplastic progression include 
SMAD2 and SMAD4, members of the TGFf3 signalling pathway, involved in 
cell cycle control, proliferation and apoptosis. SMAD proteins are activated 
via phosphorylation mediated through TG F f3 R2, commonly mutated in MMR-
deficient tumours. 
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1.2.2.3 The APe Gene and the Wnt Pathway 
Mutation of the APC gene, located on chromosome 5, is the inherited germ line 
mutation causing FAP, and is also identified as an initiating somatic mutation 
in about 80% of sporadic cancers [Fearnhead et al., 2001]. APC has a key role 
in the Wnt signalling pathway, shown in Figure 1.5. Briefly, normal APe is able 
to participate in a protein complex with GSK-3j3 and axin, which binds and 
degrades beta-catenin in the absence of Wnt signalling. Mutated APe is unable 
to effectively participate in this protein complex in order to degrade cytosolic 
beta-catenin. Beta-catenin then accumulates, enters the nucleus, and activates 
DNA transcription in the absence of appropriate Wnt signalling. Target genes 
become activated and a tumour develops. 
phosphorylation 
~ -TRCP 
Figure 1.5: The Wnt pathway 
APe in shown participating in beta-catenin binding, regulation of the cell 
cytoskeleton via Actin, and kinetochore microtubule regulation via EB 1 (see 
Table 1.4). 
APe has 16 translated exons, and has a great variety of functional domains 
shown in Table 1.4 below. As suggested in the table, APe is involved in cell 
structure and cytoskeletal organisation, cell migration and intercellular adhesion ~ 
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cell-cycle control and apoptosis [Sieber et al., 2000]. 
I Domain I Function 
Heptad repeats APC protein structure and 
dimerisation 
Armadillo Asef binding, modulation of 
actin cytoskeleton - cell adhesion 
and motility 
3 x 15-amino acid repeats beta-catenin binding and 
regulation 
7 x 20-amino acid repeats beta-catenin binding and 
regulation, GSK-3,8 
phosphorylation 
SAMP amino acid repeats axin binding (interspersed with 
20-amino acid regions) 
basic domain, carboxy-terminus EB1 microtubule-associated 
protein binding (kinetochores) 
Table 1.4: Some functional domains of APe 
Since the APe gene is a tumour-suppressor gene, both alleles must be inac-
tivated before tumorigenesis results. In FAP, where one inactivated allele is 
inherited, the somatic mutation is often readily identifiable in tumour tissue, 
particularly as they tend to occur in a pre-defined region of exon 15 (the "mu-
tation cluster region" [Miyoshi et al., 1992]). Study of somatic APe mutations 
in FAP polyps of the colorectum showed that there was an interdependence of 
the germline and somatic mutations [Lamlum et al., 1999, Rowan et al., 2000], 
according to the first three 20-amino acid repeat regions (20AARs) left intact, 
summed over both alleles. This was dubbed the "just-right" hypothesis [Albu-
querque et al., 2002]: in the colorectum, tumour development is favoured by a 
somatic mutation leaving one or two 20AARs intact [Crabtree et al., 2003]. It is 
postulated that this number allows an optimal degree of residual Wnt signalling 
in order to favour adenoma development. Table 1.5 summarises this association. 
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Germline Position of Codon Position Predicted 
mutation 20AAR in Exon 15 somatic 
mutation 
before truncating 
1264 mutation 
between 1286 to 
1400 
around 1st repeat 1264 - 1285 LOH 
1300 
after 1398 2nd repeat 1379 - 1398 truncating 
mutation before 
1264 
3rd repeat 1495 - 1514 
Table 1.5: Relationship of germline and somatic mutations, with beta-catenin 
binding sites, for colorectal polyps 
The codon positions for the 20AARs given here are used in Chapter 6. 
A similar interdependence between germline and somatic mutations has been 
demonstrated for upper gastrointestinal polyps [Groves et al., 2002a] and fundic 
gland polyps [Abraham et al., 2002] (where 3-4 20AARs tend to remain), and for 
desmoids [Latchford et al., 2007] (where 2-3 20AARs result). This is discussed 
further in Chapter 6, where the association is defined for polyps in the ileoanal 
pouch. 
1.2.3 A Molecular Classification of Colorectal Cancer 
A new classification based on five types of colorectal cancer [Jass, 2007], is 
shown in Table 1.6. Unlike the linear model of the adenoma-carcinoma sequence 
discussed above, this classification recognises that precursors other than the 
common tubular or villous adenoma may result in cancer - for example, serrated 
adenomas. In addition, it categorises DNA methylation and BRAF mutation, 
common in these lesions, as a separate pathway of tumorigenesis. Some clinical, 
morphological and molecular features may overlap in this classification system, 
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and specific lesions should be viewed as occupying a position on a continuum 
between the groups. Most Lynch syndrome-associated adenomas and cancers fall 
into group 5, while the majority of sporadic polyps, FAP-associated tumours are 
group 4. 
I Feature Group 1 Group 2 I Group 3 I Group 4 I Group 5 
MSI High Stable/Low Stable/Low Stable High 
Methylation +++ +++ ++ +/- +/-
Ploidy Dip>An Dip>An An>Dip An>Dip Dip>An 
Associated 
mutations: 
APC +/- +/- + +++ ++ 
KRAS - + +++ ++ ++ 
BRAF +++ ++ - - -
TP53 - + ++ +++ + 
Others MLHl MGMT CTNNB1, 
methyla- methyla- TGFf3RII 
tion tion 
Precursor serrated serrated serrated adenoma adenoma 
lesion polyp polyp polyp or 
adenoma 
DIp-dIplOId, An-aneuplOId 
Table 1.6: Molecular and morphological classification of colorectal cancer after 
Jass [2007] 
1.3 Familial Adenomatous Polyposis 
FAP is inherited in an autosomal dominant manner, and is due to a germline 
mutation in the APe gene, a key regulator of the Wnt pathway (section 1.2.2.3). 
Typically, the colon becomes progressively carpeted with adenomatous polyps 
from childhood, and prophylactic colectomy is almost always performed in an 
attempt to prevent colonic cancer. In patients who have undergone prophylactic 
colectomy, duodenal cancer (see Section 1.3.3.2) and desmoid disease are the 
major causes of death and morbidity [Arvanitis et al., 1990]. 
CHAPTER 1. 31 
1.3.1 Genotype-Phenotype Correlation 
The severity of the colonic polyposis is greatly affected by the position of the 
germ line APe mutation. Mild or "attenuated" FAP occurs with APe mutations 
before codon 157, after codon 1595 and in the alternatively spliced region of exon 
9. Patients with attenuated FAP may have fewer than 100 colonic polyps. Se-
vere polyposis (thousands of colonic polyps) is found in patients with mutations 
between co dons 1250 and 1464. Mutations in the remainder of the APe gene 
cause an intermediate phenotype. Other manifestations of FAP show a similar 
genotype-phenotype correlation. Congenital hypertrophy of the retinal pigment 
epithelium (CHRPE) and desmoid tumours are associated with mutations be-
tween codons 311 and 1444 and after codon 1444, respectively [Nieuwenhuis and 
Vasen, 2007]. 
Figure 1.6: Colectomy specimen from patient with codon 1309 germline muta-
tion 
Photograph taken by author with patient's permission. 
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1.3.2 The Ileoanal Pouch in FAP 
Historically, prophylactic colectomy used to result in an end ileostomy. Today, 
however, surgeons aim to avoid a lifelong stoma, and the most common surgical 
options are subtotal colectomy and ileorectal anastomosis (IRA) and restorative 
proctocolectomy with the ileoanal pouch (RPC). The first option leaves the 
patient with an intact rectum, requiring six-monthly endoscopic surveillance. 
Unfortunately the risk of developing rectal cancer after an IRA may be as high 
as thirty percent of patients over age 60 [Bulow et al., 2000], although this is very 
dependent on patient selection and rectal surveillance. Therefore, the ileoanal 
pouch procedure is an increasingly favoured option for prophylactic surgery, as 
the rectum is also excised. 
Figure 1.7: Ileoanal Pouch after restorative proctocolectomy 
(Illustration from Crohn's and Colitis Foundation, 2002, A. Pengrace) 
The ileoanal pouch is a faecal reservoir made from the small bowel, which allows 
the patient to retain continence. The pouch may be fashioned in various ways: 
using J , Wand S configurations formed with stapled or handsewn techniques 
(see Figure 1.8). In addition, the pouch-anal anastomosis may be stapled or 
handsewn, with or without mucosectomy of the anal transition zone. 
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UJ II Pouch 
Figure 1.8: Surgical formation of the ileoanal pouch 
J, Sand W pouches can be formed. Function is similar regardless of 
configuration, although stool frequency may be slightly reduced with an S or 
W configuration [Lovegrove et al., 2007] . 
Regardless of surgical technique used, pouch function is on the whole somewhat 
inferior to that of the IRA [van Duijvendijk et al., 1999]. In addition, the pouch 
requires yearly surveillance as the patient remains liable to develop large bowel 
adenomas in the remaining rectal cuff, which may be as small as a few millimetres 
in length. The risk of neoplasia arising in large bowel mucosa remains even after 
mucosectomy, as islands of large bowel mucosa may be left in situ, and there 
is also buried mucosa under the sealed edge of the anastomosis. However, the 
small bowel mucosa of the pouch may also develop adenomas; this is discussed 
further in Section 1.3.3 below. In contrast to the IRA however, only a handful 
of cancers arising in ileal pouch mucosa have been reported [Church, 2005]. 
The phenomenon of ileoanal pouch polyposis is intriguing and investigated fur-
ther in this thesis. While neoplastic lesions may frequently arise in some areas 
of the small bowel in patients with FAP (stomach, duodenum, and duodenal 
ampulla), jejunal and ileal polyps are rare in patients prior to colectomy. How-
ever, in other polyposis syndromes like Peutz-Jeghers polyposis and Juvenile 
Polyposis , diffuse small bowel polyposis is a frequent feature. Therefore, while 
APe is almost ubiquitously expressed in human tissues, the pattern of disease is 
very localised even within the gut. Understanding how tissue location influences 
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phenotypic variability may in the future allow pharmacological modulation of 
adenoma development in high-risk intestine such as the colon and duodenum. I 
have therefore reviewed the F AP phenotype by location [Will et al., 2008a]: and 
this is briefly discussed in Section 1.3.3 below. 
1.3.3 Locoregional Variation in Polyposis 
1.3.3.1 Gastric Polyps 
Patients with FAP develop two varieties of gastric polyps: fundic gland polyps 
(FGPs) and gastric adenomas. FGPs are among the most common upper gas-
trointestinallesions seen in patients with FAP; they are typically small «5mm), 
sessile and multiple. Their incidence in FAP is usually estimated at around 40% 
[!ida et al., 1984]' with true gastric adenomas being less common at 5% [Domizio 
et al., 1990]. The microscopic appearance of FGPs is characterised by a progres-
sive formation of glandular buds, glandular tortuosity and microcyst formation, 
with around 40% showing some concomitant dysplasia [Bertoni et al., 1999]. 
While FGPs also occur sporadically (usually in females on proton pump in-
hibitors [!ida et al., 1984]), different environmental factors maya playa role in 
their development in FAP. One study has shown an association with increased 
gastric exposure to bilirubin [Mabrut et al., 2006]. While sporadic FGPs tend 
to harbour beta-catenin mutations, FAP-associated FGPs show "second hit" so-
matic mutations of APC [Abraham et al., 2001]. It is not yet understood why 
APC inactivation elsewhere in the gut results in adenomatous morphology, but 
in the stomach results in the FGP [Abraham et al., 2000]. Histological evidence 
of dysplasia and Wnt pathway activation [Bertoni et al., 1999]' imply that FGPs 
are not simple indolent hamartomatous or hyperplastic lesions. 
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Gastric adenomas can occur in the absence of FGPs. They are commonly seen 
in the antrum, where micro adenomas can also be found on biopsy of macroscop-
ically normal mucosa [Bertoni et al., 1999], and in patients with gastric atrophy 
[Nakamura et al., 2002]. 
Given that two different lesions capable of dysplastic progressIOn commonly 
occur in the stomach in FAP, it is surprising that the risk of malignancy remains 
small. In a study of over 400 gastric lesions, no severe atypia or carcinoma was 
identified [Bertoni et al., 1999]. However, there are reports confirming gastric 
adenocarcinoma in FAP patients with FGPs [Hofgartner et al., 1999, Zwick 
et al., 1997]. In the West, the risk of gastric cancer in those with FAP seems 
similar to that of the general population [Offerhaus et al., 1992], but there is 
some evidence that the risk is increased in Korea and Japan, where higher rates 
of gastric cancer pertain in the general population [Park et al., 1992]. 
Figure 1.9: Fundic gland polyps: endoscopic view 
Photograph courtesy Ripple Man. 
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1.3.3.2 Duodenal and Peri-ampullary Polyps 
Duodenal and peri-ampullary dysplasia is extremely common: in a study of 102 
patients undergoing upper GI surveillance, 92% had duodenal dysplasia, and 
74% of peri-ampullary biopsies were dysplastic [Spigelman et al., 1989]. While 
most patients develop duodenal and peri-ampullary polyps , only a minority 
(around 5%) develop cancer [Gallagher et al., 2006 , Wallace and Phillips , 1998]. 
Most dysplasia occurs in the second and third parts of the duodenum [Domizio 
et al., 1990], where the small intestinal mucosa comes into prolonged contact 
with bile acids. 
Figure 1.10: Duodenal polyps: endoscopic view 
Photograph courtesy Ripple Man. 
It is possible that this environment encourages mutational changes in the primed 
mucosa or that the bile of patients with FAP is particularly mutagenic [Spigel-, 
man et al., 1990, 1991 , Scates et al., 1993]. A single, small study [Biasco et al., 
2006] suggested that duodenal polyp burden may be related to previous gastroin-
testinal surgery, the risk higher after ileorectal anastomosis than after ileoanal 
pouch formation, but this has not been reported elsewhere. 
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Unlike in the colon, there is no clear evidence that a specific germline mutation 
confers higher risk of heavy upper gastrointestinal polyp burden. Conflicting 
associations are found in the literature, including mutations between co dons 
976-1067 [Bertario et al., 2003], downstream of 1051 [Bjork et al., 2001]' 1225-
1694 [Attard et al., 2004], and after 1400 [Groves et al., 2002a]. One study 
showed no correlation with germline mutation for duodenal adenomas [Friedl, 
2001]. For peri-ampullary neoplasia, familial segregation was found without 
correlation with a specific germline APC mutation [Sanabria et al., 1996], raising 
the possibility of other modifier genes influencing the upper gastrointestinal 
phenotype. 
While the genotype-phenotype correlation remains uncertain, more is known 
about the downstream genetic changes that occur in the mucosa in polyp for-
mation. Interestingly, the way in which the wild-type APC allele is inactivated 
(the "second hit") differs from colonic polyps, in terms of the number of 20-amino 
acid repeats selected for in the resultant APC protein (see section 1.2.2.3). This 
is significant, in that it provides molecular evidence that the process of adenoma 
formation is influenced either by the tissue of origin, or by the environmental 
milieu. 
A scoring system known as the Spigelman score has been proposed to classify 
the extent of duodenal polyposis on a five grade scale, based on polyp number, 
size, histology, and dysplasia (see Chapter 5). The risk of developing Spigel-
man stage IV duodenal adenomatosis at age 70 was found to be around 50% 
[Bulow et al., 2004, Saurin et al., 2004]. Even with endoscopic surveillance, the 
risk of developing cancer within ten years in Stage IV is 36% [Groves et al., 
2002b]. Therefore, duodenal polyposis is a significant contributor to morbidity 
and mortality in patients with FAP. 
Pharmacological therapy may stave off or prevent the need for duodenal surgery 
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in some patients. Although acid suppression agents were found to be ineffective 
[Wallace et al., 2001]' two agents were found to confer benefit: sulindac and cele-
coxib. Sulindac had a non-significant trend towards duodenal polyp regression 
in one study [Nugent et al., 1993a], although another study found no benefit for 
control of peri-ampullary polyps [Richard et al., 1997]. Celecoxib resulted in a 
14 - 31% reduction in involved areas [Phillips et al., 2002], but the effect on 
cancer prevention in unknown, and its cardiac risk profile may preclude its use 
in a number of patients. 
1.3.3.3 Ampulla, Bile Duct, and Gallbladder Polyps 
Ampullary adenomata are frequently found in FAP, but the true incidence is 
difficult to estimate as identification may depend on the use of dye spray and 
side-viewing endoscopes. In one study, macroscopic lesions were found to occur 
in 28% of patients with FAP [Bertoni et al., 1996], and were correlated with the 
degree of duodenal polyposis. However, a retrospective study suggested that 
50% of macroscopically normal ampullae were in fact histologically adenoma-
tous [Church et al., 1992]. Ampullary lesions may cause pancreaticobiliary duct 
obstruction [Murakami et al., 2006], or become malignant. 
CHAPTER 1. 
Figure 1.11: Ampullary dysplasia: endoscopic view 
Photograph courtesy Ripple Man. 
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The risk of malignant transformation of ampullary lesions may be lower than 
that of duodenal polyps, and there is some evidence that most ampullary adeno-
mata do not progress over long-term follow up [Bertoni et al., 1996, Matsumoto 
et al., 2000, Burke et al., 1999], and have less proliferative activity compared to 
duodenal adenomas [Esaki et al., 2005]. However, ampullary cancers do occur, 
and often are clinically silent [I wama et al., 1994]. 
Other areas of the biliary tree can be affected in FAP. Cholangiocarcinoma has 
been reported [Smith et al., 1993], and the gallbladder does develop adenomas 
[Nugent et al., 1994], and very rarely, adenocarcinoma [Brevet et al., 2007, Hi-
rano et al., 2004, Walsh et al., 1987]. Most gallbladder adenomas are discovered 
as an incidental finding on cholecystectomy or abdominal imaging; however , 
there is no evidence that FAP confers an increased risk of cholecystitis or biliary 
colic above that of the general population. 
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1.3.3.4 Polyps in the Jejunum, Ileum, and Ileum above Ileorectal 
Anastomosis 
Jejunal and ileal adenomas are not a typical feature of FAP: there is just a 
single published case of intussusception due to jejunal polyps, occurring in a 
post-colectomy patient [Ishida et al., 2002]. Similarly, jejunal cancer has been 
reported rarely [Zuidema and Dekker, 1989]. 
In a study of 20 young patients undergoing on-table terminal ileoscopy at the 
time of prophylactic colectomy, none were found to have macroscopic polyps, 
although 5% had microadenomas [Groves et al., 2005]. However, there is some 
evidence that the incidence of jejunal and ileal polyps may rise after abdominal 
surgery. One study of 15 post-operative FAP patients with mean age >40 years 
undergoing capsule endoscopy (CE), found 60% of patients had ileal or jejunal 
polyps, although all were too small to warrant intervention [Burke et al., 2005]. 
Lymphoid hyperplasia may result in an overestimate of adenomas by CE, but 
this study suggested an association with patient age and stage of duodenal poly-
posis, and advocated CE for patients with advanced duodenal polyposis. How-
ever, in a study comparing MRI with CE in 16 patients with FAP, no polyps 
larger than 5mm were identified [Caspari et al., 2004]. 
Most ileal polyps occurring above an IRA or an ileoanal pouch are visible dur-
ing flexible sigmoidoscopy. I performed a retrospective review of 202 patients 
undergoing 6 monthly flexible sigmoidoscopy following IRA at St Mark's Hospi-
tal. This found that 16% had macroscopic ileal polyps above the anastomosis, 
and 20% of the polyps biopsied were moderately dysplastic [Will et al., 2007b]. 
This figure was higher than a previous prospective study which suggested that 
only 2% of patients with IRA had ileal polyps [Groves et al., 2005]. St Mark's 
Hospital to date has had no cases of severely dysplastic polyps at this site, and 
there are no published cases of small bowel cancers arising in this situation. 
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This finding may suggest that these polyps do not progress to severe dysplasia 
or cancer. 
1.3.3.5 Ileoanal Pouch Polyps 
As discussed above, yearly endoscopic surveillance of the ileoanal pouch is per-
formed in most centres in patients who have undergone RPC. The rationale for 
this was primarily to survey the remaining cuff of large bowel mucosa remaining 
at risk of malignancy. However , it has become increasingly apparent that the 
ileoanal pouch mucosa develops adenomas (see Figure 1.12). 
Figure 1.12: Ileoanal pouch polyps: endoscopic view 
Photograph courtesy Ripple Man. 
The estimated incidence of true pouch adenomas is around 60% [Groves et al., 
2005, Parc et al., 2001, 2004]. Since the incidence of adenomas in the ileum pre-
operatively is so low, this suggests that formation of the ileal reservoir triggers 
adenoma development. 
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Surgical technique does not seem to influence the development of pouch polyps 
[Groves et al., 2005, Polese and Keighley, 2003]. In addition, pouch polyp burden 
is seemingly independent of duodenal or colonic polyp burden [Groves et al., 
2005, Wu et al., 1998, Thompson-Fawcett et al., 2001]' and of germline mutation 
[Groves et al., 2005, Parc et al., 2001]. The only factor consistently found to 
increase the risk of pouch dysplasia was pouch age [Groves et al., 2005, Parc 
et al., 2001, Polese and Keighley, 2003, Wu et al., 1998, Thompson-Fawcett 
et al., 2001]. This evidence suggests that the development of ileoanal pouch 
polyps is triggered by a change in the mucosal environment, when ileum is 
fashioned into a reservoir. 
Since ileal polyps are rare prior to pouch formation, (see Chapter 6), environ-
mental factors are likely to be implicated in adenoma initiation. Histological 
studies have noted reduced enzyme production [Kawaguchi et al., 2000]) in the 
pouch mucosa, and villous atrophy and crypt hyperplasia occurring in the setting 
of inflammation [Fruin et al., 2003]. However, true colonic metaplasia does not 
occur [Bertoni et al., 1995]. Interestingly, pouch dysplasia is extremely rare in 
patients with ulcerative colitis (UC) [Borjesson et al., 2004, Thompson-Fawcett 
et al., 2001]. However, FAP and U C pouches may differ, especially in terms of 
colonising bacteria [Duffy et al., 2002]. 
It is possible that as RPC is increasingly performed, and the worldwide pa-
tient cohort with ileoanal pouch ages, the incidence of pouch excisions and even 
pouch cancers may rise. Management of the ileoanal pouch in St Mark's Hos-
pital currently involves pouch surveillance by flexible endoscopy with dye spray, 
surveying the pre-pouch ileum, the pouch mucosa, and the anorectal transition 
zone. This is performed on an annual basis, decreasing the interval for selected 
patients with heavy polyp burden, large or advanced adenomas. Where the 
polyp number rises above about 20~ or the polyps are large, endoscopic polypec-
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tomy is performed. Pharmacological therapy (as used for duodenal polyposis) 
is offered to selected patients with pouches at risk of advanced dysplasia. 
In summary, a wide range of small bowel lesions is found in FAP. Continuing epi-
demiological and molecular research into small bowel tumorigenesis may shed 
light on different modulating factors. In this section, we have seen that bile 
acids have been strongly implicated in lesions occurring de novo (gastric, duo-
denal and ampullary polyps), and these are discussed further in Section 1.5.1. 
However, the occurrence of polyps of the ileostomy, above the ileorectal anas-
tomosis, and in the ileoanal pouch, suggests that surgery may trigger polyp 
development by alteration of the local environmental milieu, perhaps through 
faecal stasis. Despite the fact that small bowel polyps are almost ubiquitous, 
malignant transformation is rare. This is reflected by experiences in clinical 
practice, in the follow-up of patients with an ileoanal pouch. While high grade 
dysplasia is commonly seen in anorectal transition zone polyps, most polyps of 
small bowel origin show only mild dysplasia. The site-specific initiation and 
progression of FAP polyps is further investigated in Part 1 of this thesis. 
1.4 Lynch Syndrome 
Lynch syndrome is caused by mutation in mismatch repair (MMR) genes MLH1, 
MSH2, MSH6, and PMS2, and is inherited in an autosomal dominant manner. 
(The pathogenic role of two other mismatch repair genes, MLH3 and PMS1, 
is less clear [Peltomaki, 2005]. ) At present, about 90% of cases are caused by 
germline mutations identified in MLHl or MSH2, with mutation of MSH6 found 
in 7%, and PMS2 mutation in fewer than 5% [Umar et al., 2004]. The lifetime 
heterozygous risk of colon cancer is between 70 and 80%, usually presenting at 
around 50 years. In women, there is also a substantial risk of endometrial cancer 
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of around 40%. Other associated cancers include gastric, small intestinal: brain, 
ovarian, urothelial and hepatobiliary malignancies [Vas en , 2007]. Homozygous 
MMR mutation is a cause of Turcot's syndrome, characterised by childhood-
onset brain tumours, haematological malignancies and colorectal cancers. This 
is further discussed in Chapter 8. 
1.4.1 Genetic Testing of Tumours and Individuals 
Accurate diagnosis of an inherited cancer syndrome affects clinical management 
of an individual patient and family members. Ideally, genetic testing is under-
taken in a dedicated familial cancer clinic, where adequate counselling about 
the implications of genetic testing can be offered. However, identifying patients 
at risk of inherited conditions is not always straightforward in the absence of 
a pathognomonic phenotype. The Amsterdam criteria and Bethesda guidelines 
are commonly used to guide referral for genetic testing. 
The Amsterdam I criteria (see Table 1.7) were originally designed as a research 
tool to identify families very likely to have an autosomal dominant colorectal 
cancer syndrome for linkage studies. They were modified to Amsterdam II 
criteria, once the importance of other non-colorectal cancers in Lynch syndrome 
became evident. Although not designed as diagnostic criteria, in clinical practice 
they remain a useful characterisation of an autosomal dominant pedigree, and 
thus well describe high risk families. However, if used as diagnostic criteria, many 
patients with Lynch syndrome would be missed, since about half of patients 
with Lynch syndrome will not be identified by the criteria [Lindor et al.. 2006]. 
Their lack of sensitivity may be due to limited available family history, small 
families, early deaths in family members from other causes, new mutations. and 
the incomplete penetrance of Lynch syndrome. 
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Amsterdam II Criteria: Family Risk for Hereditary N onpolyposis 
Colorectal Cancer [Lindor et al., 2006] 
At Least 3 Relatives Have a Cancer Associated With Hereditary 
Nonpolyposis Colorectal Cancer*: 
1. One should be a first-degree relative of the other 2 relatives 
2. At least 2 successive generations should be affected 
3. At least 1 relative should be diagnosed before age 50 years 
4. Familial adenomatous polyposis should be excluded 
5. Tumours should be verified by pathological examination 
Table 1.7: Amsterdam criteria 
*cancer of the colorectum, endometrium, small bowel, or renal pelvis. Amster-
dam I criteria included only colorectal cancer; Amsterdam II Criteria included 
all cancers listed. 
In addition, some patients may fulfil Amsterdam criteria and yet not have mi-
crosatellite unstable tumours. This group of patients have been dubbed as hav-
ing "Familial Colorectal Cancer Type X"; they have a lower risk of colorectal 
cancer, and no increased risk of other cancers associated with Lynch syndrome 
[Lindor et al., 2005]. This group of patients probably represent a mixture of 
chance clusters of cancers in families, and others may have mutations of as yet 
unidentified genes. 
The Bethesda guidelines [Umar et al., 2004] given in Table 1.8, were designed 
to be applied to people presenting with cancer to identify which cancers should 
be tested for MSI or MMR immunohistochemistry, in order to identify Lynch 
syndrome. The Bethesda guidelines were found to be the most sensitive criteria 
for identifying families with pathogenic mutations of MLHl and MSH2, having 
a sensitivity of 94% (although the specificity was 25%). (By contrast, the same 
study found the sensitivity and specificity of the Amsterdam II criteria were 
72% and 78% respectively [Syngal et al., 2000].) 
Genetic work-up after counselling and consent would include tumour immuno-
histochemistry for mismatch repair genes, and possibly microsatellite instability 
testing. Immunohistochemistry showing absent expression of a mismatch repair 
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The Revised Bethesda Guidelines for genetic testing of colorectal 
tumours, from U mar et al. [2004] 
1. Colorectal cancer diagnosed under 50. 
2. Synchronous, metachronous colorectal, or other 
HNPCC-associated tumours*, regardless of age. 
*colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, 
and brain tumours, sebaceous gland adenomas and keratoacanthomas in Muir-Torre 
syndrome, and carcinoma of the small bowel 
3. Colorectal cancer with microsatellite instability or MSI-H 
histology* diagnosed in a patient who is less than 60 years of age. 
*tumour infiltrating lymphocytes, Crohn's-like lymphocytic reaction, mucinous/signet-ring 
differentiation, or medullary growth pattern. 
4. Colorectal cancer diagnosed in one or more first-degree 
relatives with an HNPCC-related tumour, with one of the cancers 
being diagnosed under age 50 years. 
5. Colorectal cancer diagnosed in two or more first- or 
second-degree relatives with HNPCC-related tumours, regardless 
of age. 
Table 1.8: Bethesda guidelines 
protein nearly always corresponds to microsatellite instability in the tumour, 
and germline DNA testing of a specific MMR gene is guided by the immunohis-
tochemistry result. However, the presence of tumour microsatellite instability 
does not necessarily indicate Lynch syndrome, as epigenetic events (particu-
larly MLHl promotor hypermethylation) may cause microsatellite instability in 
the absence of an inherited germ line mismatch repair gene defect (see Section 
1.2.2.1) . 
Individuals with Lynch syndrome who develop cancer should preferably un-
dergo colectomy rather than a limited resection, as the risk of a metachronous 
tumour is high (40% within seven years [Lindor et aI., 2006]). Unaffected indi-
viduals identified on predictive testing can be managed by annual or biannual 
surveillance colonoscopy, since adenomatous polyps are generally scanty and 
amenable to biopsy and removal. Screening for associated cancers (for example, 
endometrial biopsy or transvaginal ultrasound) has not :vet proved effective on a 
population basis [Dove-Edwin et al., 2002]. but screening interventions could be 
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individualised depending on family history. However, depending on the patient's 
preferences and family history, there may be a role for prophylactic colectomy 
[Lynch et al., 2006] or hysterectomy and oophorectomy [Schmeler and Lu, 2008]. 
1.5 Sporadic Colorectal Cancer 
Sporadic colorectal cancer differs from syndrome-associated colorectal cancer in 
a number of clinical and genetic respects. In common with FAP, the initiating 
mutation is usually inactivation of APe, and subsequent neoplastic progression 
is frequently accompanied by chromosomal instability, rather than microsatellite 
instability as seen in Lynch Syndrome. As in FAP, cancers more commonly occur 
in the descending colon, sigmoid or rectum rather than the right colon, although 
sporadic right-sided adenomas may increase with age [Yamaji et al., 2006]. The 
peak incidence in the UK is over the age of 60; hence biennial faecal occult blood 
testing has recently been introduced as a surveillance strategy for people aged 
60-69 (60-74 from 2010) [Parkin et al., 2008]. 
1.5.1 Environmental Factors and Neoplasia 
Environmental and dietary factors may influence the risk of colorectal cancer: 
higher risk is associated with intake of meat, dairy products, and saturated fat. 
Vegetables, calcium, Vitamin D, and folate may reduce risk [Forte et al., 2008]. 
However, epidemiological studies are often contradictory. This may partly be 
due to inherent difficulties in tracking long-term food exposure in subjects, but 
may also be due to metabolic differences between individuals. In addition, some 
dietary factors may affect cancer incidence at specific colonic sites only: for 
example, rectal cancer in women has been associated with increased Vitamin 
B6 intake [de Vogel et al., 2008]. 
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A protective association between NSAIDs and sporadic colorectal neoplasia has 
been established. Although celecoxib was found effective in reducing adenomas 
in FAP (see Section 1.3.3.2) as well as in sporadic colorectal neoplasia [Bertag-
nolli et al., 2006, Siemes et al., 2008] a protective effect it is not seen in carriers 
of Lynch syndrome [Burn et al., 2008]. 
Bile acid metabolism has been implicated as a contributory factor in both FAP-
associated and sporadic neoplasia. Bile salts are synthesised in the liver and 
conjugated before excretion in the bile. After release into the small intestine to 
assist fatty acid absorption, the bile salts are reabsorbed, predominantly in the 
terminal ileum. Around five percent of the bowel salts escape enterohepatic cir-
culation, and enter the colon to be deconjugated and dehydroxylated by colonic 
anaerobes, and excreted in the faeces. Surgical formation of an ileoanal pouch 
or colonic resection may therefore disrupt this process. 
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Figure 1.13: Bile salt circulation 
Figure modified from University of Washington Division of Gastroenterology Online; and American 
Gastroenterological Association Milner-Fenwick/ Timoni urn , MD. 
Some bile acids may be chemopreventive and others tumorigenic. Conjugated 
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bile acids were found to induce apoptosis in colorectal cancer cells [Katona et al.. 
2008], and ursodeoxycholic acid (a secondary bile acid formed by intestinal mi-
croflora metabolism) suppressed COX-2 expression in colon cancer cells [Khare 
et al., 2008], an effect similar to that of NSAIDs. However, deoxycholic acid, 
another secondary bile acid, may promote human colon cancer cell proliferation 
by activating EGF receptors [Shant et al., 2008]. 
Colonic microflora affect bile acid metabolism, and may also modulate the in-
fluences of dietary exposure. Studies in inflammatory bowel disease have also 
stressed their importance in the gut mucosal immune response. In colorec-
tal cancer, most studies have aimed to identify a probiotic associated with a 
decreased risk of colorectal cancer; however studies in humans are limited by 
confounding effects of exposure to dairy products, fibre, and vitamin D [Ca-
purso et al., 2006]. There is evidence that restorative proctocolectomy alters 
microflora [Almeida et al., 2008] but the clinical significance of these findings in 
unknown. 
1.6 Summary 
Colorectal cancer is a significant clinical problem causing substantial morbidity 
and mortality. In order to reduce the burden of the disease, clinicians need 
preventative and therapeutic strategies which can be applied to the whole pop-
ulation. 
Scientific study of strongly-inherited colorectal cancer syndromes had estab-
lished the efficacy of identifying at-risk patients and offering tailored endoscopic 
surveillance. These syndromes have also provided keys to understanding impor-
tant molecular events in the initiation and progression of tumorigenesis. :l\Iuch 
still needs investigation in colorectal neoplasia, arising in both inherited and 
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sporadic contexts, in order to improve the preventative and therapeutic arma-
mentarium. 
Further genes remain to be identified contributing to cancer risk and neoplastic 
progression, and the genetic pathways and molecular interactions responsible 
for the adenoma-carcinoma sequence need further characterisation. In the fu-
ture, genome-wide genetic analysis of individuals may become the norm, and 
tailored surveillance - at present possible only for patients at risk of strongly 
familial colorectal cancer syndromes - may also be applicable to the wider popu-
lation. Chemopreventative manipulation of the adenoma-carcinoma sequence on 
a molecular level may become possible. As scientific understanding of environ-
mental influences on molecular events develops, simple evidence-based dietary 
or microbacteriological modifications could impact greatly on the population 
incidence of colorectal cancer. 
For those developing colorectal cancer, quality of life and survival may be im-
proved if surgical and oncological therapy could be tailored to the molecular 
make-up of individual and tumour. New molecular markers may allow improved 
detection of early tumours and may help guide prognosis for individual lesions, 
both benign and malignant. 
Therefore, improved understanding of neoplastic initiation and progression is 
vital, in order to reduce the mortality from bowel cancer through bowel screening 
and the development of novel preventative and therapeutic techniques. 
Chapter 2 
Aims and Outline 
This dissertation describes investigations into aspects of adenoma formation and 
progression, in syndromic and sporadic contexts. 
Part I examined polyps arising within the context of familial adenomatous poly-
posis. Studies were designed to clarify how adenoma formation may be affected 
by the region of the gut wherein the adenoma arises: 
1. To identify whether "just-right" Wnt signalling is similar throughout the 
colon, adenoma initiation by APC LOR was studied in matched polyps from 
ascending, transverse, descending colon and rectum. 
2. To elucidate the natural history of ileoanal pouch dysplasia, a retrospective 
longitudinal review of pouch polyposis was undertaken using clinical records. 
3. To investigate the relative indolence of ileoanal pouch polyps compared to 
rectal polyps, a comparative study of their histogenesis was undertaken using 
crypt dissection of pouch and rectal polyps obtained at endoscopy. 
4. To determine whether somatic APC inactivation in ileoanal pouch polyps 
resembled the mutational spectrum typical of colonic or duodenal polyps. an 
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analysis of the "second hit" in ileoanal pouch polyps was performed. 
Part II focused on neoplasia arising in the context of a novel phenotype involving 
young-onset colorectal cancer, multiple adenomas, and neurological deficit. It 
aimed therefore: 
1. To identify the underlying germline mutation resulting in the phenotype, 
and to investigate molecular events downstream of the primary mutation to 
determine how it resulted in neoplasia. 
2. To investigate whether the identified germline mutation was responsible for 
related bowel and neurological phenotypes in other patients. 
Part III studied sporadically-occurring adenomas and cancers. By molecular 
investigation of lesions with contiguous areas of adenoma and carcinoma, the 
study aimed: 
1. To assess clonality in adenomas and carcinomatous crypts, and the inferred 
order of mutational events in malignant transformation, using mutational anal-
ysis of key cancer genes in individual adenomatous and carcinomatous crypts. 
2. To characterise ploidy alterations occurring in neoplasia by cytometry of 
contiguous adenomas and carcinomas, and the correlation with genome-wide 
SNP-based LOR analysis and beta-catenin dysregulation. 
Chapter 3 
Materials and Methods 
3.1 Ethical Approval for Human Tissue 
Archival tissue was obtained from St Mark's Hospital histopathology archives 
under the ethics study 05/MRE/02/21, approved until Jan 2009 by the Harrow 
Research Ethics Committee (principal investigator, Ian Tomlinson). Additional 
archival samples from other hospitals, and blood samples, were obtained un-
der the LREC 05/Q1605/66 (CORGI Research Project, Ian Tomlinson). Fresh 
frozen tissue was obtained from consenting patients at endoscopy under Harrow 
Research Ethics Committee 3208 December 2003 (principal investigators Brian 
Saunders and Ian Tomlinson). Samples were tracked and stored appropriately. 
and data were anonymised. 
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3.2 DNA Extraction from Samples 
3.2.1 Formalin-Fixed, Paraffin-Embedded Archival Sam-
ples 
Formalin fixation causes DNA cross-linkage and breakage, and DNA obtained 
from these samples is of poor quality. However, most tumour samples are 
archived in this form for long periods of time, and PCR amplification of short 
lengths of DNA (under 300 base pairs) is usually possible. 
Paraffin blocks were cut by histopathology services, so that 5 sections of 10pm 
were placed on glass slides. The sections were dewaxed by immersion in xylene 
for 10 minutes, and then rehydrated by sequential immersion for 5 minutes each, 
in 100%, 90% and 70% ethanol. The slides were then air dried. Tissue was 
carefully scraped from the slide with a needle, using the H&E slide as a guide. 
Tissue fragments were transferred to an Eppendorf tube containing 30 to 200pl 
proteinase kinase solution. The tissue was incubated for 48 hours at 55°C. At 
24 hours, Ipl of Qiagen proteinase kinase solution was added to aid digestion. 
Subsequent inactivation of the proteinase kinase was achieved by heating the 
samples to 75°C for 10 minutes. 
Where absolutely necessary, purification of the DNA was performed using Qia-
gen PCR Cleanup columns. This resulted in gain of purity of the DNA at the 
expense of loss of DNA concentration, since the small fragments are not retained 
well in column purification. 
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3.2.2 Fresh-Frozen Samples 
Fresh-frozen samples were snap-frozen in liquid nitrogen immediately after sam-
ple removal until transported to histopathology services on dry ice, where 5 
sections of 10jLm were obtained on glass slides, with an H&E section. The tissue 
was then scraped directly off the slide as described above, into a proteinase ki-
nase solution. Incubation and heat inactivation were performed as above. DNA 
quantification was performed using a N anoDrop spectrophotometer ND-IOOO 
(N anoDrop Technologies); working concentrations were typically 50ng/ ILL 
3.2.3 Blood Samples 
DNA extraction from blood was performed using an automated magnetic bead 
system (Chemagen Technologies). Briefly, whole blood stored in EDTA tubes 
was lysed in lysis buffer and proteinase kinase solution. Genomic DNA was 
then bound to paramagnetic beads and contaminants were removed with wash 
buffers. DNA was then eluted from the magnetic particles and transferred to 
Eppendorf tubes for experimental analysis. 
3.3 Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) is a technique which exponentially amplifies 
segments of DNA using Taq polymerase, a thermostable enzyme. Primers (usu-
ally 15-25bp in length) were designed to flank the region to be amplified, and 
the polymerase replicated the template DNA with repeated cycles of heating 
and cooling on a thermal cycler. The first step was an initiation step, melting 
DNA template and primers into single strands, and activating the "hot start" 
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Taq. Subsequently 3 steps were repeated about 30 to 35 times as follows: firstly. 
a denaturation step by heating; secondly, an annealing step allowing primers to 
anneal to the template; and lastly, an elongation step, where the primers were 
extended by the polymerase. Eventually the amplification was exhausted as 
primers, deoxyribonucleoside triphosphate (dNTP) substrate and active enzyme 
were depleted. A final elongation step was followed by a cooled holding step. 
A typical PCR reaction used 50ng template DNA, and 10/_11 Qiagen Hot-Start 
Multiplex PCR Mix (containing buffer, magnesium, dNTP, and Taq), with 4/,ll 
of Q solution (Qiagen). This newly-available PCR master mix was used because 
it worked particularly well with paraffin samples. Most PCR reactions were run 
on a tetrad PCR machine with the following program: at 95°C for 15 minutes, 
and 28 cycles of 0.45 minutes each, at 95°C, 55°C, and 72°C. This was followed 
by 72°C for 15m, and 10°C indefinitely. Primer-specific annealing temperatures 
are given in Section 3.16. 
3.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is a method able to separate PCR products and DNA 
fragments by size. DNA is negatively charged and migrates towards the anode 
when allowed to travel through an agarose gel in an electrical field. Smaller 
molecules move faster and migrate further than larger ones, and they can be 
compared with a standard size marker (a DNA "ladder") of 500bp or 1Kb. Ethid-
ium bromide incorporates into the DNA and is used to make the PCR products 
fluoresce when viewed under UV light at 302nm. 
Agarose gel electrophoresis was performed with 1 % gels for larger PCR products 
or DNA fragments, while 2% gels were used for products under 500bp. Agarose 
(Invitrogen) was dissolved by boiling in Ix TBE buffer. Ethidium bromide ,yas 
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added to a final concentration of 0.25J.Lg/ml. The liquid gel was left to cool and 
set in trays with a well comb, and then placed in an electrophoresis tank and 
immersed in Ix TBE buffer. 5J.Ll of PCR product was combined with 2J.Ll Orange 
G loading dye (Thevigen) , with a DNA ladder (Gibco BRL) as a size marker. 
Gels were usually run at 120V DC current for 20 minutes, viewed under UV 
light, and digitally photographed. 
3.5 High-Resolution Melting (LightScanner) 
High-resolution melting is a method that can detect sequence variation in ampli-
fied DNA fragments. Control DNA and test samples were separately amplified 
by PCR using a fluorescent dye binding to double stranded DNA. The PCR 
products were then melted in the LightScanner instrument (Idaho Technology), 
and the varying fluorescence from each sample was captured electronically. Melt-
ing curves of fluorescence as a function of temperature were then compared. This 
method allows both heterozygous and homozygous variations from the control 
to be detected with a sensitivity of 100% and a specificity of 90%. Samples 
varying from the control melting curve were then used directly for a sequencing 
reaction, as described in section 3.6. 
A typical PCR reaction for LightScanner mutation detection was set up as fol-
lows: Multiplex master mix (Qiagen) 10J.Ll, Q solution (Qiagen) 2.5J.Ll, forward 
primer (20mM) 1J.Ll, reverse primer (20mmM) 1J.Ll, LC Green Dye (BioChem) 
1. 25J.Ll, DNA 0.625J.L1. The PCR programme was the same as that used in section 
3.3. A layer of mineral oil (20J.Ll) is laid over the PCR reaction to prevent evap-
oration. Samples were analysed on the instrument using the Idaho Technology 
software. 
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3.6 DNA Sequencing for Mutation Analysis 
Fluorescence-cycle sequencing was used for automated sequencing of PCR prod-
ucts. This technique used the chain-termination method: a sequencing reaction 
for DNA synthesis used a single primer (forward or reverse, identical to that 
used to generate the PCR product), and incorporated normal dNTPs, but also, 
at random junctures, specifically-labelled chain-terminating dNTPs which lack a 
3' hydroxyl group, thus preventing further extension. Thus all fragments gener-
ated with this method had the same 5' end corresponding to the single primer, 
and the chain-terminating fluorescent nucleotides were read automatically by 
the fluorescence detector (ABI 3100, Applied Biosystems). 
Sequencing reactions used 811,1 BigDye Terminator Ready Reaction Mix (Applied 
Biosystems), 411,1 PCR product (diluted 1:40), 8111 dH20, and 111,1 20mM primer, 
to a final volume of 20jLl. Cycle conditions were: 94°C for 4 minutes, followed 
by 25 cycles of 94°C for 30 sec, 50°C for 10 sec, and 60°C for 4 minutes, with a 
final extension step of 60°C for 7 minutes. Sequencing reaction products were 
purified using Qiagen Dye-Ex 2.0 columns. 
3.7 Loss of Heterozygosity Analysis 
Loss of heterozygosity refers to allelic loss, which may result from large-scale 
loss of chromosomal material from a cell (e.g. non-disjunction during mitosis), 
mitotic recombination, or small-scale interstitial deletions. 
The method of interrogating the gene of interest for loss of heterozygosity used 
microsatellite markers flanking the gene. These are short regions of repetiti,'e 
sequences of nucleotides (mono-, di-, tri- or tetranucleotides) which haye been 
found to be frequently polymorphic in the general population (that is. the length 
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of the region often varies slightly between chromosomal pairs). A PCR using 
fluorescent-labelled forward primers (FAM or HEX) was designed to amplify the 
microsatellite(s) present in the tumour and matched normal DNA, allowing anal-
ysis of the region for allelic loss. After diluting the product approximately 1 :40 
with dH20, the product was denatured with formamide and heat and run on an 
AB3100 machine (Applied Biosystems), together with a Genescan-500 TAMRA 
size marker (Applied Biosystems). The data were analysed with Genescan and 
Genotyper software (Applied Biosystems). The area under each peak was deter-
mined, and the ratio calculated by dividing the peak area of the normal tissue by 
that of the tumour tissue. If genescan analysis of the PCR product showed one 
peak on the normal tissue, that individual was homozygous for the marker, ren-
dering it uninformative. However, if the normal tissue showed two peaks, but 
the tumour tissue had unequal peaks as assessed by ratios of normal:tumour 
peak areas, then loss of heterozygosity was deemed to have occurred. Values 
less than or equal to 0.5 or greater than or equal to 2, were scored as allelic loss, 
since the technique depended on there being more than 50% neoplastic material 
in the tumour specimen, confirmed on histological examination. 
3.8 Real-time Quantitative peR 
Where loss of heterozygosity was demonstrated, the technique of RT -qPCR was 
used to assess whether LOH occurred by deletion (implying copy number change) 
or by mitotic recombination (with stable copy number). This method used the 
5' nuclease activity of Taq polymerase to cleave a hybridization probe during 
the extension phase of the PCR [Heid et al., 1996]. The hybridization probe was 
labelled with two fluorescent dyes, a reporter (FAM) and a quencher (TAl\IRA). 
which silenced the reporter dye emission. However, during the peR process, the 
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quencher dye was released, and thus the FAM fluoresced increasingly as PCR 
product accumulated. This was detected in real-time by the detector instrument 
(ABI Prism 7700, ABI Biosystems). The amount of template DNA was carefully 
measured, and reactions were performed in triplicate. CT values were calculated 
by determining the point at which the threshold limit of fluorescence was ex-
ceeded (10 times the standard deviation of the baseline fluorescence). Sample 
signals (APe exon 14) were measured against an internal control (albumin gene 
exon 12), as described in Sieber et al. [2002a]. Briefly, a formula was applied to 
the samples, such that test samples without a deletion, were expected to give 
2-6.6.CT values close to 1, while those with a deletion showed values close to 0.5. 
3.9 Microsatellite Instability Analysis 
Microsatellite markers as described above in Section 3.7 were used to deter-
mine whether there was evidence of microsatellite slippage in tumour samples. 
DNA was extracted from paraffin-embedded tissue. peR using Bat25 and Bat26 
primers was performed; the forward primers were fluorescently labelled as de-
scribed in Section 3.7. Where possible, at least two microsatellite markers were 
used to assess microsatellite instability to ensure concordance in results. The 
denaturation process, automated analyser and software were the same as those 
used in Section 3.7. 
Whereas the technique of LOR analysis required assessment of peak area, mi-
crosatellite slippage was assessed based on visual inspection of characteristic 
peak patterns. Microsatellite stable tissue revealed two distinct peaks, whereas 
numerous multiple peaks were seen in place of two major allele peaks where 
slippage had occurred. 
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3.10 Array Comparative Genomic Hybridisation 
Array CGH allows detection of copy number changes - amplifications and dele-
tions - of 5Kb size. An Affymetrix Genome-Wide Human SNP Array 5.0 was 
used, and the technique was performed by Kimberley Howarth. Briefly, 500ng of 
germline DNA from a proband and from a normal reference sample were digested 
into fragments using restriction enzymes Sty and Nsp. The fragments were lig-
ated to adaptors recognising the Nsp/Sty 4bp overhangs. This was followed 
by a PCR step in which PCR primers recognised the adaptors. The amplified 
SNPs were purified with polystyrene beads, combined, and labelled before being 
hybridized to thousands of probes printed on a glass slide. The slide was then 
scanned by laser detection and analysed by Affymetrix software. The ratio of 
the fluorescence intensity of the proband's DNA to that of the reference DNA 
was then calculated, to measure the copy number changes for a particular SNP 
in the genome. 
3.11 Karyotype Analysis 
Karyotype analysis was performed using peripheral blood leukocytes, with Pa-
tricia Gorman. Briefly, blood was cultured in RPMI solution at 37'C for 96 
hours. Colcemid solution was added and the sample incubated for 30 minutes 
at room temperature. Centrifugation and removal of the supernatant was fol-
lowed by cell lysis using hypotonic KCl. Further centrifugation was followed 
by fixing in Carnoy's solution. The mixture was dropped onto a glass slide. 
air dried, trypsinized, and Giemsa stained. The slides were examined under 
a Zeiss microscope at x1000 magnification. Representative metaphase spreads 
were digitally photographed using Karyotyper 2.1 software. and digitally and 
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manually arranged by chromosome morphology, SIze, centromere and arm to 
facilitate band analysis. 
3.12 Crypt Dissection 
Fresh polyps were removed at endoscopy and transferred to Carnoy's solution 
in a glass container (see Section 3.17), and then into 70% ethanol after 2 hours, 
as described by Goodlad et al. [1991]. Since Carnoy's solution carries a chloro-
form inhalation risk especially undesirable in the clinical endoscopy setting, the 
protocol was modified to using Clark's Fluid in a plastic container for collection 
and storage. In both cases, samples were stored at 4°C until use. There was no 
discernible difference in staining quality or tissue handling. 
If the specimen was preserved with Carnoy's, preparation was as follows. The 
tissue was transferred to a glass tube, and incubated at room temperature for 5 
minutes each in 50% and 25% ethanol. The ethanol was drained away, and the 
specimen was incubated with IN HCI for 10 minutes in a waterbath at 60°C. 
The specimen was removed from the acid and left in Schiff's solution at room 
temperature for 45 minutes. 
If the specimen was preserved in Clark's, preparation was slightly modified. The 
tissue was transferred to a glass tube and incubated at room temperature in 50% 
ethanol for 15 minutes, and then for 10 minutes. Subsequently the specimen was 
incubated in IN HCI for 7 minutes in a waterbath at 60°C. The section was then 
rinsed in dH20, before addition of Schiff's as above. 
The tissue was transferred to a glass slide on the stage of a dissecting microscope 
and wetted with 45% acetic acid. Using blunt and sharp dissection by probe and 
ophthalmic scalpel, individual crypts were teased apart. A cover slip was applied 
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and gentle tapping over the glass enabled the crypts to be further separated and 
flattened. 
Crypts were assessed for mitotic figures under x40 magnification, and crypt 
fission under xlO magnification on an ordinary viewing microscope. The slide 
was transferred to a microscope with a drawing tube. Ten crypts were drawn 
onto paper of known thickness, at x16 magnification. The crypts were cut out 
of the paper, and weighed on an electronic scale. The appropriate mathematical 
conversion for the thickness of paper and magnification was used, and the area 
of the crypts was calculated. 
3.13 Immunohistochemistry 
The technique of immunohistochemistry uses antibodies to detect specific pro-
teins present in tissues. The cell membranes were first lysed by pre-treating 
the tissue by heat and steam pressure to expose the antigens in the cytoplasmic 
and nuclear proteins. The indirect method of antigen detection required two 
antibodies. An unlabeled, specific primary antibody (e.g. anti-human PMS2 
antibody raised in mouse) reacted with tissue antigen, and a biotin-labelled sec-
ondary antibody (e.g. horse anti-mouse antibody) reacted with the primary 
antibody. Since more than one molecule of secondary antibody was able to with 
different antigenic sites on the same molecule of primary antibody, this method 
allowed signal amplification and increased sensitivity of detection. To prevent 
secondary antibody also binding directly to the tissue in a non-specific man-
ner, a blocking serum (e.g. horse serum) was applied to the tissue before the 
antibodies. Finally, for detection of bound secondary antibody, an avidin and 
biotinylated horseradish peroxidase macromolecular complex (AB complex) was 
used. Avidin binds strongly to the biotin label of the secondar~' antibody. The 
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attached horseradish peroxidase metabolised an applied peroxidase substrate 
(DAB, 3,3'-Diaminobenzidine) to produce a brown staining, evident wherever 
primary and secondary antibodies were attached. 
Formalin-fixed, paraffin-embedded samples were cut to 5f-Lm sections with a mi-
crotome and placed on glass slides by histopathology services. They were de-
waxed and rehydrated by submersion in xylene for 10 minutes, and then 5 minute 
sequential immersion in 100%, 90% and 70% ethanol, and water. Endogenous 
peroxidase activity was quenched by immersion in methanol and 2% hydrogen 
peroxide for 5 minutes, after which the slides were washed in running water 
for 5 minutes. Antigen retrieval was achieved as shown in Table 3.1. After 
cooling, wax pen was used to delineate the specimen edges on the slides, and 
they were washed with PBS. Subsequent incubations were all performed with 
75f-LI of solutions. Non-specific antigens were blocked with 1.5% blocking serum 
(normal horse/swine serum as appropriate, Vector Laboratories, 15f-LI in 985f-LI 
PBS), for 30 minutes. Primary antibody was applied and slides were incubated 
at 4°C overnight. The primary antibody was then washed off with PBS, and 
sections were incubated for 30 minutes with secondary antibody. After washing 
in PBS, AB complex (Vectastain, Vector Laboratories, one drop A and one drop 
B in 2.5ml PBS) was applied for 30 minutes, and then washed off with PBS. 
Slides were then incubated in DAB (Sigma, one tablet H20 2 and one tablet DAB 
in 10ml dH20) for 12 minutes before rinsing in running water. The slides were 
counter-stained with Mayer's haematoxylin for 45 seconds, washed in water, and 
then dehydrated with 70%, 90% and 100% ethanol for 5 minutes each, followed 
by xylene for 10 minutes. A coverslip was applied and the slides examined under 
a microscope. 
[ Antibody I Specificity I Species I Dilution I Antigen retrieval _ I Source __ ---' 
-- .-
Ki67 (MIBl) S-phase marker (proliferation) mouse 1:100 microwave, citrate Dako 
buffer, 20 minutes 
Caspase-3 apoptotic marker rabbit 1:200 microwave, citrate R&D Systems 
buffer, 20 minutes 
Beta-catenin Wnt pathway activation mouse 1:100 mIcrowave or BD 
pressure cooker, Transduction 
citrate buffer, 10 Labs 
minutes 
TP53/D07 nuclear accumulation of TP53 rabbit 1:100 microwave in citrate Dako 
buffer, 10 minutes 
MLHI MMR protein expression mouse 1:50 pressure cooker, BD 
citrate buffer, 20 Pharmingen 
minutes 
Lysozyme paneth cells rabbit 1:200 microwave in citrate Dako 
buffer, 10 minutes 
PMS2 MMR protein expression mouse 1:25 pressure cooker, BD 
citrate buffer, 9 Transduction 
minutes Labs 
IgG-biotin conjugate anti-mouse horse 1:300 applied as secondary Vector 
layer 
IgG-biotin conjugate anti-rabbit SWIne 1:500 applied as secondary Dako 
layer 
--- -- -
Table 3.1: Immunohistochemistry antibodies 
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3.14 Illumina GoldenGate SNP Genotyping 
The GoldenGate platform platform contains 5861 markers, distributed evenly 
over the genome with an average physical distance of 482 kb. In paraffin-derived 
DNA, LOR and copy number changes can be detected across the genome. The 
GoldenGate Assay work flow was performed by Angela Jones. 
Paraffin-derived DNA was purified where possible, and prepared as 2011,1 of 
50ng/I1J concentration. The process began with an activation step, where a 
streptavidin/biotin activator was added to the DNA sample, allowing its stabili-
sation onto a solid support. Subsequently, assay oligonucleotides were hybridized 
with the activated DNA. Each SNP locus had 3 specific oligonucleotides. Two of 
these were specific to the allele, and one bound slightly downstream of the SNP 
site, known as the locus-specific oligonucleotide. After hybridization, the allele-
specific and locus-specific oligonucleotides were extended and ligated, providing 
the template for PCR using universal primers incorporated into the oligonu-
cleotides. The single-strand DNA products were then hybridised to a comple-
mentary bead on an array chip using the locus-specific sequence. The beads 
were arranged in fibre-optic array bundles. Because the universal primers were 
labelled with Cy3 and Cy5, hybridization of the products onto the BeadChip 
allowed the fluorescence to be read by a specifically designed scanner. 
Samples with call rates under 0.99 were discarded from further analysis. Image 
data were analysed using Beadstudio 3 (Illumina, San Diego, USA) and LOR 
was called when at least 10 consecutive markers displayed homozygous patterns. 
CHAPTER 3. 67 
3.15 Image Based Cytometry 
Image based cytometry allows assessment of the DNA content of cells and , 
therefore estimation of ploidy. While flow cytometry can be used with large 
quantities of cells (typically more than 20 000), image-based cytometry allows 
assessment of a small number of cells from paraffin-derived samples. However, 
comparative studies have shown that there is excellent concordance of around 
90% between the two methods [Sasaki et al., 1996a]. 
Needle-dissected samples were prepared as follows. The tissue was incubated 
at 3rC with 0.5mg/ml protease, placed on ice, and centrifuged. The pellet 
was re-suspended and cytospun to prepare a monolayer slide, which was incu-
bated in HCI prior to staining with Schiff's solution. The resulting intensity 
of nuclear Schiff's staining was proportional to the DNA content. Slides were 
then dehydrated and mounted in DPX. The slides were then scanned using a 
Zeiss Axioplan microscope, coupled to a high-resolution digital camera. Optical 
density was plotted against number of nuclei by computer software. Contami-
nating fibroblasts and lymphocytes were excluded from analysis based on their 
characteristic nuclear sizes and shapes, and imperfect or overlapping nuclei were 
similarly discarded. 
Integrated optical density histograms were generated using Histogram Drafts-
man 1.4 software (Fairfield Imaging, UK). Aneuploidy was defined as > 10% of 
cells in > 2C fraction. 
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3.16 PCR Conditions and Primers 
Name Sequence Amplicon Annealing 
Size, bp Temp 
MCR IF CAAGCAGTGAGAATACGTCCA 134 55 
MCR1R TTTCTTGGTTAATAGAAGAAACTTTGC 
MCR2F GCCACTTGCAAAGTTTCTTCT 153 55 
MCR2R TGCTTCCTGTGTCGTCTGA 
MCR3F AGTTCATTATCATCTTTGTCATCAGC 177 55 
MCR3R GCAGTCTGCTGGATTTGGTT 
MCR4F GATCCTGTGAGCGAAGTTCC 149 55 
MCR4R CTGAGCACCACTTTTGGAGG 
MCR5F AGAATCAGCCAGGCACAAAG 173 55 
MCR5R GCAATCGAACGACTCTCAAA 
MCR6F CACTATGTTCAGGAGACCCCA 149 55 
MCR6R TGGAAGATCACTGGGGCTTA 
MCR7F GTGAACCATGCAGTGGAATG 135 55 
MCR7R ACTTCTCGCTTGGTTTGAGC 
MCR8F AAACACCTCCACCACCTCCT 145 55 
MCR8R AGCATCTGGAAGAACCTGGA 
MCR9F CCTAAAAATAAAGCACCTACTGCTG 165 55 
MCR9R CACTCAGGCTGGATGAACAA 
MCR 10F ACATTTTGCCACGGAAAGTA 158 55 
MCR lOR GGCTGCTCTGATTCTGTTTC 
MCR 11F CAGGAAAATGACAATGGGAAT 168 55 
MCR 11R TGGCATGGCAGAAATAATACA 
MCR 12F GGACCTATTAGATGATTCAGATGATG 148 55 
MCR 12R ACTTGGTTTCCTTGCCACAG 
Table 3.2: APe primers for paraffin tissue 
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Name Sequence Amplicon Annealing 
Size, bp Temp Exon 15A GTTACTGCATACACATTGTGAC 417 55 Exon 15AR GCTTTTTGTTTCCTAACATGAAG 
Exon 15B AGTACAAGGATGCCAATATTATG 346 55 Exon 15BR ACTTCTATCTTTTTCAGAACGAG 
Exon 15C ATTTGAATACTACAGTGTTACCC 
Exon 15CR CTTGTATTCTAATTTGGCATAAGG 
399 55 
Exon 15D CTGCCCATACACATTCAAACAC 382 55 Exon 15DR TGTTTGGGTCTTGCCCATCTT 
Exon 15E AGTCTTAAATATTCAGATGAGCAG 420 55 Exon 15ER GTTTCTCTTCATTATATTTTATGCTA 
Exon 15F AAGCCTACCAATTATAGTGAACG 428 55 Exon 15FR AGCTGATGACAAAGATGATAATG 
Exon 15G AAGAAACAATACAGACTTATTGTG 382 55 
Exon 15 GR ATGAGTGGGGTCTCCTGAAC 
Exon 15H ATCTCCCTCCAAAAGTGGTGC 420 55 
Exon 15 HR TCCATCTGGAGTACTTTCTGTG 
Exon 151 AGTAAATGCTGCAGTTCAGAGG 508 55 
Exon 15 IR CCGTGGCATATCATCCCCC 
Exon 15 J CCCAGACTGCTTCAAAATTACC 317 55 
Exon 15 JR GAGCCTCATCTGTACTTCTGC 
Exon 15 K CCCTCCAAATGAGTTAGCTGC 352 55 
Exon 15 KR TTGTGGTATAGGTTTTACTGGTG 
Table 3.3: APC primers for fresh frozen tissue 
Name Position Sequence Label Amplicor Annealing 
relative Size, Temp 
to bp 
APe 
D5S1385 3' AGCCTGTGTGCAACAGAAGTGA FAM 128 55 
D5S1385R GAAGGTGAACAAAGGACATGAAC 
D5S346 3' ACTCACTCTAGTGATAAATCGGG HEX 96 55 
D5S346R AGCAGATAAGACAGTATTACTAGTT 
D5S82 5' ATCAGAGTATCAGAATTTCT HEX 169 55 
D5S82R CCCAATTGTATAGATTTAGAAGTC 
D5S299 5' GCTATTCTCTCAGGATCTTG FAM 156 55 
D5S299R GTAAGCCAGGACAAGATGACAG 
D5S1965 5' TGTCCCGTTGATAAAAATTACTGCG FAM 230 55 
D5S1965R GTGTCTGGGATTTCCTACGCAATG 
Table 3.4: APC LOH primers 
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I Name I Sequence Label 
APe exon GCCAGACAAACACTTTAGCCATTA 
14 forward 
APe exon TACCTGTGGTCCTCATTTGTAGCTAT 
14 reverse 
APe exon CTGGACACATTCCGTAATATCCCACCTCC 5'-FAM, 
14 probe 3'-
TAMRA 
Alb exon TTGCATGAGAAAACGCCAGTA 
12 forward 
Alb exon GTCGCCTGTTCACCAAGGA 
12 reverse 
Alb exon TCTGTGCAGCATTTGGTGACTCTGTCAC 5'-VIC, 
12 probe 3'-
TAMRA 
Table 3.5: APe RTqPCR primers [Sieber et al., 2002b] 
I Label I I Name I Sequence 
151F GGATGTAATCAGACGACACAGG HEX 
151R GCAGTCTGCTGGATTTGGTT 
102F CAGACGACACAGGAAGCAGA HEX 
102R TGGAACTTCGCTCACAGGAT 
Table 3.6: APe 5bp deletion primers 
Amplicon 
Size, bp 
151 
102 
70 
Amp 
Size bp , 
91 
70 
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24F (PMS2del) 
32R (PMS2del) 
PMS2ex6F 
PMS2ex6R 
PMS2ex7F 
PMS2ex7R 
PMS2ex8F 
PMS2ex8R 
PMS2ex9F 
PMS2ex9R 
PMS2ex10F 
PMS2ex10R 
PMS2ex11.1F 
PMS2ex11.1R 
PMS2ex11.2F 
PMS2ex11.2R 
P MS2ex11.3F 
P MS2ex11.3R 
PMS2ex12F 
PMS2ex12R 
PMS2ex13F 
PMS2ex13R 
PMS2ex14F 
PMS2ex14R 
PMS2ex15F 
PMS2ex15R 
I Sequence 
CCATCTGGAGCTCGTTCTGT 
GATGTGGTTGAACTTCTAAATTTTT 
GAGAACCTTGCGTTGGATGT 
GTTGAAGTAACCGGCCATCA 
AAGAAAACAGATTAAGTCCACTCTGTC 
TGTAGTTCTCTTGCCAGCAATC 
TCCCTTTCACTCTGGAATCCT 
CCCGAGCTCCACGTAAACT 
GGCTGGGAACATTTGTCATTTA 
CTCATTCCAGTCATAGCAGAGC 
AGCCTAGGCGACAGAGTGAG 
GCTTTAGAAGCTGTTTGTACACTG 
GTTTTATTTTGAACATTGAACTGTG 
GCACCTGAAGTGCTAGAAGACAG 
AGGACAGAAAAGGGGTATGCT 
GCTTTGTGTTTGGGGTTGC 
AAGATACCGGATGTAAATTTCG 
CTGCAGTGAGCCAAGATCA 
TAGCCTGGGTGACAGAACGA 
TTGGCCTCTATTAGATCTTCAA 
ACACTTAGCTGAGTAGTGTTGTTATTT 
ATGGGGTTTCACCATGTTAGCCA 
TCCCAAAGTGCAGGGATTAC 
GCTGAGACCTTCCTCGACTG 
AGAGCTGCCATTCTGACG 
AAAACCAATTATTCCATACAGTGACTC 
Table 3.7: PMS2 primers 
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Amplicon 
Size bp , 
450 
283 
196 
243 
225 
292 
381 
392 
470 
400 
382 
358 
234 
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AXINl IF 
AXINl lR 
AXIN12F 
AXIN12R 
TCF4 F 
TCF4 R 
Beat ex3 F 
Beat ex3 R 
TGFBR2 F 
TGFBR2 R 
BAT25 F 
BAT25 R 
BAT26 F 
BAT26 R 
KRASF 
KRAS R 
BRAF F 
BRAFR 
APCdinueF 
APCdinueF 
I Sequence 
TGTTTAGTGCCCAAAGCACA 
CAGGGTCCTGGGTGAACA 
CCACCTGTTCACCCAGGAC 
CCCTGCCTCAACCTA 
CTCTCTCCCTTGGCATCTGT 
CTGAAGAGGGTGGGCTGAG 
GAACCAGACAGAAAAGCGGCTG 
ACTCATACAGGACTTGGGAGG 
CTTTATTCTGGAAGATGCTGC 
GAAGAAAGTCTCACCAGG 
TCGCCTCCAAGAATGTAAGT 
TCTGGATTTTAACTATGGCTC 
TGACTACTTTTGACTTCAGCCAGT 
TTCTTCAGTATATGTCAATGAAAACA 
TTTGATAGTGTATTAACCTTATG 
TATTAAAACAAGATTTACCTC 
TCATAATGCTTGCTCTGATAGGA 
GGCCAAAAATTTAATCAGTGGA 
ATTTTTCAGTGCCAGCTCCT 
TCATTCATTGCATGTCTATGCTC 
Table 3.8: Primers used in Chapter 8 
I Label I 
FAM 
HEX 
FAM 
FAM 
FAM 
FAM 
72 
Amplieon 
Size bp , 
150 
150 
123 
154 
73 
124 
154 
210 
224 
100 
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Name Sequence Amplicon Annealing 
Size, bp Temp Exon1.1 CAGCGGCCTCTCGTCTACT 187 64 Exon1.1 R: CTCGTCAGGGGGCTGCTC 
Exon 1.2 GAGCAGCCCCCTGACG 141 55 Exon 1.2 R CGCCACGATGAGGAAA 
Exon 1.3 CGACTGCCGTTTCCTCAT 190 55 Exon 1.3 R CTTACGGGTGACGCTGT 
Exon 1.4 CACCCTCAGGTCAACATCTACA 131 55 Exon 1.4 R TGGAAGGCGAGGGTGAT 
Exon 1.5 CCTCGCCTTCCAGGAC 126 64 Exon 1.5 R TTGCCGGAGCGGAACTC 
Exon 1.6 AGTTCCGCTCCGGCAAG 206 60 Exon 1.6R GCAGCGTCCCCACTCAC 
Exon 2 CCCAAGGCCTCCTCTCTG 196 60 Exon 2 R TGGGAGCGAGGCACTCA 
Exon 3 CACCTTGCCTGGGCTACC 191 64 
Exon 3 R GGAACTGGGGCTTTAGTGTT 
Exon 4 CCCCTCTTTCTGGGACAG 206 60 
Exon 4 R CTGCCCACAGGAGAACCT 
Exon 5 CCCCAGACTCCACAGG 216 60 
Exon 5 R GCCGGCCCTAGTACTCC 
Table 3.9: FSCN primers 
Name Sequence Label Amplicon Annealing 
Size, bp Temp 
D17S786 F TACAGGGATAGGTAGCCGAG HEX 140 60 
D17S786 R GGATTTGGGCTCTTTTGTAA 
D17S1832 F ACGCCTTGACATAGTTGC FAM 160 60 
D17S1832 R TGTGTGACTGTTCAGCCTC 
D18S46 F CCAATGTGACAGTTCTTTGGAA HEX 160 60 
D18S46 R ATTGGGCATGGGGAAAATA 
D18S69 F TCCTCTTTCTCTGACTCTGACCTT HEX 142 60 
D18S69 R GGTGGGATGCGTGAATTTTA 
TP53ex5 F TCTGTCTCCTTCCTCTTCCTACA 245 55 
TP53ex5 R AACCAGCCCTGTCGTCTCT 
TP53ex6 F CAGGCCTCTGATTCCTCACT 185 60 
TP53ex6 R CTTAACCCCTCCTCCCAGAG 
TP53ex7 F CTTGGGCCTGTGTTATCTCC 161 60 
TP53ex7 R GTGTGCAGGGTGGCAAGT 
TP53ex8 F GCCTCTTGCTTCTCTTTTCC 191 60 
TP53ex8 R GCTTCTTGTCCTGCTTGCTT 
Table 3.10: Primers used in Chapter 9 
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3.17 List of Solutions 
Citrate 21g citric acid, 8g NaOH pellets, 10L dH20, made to 
buffer pH6 with sodium hydroxide 
8g NaCI, 0.2g KCI, 1.44g Na2HP04, 0.24g KH2P04 , 
PBS 800ml dH20, adjusted to pH 7.2 with HCI, made up to 
1L with dH20 
Proteinase 5ml of Promega lOX Taq polymerase reaction buffer 
kinase without MgCI2, in 45ml dH20, 10.2 ml Qiagen PK 
solution solution added. Stored at -20C . 
TBE 
54g Tris base (Sigma), 27.5g boric acid powder (BDH), buffer 
solution, 20ml 0.5M EDTA pH 8, made up to 1L with dH20 and 
autoclaved 5X 
Propidium 1mg propidium iodide (Sigma), 20 ml dH20, stored at 
iodide -4C 
Pepsin 
0.25mg pepsin (Sigma), 50ml 0.9% NaCI pH 1.5, stored 
solution 
at -20C 0.5% 
RPMI 0.25% ampicillin, 0.01% streptomycin, 20% fetal bovine 
solution serum, phytohaemagglutinin, concanavalin A 
Carnoy's 6 parts absolute ethanol, 3 parts chloroform, 1 part 
Solution glacial acetic acid 
Clark's 3 parts absolute ethanol, 1 part glacial acetic acid Fluid 
Table 3.11: List of solutions 
Part I 
Adenoma Initiation and 
Progression in Familial 
Adenomatolls Polyposis 
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Chapter 4 
The Influence of Colonic Location 
on Somatic APe Inactivation 
4.1 Introduction 
In FAP, the distribution of colonic polyps is not uniform throughout the colon. 
Patients with a codon 1309 germline mutation usually have dense rectal polypo-
sis, while rectal sparing is observed in patients with more proximal mutations of 
APC[Ficari et al., 2000]. This variation in polyp density has important clinical 
implications in FAP, especially in the decision between ileorectal anastomosis 
and restorative proctocolectomy. However, the clinical finding that colonic site 
influences tumorigenesis pertains also to sporadic colorectal cancer, where as in 
FAP, left-sided tumours predominate [Keating et al., 2003]. 
The right (proximal) colon can most conveniently be considered to comprise the 
caecum, ascending colon, hepatic flexure and transverse colon, whereas the left 
(distal) colon comprises the splenic flexure, descending colon, sigmoid colon and 
rectum. The right and left sides of the colon differ in terms of their environmen-
76 
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tal milieu (lumenal contents, bacterial colonization), embryological origin (mid-
versus hindgut) and function (water/salt homeostasis and bile acid absorption 
[van Gorkom et al., 1997]). In light of this, it is unsurprising that epidemiological 
studies similarly find variations between right- and left-sided colon neoplasia, in 
terms of aetiological risk factors [Oh et al., 2008], adenoma aggressiveness [Nusko 
et al., 1997] and cancer prognosis [Park et al., 1999, Sjo et al., 2008]. 
Laboratory studies thus far have suggested that colonic location can affect crypt 
cell turnover and function. some examples are as follows: apoptosis was found 
to be reduced in the mucosa of the left colon[Anti et al., 2001, Liu et al., 1999]: 
production of TGF-beta1, an anti-tumorigenic factor, has been found to decrease 
from the right colon to the rectum in mucosa from normal controls [K ushiyama 
et al., 2000]. Cryptal mitoses were shown to decrease linearly from caecum to 
the rectum in controls and in patients with FAP [Mills et al., 2001]. 
Genetic studies have found different pathways of carcinogenesis between left- and 
right-sided colorectal cancers, with some suggesting that right-sided cancers of-
ten develop from hyperplastic polyps rather than adenomas [Baker et al., 2004]. 
Right-sided colorectal cancers tend to show microsatellite instability, high levels 
of CpG island methylation, global hypomethylation, near-diploid DNA content, 
infrequent loss of heterozygosity (LOR) and BRAF mutations. Left-sided colo-
rectal cancers tend to be polyploid and aneuploid, and to acquire KRAS2 and 
TP53 mutations [Deng et al., 2008]. Somatic APe mutations may also be less 
frequent in proximal colorectal cancers [Liichtenborg et al., 2004]. 
As discussed in Chapter 1, tumour initiation in FAP occurs after somatic mu-
tation of the germline wild type APe allele. The "second hit" can occur either 
by LOR, usually by mitotic recombination where the wild-type allele mutates 
to resemble the mutated allele, or more often by a protein-truncating mutation. 
APe regulates the Wnt pathway responsible for control of cell proliferation in 
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the colonic crypt. The locations of the APe mutations depend on the number 
of 20-amino-acid beta-catenin binding and degradation repeats (20AARs) that 
remain in the truncated protein. In the colorectum, most FAP tumours retain 
a total of two (or one) 20AARs; this phenomenon is also observed in sporadic 
colorectal cancers with APe mutations. In the duodenum, it is more common 
for tumours to retain four (or three) 20AARs [Groves et aI., 2002a]. It is likely 
that the number of 20AARs modulates the level of Wnt signalling that results 
from APC inactivation [Lamlum et al., 1999, Albuquerque et al., 2002, Crabtree 
et al., 2003]. 
Molecular studies investigating the influence of intestinal site on tumour initi-
ation have thus far focused on differences in the mutational spectrum of APe 
between small and large bowel adenomas [Groves et al., 2002a, Crabtree et al., 
2003, Will et al., 2008b]. Overall, colonic polyps differ from duodenal polyps, 
retaining fewer 20-amino-acid repeat regions in the mutant APC proteins [Al-
buquerque et al., 2002, Crabtree et al., 2003]. This indicates that small versus 
large bowel environment - broadly defined - influences which mutations result in 
a selective advantage and hence tumour growth. However, studies have not yet 
looked for evidence that the mutational spectrum of APe varies within the large 
bowel. Therefore, the aim of this study is to investigate whether there is evi-
dence for intra-colonic variation in tumour-initiating APe mutations, and hence 
that the optimal level of Wnt signalling for tumorigenesis varies with location 
in the large bowel . 
4.2 Methods 
Patients with FAP were identified from the St Mark's Hospital Polyposis Reg-
istry. Tissue specimens were chosen only if a clear and specific colonic site of 
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origin was documented in the pathology report. Sample collection aimed to 
sample similar numbers of lesions from each location around the large bowel 
rather than to collect in proportion to site-specific incidence. Adenomas were 
restricted to 1-2mm diameter and mild dysplasia in order to ensure morpholog-
ical homogeneity. No adenoma had notably greater non-epithelial component 
than any other. These selection criteria proved unexpectedly strict, and resulted 
in the identification of only 127 formalin-fixed paraffin-embedded colonic ade-
nomas from five individuals with germ line mutations at APC codon 1309 that 
leaves one intact 20AAR in the protein, plus 41 adenomas from three patients 
with a mutation proximal to the first 20AAR at codon 1265 (2 patients with a 
germ line mutation in exon 6 and the other with a mutation in exon 13). Table 
4.1 shows the patient and sample data. 
Patient Germline Ascending Transverse Descending Rectum 
Mutation 
1 1309 5bp del 9 (-) 8 (-) - (-) 18 (-) 
2 1309 5bp del 8 (1) 7 (1) 3 (1) 2 (1) 
3 1309 5bp del 6 (2) 9 (1) 6 (1) - (-) 
4 1309 5bp del 8 (1) 8 (1) - (-) 8 (1) 
5 1309 5bp del - (-) - (1) 16 (1) 11 (1) 
6 ex 6 cd 233 seq 12 (4) 5 (2) 4 (1) 7 (1) 
697 c>t 
7 ex 13 seq 1660 - (-) 2 (-) - (-) 2 (1) 
g>t 
8 ex 6 cd 233 seq 1 (1) 4 (1) 4 (1) - (1) 
697 c>t 
Table 4.1: Patient and sample details 
Samples shown as: laser microdissection (immunohistochemistry). 
DNA was extracted after laser-capture microdissection of adenoma epithelium 
as described in Chapter 3. Extraction for patient 1 was performed by Dr 
S. Leedham. For the codon 1309 mutants, loss of heterozygosity (LOR) was 
assessed using the germline mutation, since the germline mutant and wild type 
alleles could be readily identified on the basis of their size and this method 
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has proven the most reliable for assessing LOR. For the other patients: cases 
with frameshift germ line mutations were not available and therefore reliable 
microsatellite markers (D5S346, D5S82 and D5S1385) close to APC were used 
to score LOR. Cross-comparison between these methods has previously shown 
consistency of >80% [Lamlum, unpublished]. 
In addition to analysis of epithelium from whole adenomas, laser microdissection 
of individual crypts was performed for a total of 8 adenomas, 2 with LOR and 
2 without from the ascending colon and 2 with LOR and 2 without from the 
rectum. DNA from each of 3-4 crypts per adenoma was analysed for LOR. 
Immunohistochemistry was performed on samples shown in Table 4.1, as de-
scribed in Chapter 3. They were stained for beta-catenin in order to provide 
a measure of wnt pathway activation. Caspase-3 was used to assess apoptosis. 
Ki-67 was used to assess proliferation. Caspase-3 and Ki-67 immunostaining 
was performed by Mr G. Elia, histopathology unit. Scoring was performed by a 
single observer (OW). For each patient, staining positivity of 2000 cells (approx-
imately 10 longitudinally-orientated crypts) from an average of four separate 
lesions in each colonic area was assessed. 
Statistical analysis was performed by Professor Ian Tomlinson. 
4.3 Results and Discussion 
4.3.1 Whole Polyp Analysis 
The codon 1309 germline APC mutations left a single 20AAR (lx20AAR) in the 
mutant protein whereas the other patients had more proximal mutations that 
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left zero 20AARs (Ox20AARs). Results for these two patient groups are given 
in Tables 4.2 and 4.3 below. 
Patient Ascending Transverse Descending Rectum 
1 2/9 3/8 - 13/18 
2 1/8 1/7 1/3 2/2 
3 1/6 4/9 0/6 -
4 2/8 2/8 - 5/8 
5 - - 7/16 5/11 
Total for 6/31 10/32 8/25 25/39 
1x20AAR 
patients 
Table 4.2: Results for patients with 1309 germ line mutation 
Results shown as: polyps with LOR/total number polyps analysed 
I Patient I Ascending I Transverse I Descending I Rectum I 
I~ 
Total for 5/13 7/11 3/8 2/9 
Ox20AAR 
patients 
Table 4.3: Results for patients with Ox20AAR germline mutation 
Results shown as: polyps with LOR/total number polyps analysed 
On the basis of previous data, we expected a higher frequency of LOR in the 
former group's polyps based on tumours unselected for location in the large 
bowel: previous studies have found LOR in around 60% of polyps from patients 
with a 1309 mutation [Albuquerque et al., 2002]). Overall, however, the rate of 
LOR was similar at around 40% in the two patient groups. Rowever, there was 
marked variation by site. The rate of LOR in rectal polyps was much higher for 
patients with a 1309 germline mutation compared with the "null allele" group. 
This latter group had relatively higher rates of LOR in the proximal large bowel, 
especially the transverse colon. 
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In the absence of evidence of LOR heterogeneity among patients (P=0.17 for 
Ox20AAR mutations, P=0.18 for 1x20AAR mutations), we used ANOVA to test 
whether there was any association between the frequency of LOR, site of lesion in 
the colon (caecum/ascending, transverse, descending and sigmoid, rectum) and 
germ line mutation (lx20AAR versus Ox20AAR). Treating location as a continu-
ous variable, there was a significant association between site of lesion and LOR 
(logistic regression analysis, z=2.81 P=0.0050). A trend test confirmed a ten-
dency towards a gradient of LOR from the highest frequency in the rectum to 
the caecum/ascending colon (z=2.80, P=O.Ol). This finding resulted entirely 
from the 1x20AAR case data (z=3.79, P=0.00015), with the Ox20AAR cases 
showing only a non-significant tendency to an LOR gradient in the opposite 
direction (z=-0.93, P=0.35). 
4.3.2 Single Crypt Analysis 
Since FAP polyps can be polyclonal, the above LOR data were checked to ensure 
consistency with the predominant findings from individual crypt analysis after 
microdissection. Results are shown in Table 4.4 below. In all cases, whole polyps 
scored as having LOR overall had >50% of individual crypts with LOR, whereas 
all those polyps without LOR had <33% individual crypts without LOR. 
Patient Germline Anatomical site Whole-polyp Crypts with 
mutation LOR LOR/total 
analysed 
1 1x20AAR Ascending + 3/4 
2 1x20AAR Ascending - 0/3 
3 1x20AAR Descending + 3/4 
4 1x20AAR Descending - 0/4 
5 Ox20AAR Ascending + 2/4 
6 Ox20AAR Ascending - 1/3 
7 Ox20AAR Descending + 2/3 
8 Ox20AAR Descending - 1/4 
Table 4.4: Results of individual crypt analysis 
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4.3.3 Immunohistochemistry 
Although both beta-catenin and caspase-3 were expressed more strongly in tu-
mours than normal tissue, there was no significant variation with colonic location 
(N=8 for each; for beta-catenin, P=O.56 for tumours and P=O.38 for normal; 
for caspase-3, P=O.083 and P=O.56 respectively, Wilcoxon test). Data shown in 
Table 4.5 below. 
Ki-67 expreSSIOn was stronger in adenomas than normal tissue (P=O.006, 
Wilcoxon test), particularly in tumours from patients with a 1x20AAR mutation 
(P=O.026, Wilcoxon test). Moreover, Ki67 expression was present in a gradient 
along the colon from caecum/ascending colon (highest) to rectum, both in tu-
mours (z=2.75, P=O.0059, trend test) and normal tissue (z=4.09, P=O.000043, 
trend test). ANOVA showed that each of the associations with Ki-67 status 
was independent (details not shown). Ki-67 results are shown in Table 4.5 and 
Figures 4.1 and 4.2 below. 
-Site 
Normal Ascending 
Tissue 
Transverse 
Descending 
Rectum 
Adenoma Ascending 
Transverse 
Descending 
Rectum 
-~- ~-
- -
Ki 67 1309 Ki67 Caspase-3 Caspase-3 
Ox20AAR 1309 Ox20AAR 
13.7 11.5 1.00 0.34 
12.1 8.7 0.98 0.13 
6.8 10.4 0.57 0.65 
2.8 4.7 0.12 0.92 
42.7 29.5 5.58 0.70 
42.2 24 8.70 0.34 
33.6 10.4 2.40 0.73 
18.5 4.7 0.91 3.37 
'----- -~ 
-
~- ---
Table 4.5: Immunohistochemistry results 
Results given as percentage positivity. 
Beta-
catenin 
1309 
0.12 
0.39 
0.18 
0.36 
3.34 
3.68 
3.87 
1.18 
-- --~~ 
Beta-
catenin 
Ox20AAR 
0.31 
0.12 
0.30 
0.86 
0.72 
0.61 
0.77 
1.21 
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Figure 4.1: Ki67 immunohistochemistry results 
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Figure 4.2: Ki-67 expression in polyps of patient with codon 1309 APe mutation 
Relatively frequent nuclear expression is seen in tissue sections from codon 
1309 (1x20AAR) patient's adenomas; expression more marked in ascending 
colon (left) than rectum (right). 
4.3.4 Conclusions 
In summary, our data show that there exist differences within the large bowel 
in the type of "second hit" found in FAP polyps. Patients with germline codon 
1309 APe mutations (and, by extension, other patients with mutations that 
leave 1x20AAR) have higher frequencies of LOR as tumour location becomes 
more distal. This association is not present in patients with mutations that 
leave Ox20AARs. These findings may help to explain the preponderance of 
rectal polyps seen in many FAP patients with codon 1309 mutations. Some-
what surprisingly, we did not find a higher rate of LOR overall in patients with 
1x20AAR germline mutations, in spite of previous strong associations in this 
regard. In part , this may reflect the relative enrichment of our sample for right-
sided tumours. Additionally, we cannot exclude differential effects of the use of 
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frameshift mutations and microsatellites to score LOR; although these method-
ological differences should not have a substantial effect and, crucially, should 
not affect associations between LOR and polyp location, they may influence 
overall LOR frequencies in one patient group. Despite these potential problems, 
our data show overall that the optimal combination of APe mutations varies 
with the location in the large bowel. Patients with lx20AAR germline APe 
mutations acquire "second hits" by LOR much less often in the proximal than 
distal colon compared with patients with Ox20AAR mutations. The underlying 
explanation of this difference is unclear, but others and we have demonstrated 
differences in crypt dynamics that are a potential cause. This study emphasises 
that the mutations selected in colorectal tumorigenesis are dependent on the 
local environment in which they arise. 
Chapter 5 
A Longitudinal Study of Ileoanal 
Pouch Neoplasia 
5.1 Introduction 
Modern management of FAP has resulted in more patients undergoing prophy-
lactic colectomy, and fewer early deaths from colorectal cancer. As discussed in 
Section 1.3, the ileoanal pouch procedure removes nearly all large bowel mucosa 
with its attendant cancer risk, and thus has become favoured over the ileorec-
tal anastomosis for patients needing colectomy, particularly in those with dense 
rectal polyposis or a germline mutation predictive of this. The pouch procedure 
has been increasingly performed since the 1980s, both as a primary procedure 
and also in patients who previously had an IRA but require rectal excision due 
to neoplasia. Therefore, there is a growing cohort of patients with longstanding 
ileoanal pouches, many of whom are gradually developing pouch polyposis as 
time passes. Some patients have already required pouch excisions at St :l\Iark"s 
Hospital (see Figure 5.1). 
88 
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Figure 5.1: Pouch excision specimen 
Photograph taken by author, with patient permission. The anus is on the left , 
and the neoterminal ileum is on the right of the specimen. The mucosal 
surface of the pouch was studded with 1-2mm polyps , and there was a 4cm 
tubulovillous lesion. The patient had an end stoma created from the remaining 
small bowel. Moderate and severe dysplasia was confirmed on histological 
examination of this specimen, but there was no definite invasion. 
Published studies investigating pouch adenoma development (see Table 5.1) have 
thus far been based on cross-sectional, single-endoscopy data. Overall , most of 
these studies show an incidence of around 60%, although they differ widely in 
confirmatory histological diagnosis, the inclusion of microadenomas , and the use 
of chromendoscopy. As discussed in Section 1.3, pouch or patient age has been 
found to be associated with pouch polyp development , but no correlation has yet 
been found with germline mutation. As shown in Table 5.1, there are confiicting 
published results concerning an association with the severity of upper duodenal 
polyposis. 
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Study type 
N umber of Patients 
Time since pouch (mean) 
No. of endoscopies 
Screening method 
Dye spray 
Microadenoma incl 
Unrelated factors 
Related factors 
Overall frequency 
Wu et al. [1998] Thompson-
Fawcett et al. 
[2001] 
Prospective Prospective 
26 33 pouch 
21 controls 
(terminal 
ileostomy) 
11-156 months 1-19 years (7) 
(66) 
single single 
rigid and flexible 
flexible 
no yes 
none yes 
duodenal/ colonic duodenal 
polyps burden, 
germline 
mutation 
pouch age pouch age 
42.3% 60% 
Parc et al. Polese and 
[2001] Keighley [2003] 
Prospective Retrospective 
85 30 
31-139 months 4 months-12y 
(85) (6y) 
single single 
flexible rigid 
no no 
yes no 
germline pouch 
mutation metaplasia, 
adenomas in 
resection 
margins, hand-
sewn/ stapled 
duodenal and pouch age 
ampullary 
polyps, 
pouch age 
35% (7, 35 and 7% 
75% 
at 5, 10, 15y 
pouch) 
Parc et al. 
[2004] 
Prospective 
54 endoscopies 
11-18years 
(14.6) 
single 
flexible 
no 
yes 
n/ a 
n/ a 
53% 
Groves et al. 
[2005] 
Prospective 
60 
1-17 years (6) 
single 
flexible 
10 of 60 
yes 
duodenal/ colonic 
polyps, primary 
pouch, 
pouch 
construction, 
germline 
mutation 
Patient age, 
pouch age 
57% 
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In clinical practice, pouch surveillance and management would best be tailored 
according to an evidence-based understanding of risk factors for pouch adenoma 
development (e.g. germline mutation, type of pouch surgery, possible modifier 
genes, and the severity of duodenal polyposis) and the natural history of ade-
noma progression in the pouch (e.g. the pattern of increasing polyp density, and 
the risk of malignancy). 
This longitudinal study therefore investigated pouch adenoma development over 
time in individual patients, by reviewing yearly surveillance endoscopy episodes 
performed as part of the standard surveillance protocol at St Mark's Hospital. 
By correlating these endoscopy findings with operative, clinical and genetic data, 
this study aimed to better describe the process of pouch polyp development, and 
identify factors contributing to the risk of pouch neoplasia. 
5.2 Study Population 
Two hundred and six patients from the St Mark's Pouch Database were identi-
fied. This database was initiated by Paris Tekkis and contained both prospec-
tively and retrospectively collected data on ileoanal pouch procedures performed 
for FAP between 1978 and 2004. One hundred and forty patients attended for 
endoscopic follow-up at St Mark's Hospital and were included in the study. Fifty-
nine patients were excluded due to absent follow-up records due to emigration, 
or surveillance outside the National Health Service. A further seven patients 
had died: three from FAP-related disease (two duodenal malignancies, and one 
of lung metastases from rectal cancer). 
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5.3 Methods 
For each patient, records were reviewed from the following sources: medical 
notes, endoscopy computer database records, St Mark's Hospital Polyposis Reg-
istry family files, and pathology reports. 
Patient data collected included age, gender, and genotype. Surgical data 
recorded included date of pouch procedure, whether primary procedure or con-
version from IRA, and surgical technique (including pouch configuration, and 
whether handsewn or stapled anastomosis as discussed in Section 1.3). En-
doscopy data included timing of endoscopy (age of pouch and age of patient 
at each endoscopy), polyp location, number and size, and histology. The most 
recent Spigelman stage at each endoscopy was also calculated using the scoring 
system given in Table 5.2. 
Polyp Number 
Polyp Size 
Histology 
Dysplasia 
I 
Points to be 
Allocated 
1-4 
1-4mm 
Tubular 
Adenoma 
Mild 
5-20 >20 
5-10mm >lOmm 
Tu bulovillous Villous 
Adenoma Adenoma 
Moderate Severe 
Table 5.2: Spigelman scoring system for duodenal polyposis 
The above system assigns a Spigelman stage based on the number on points 
scored, and a management plan is instituted based on the stage. Patients with 
stage I duodenal polyposis (0-4 points) undergo 5-yearly 
oesophagogastroduodenoscopy. Stage II patients have 3-yearly surveillance. 
Patients assigned to stage III (7-8 points) have yearly surveillance, and are 
considered for endoscopic therapy and chemopreventative agents. Stage IV 
patients may be offered surgery (pylorus-preserving pancreaticoduodenectomy, 
pancreas-preserving duodenectomy, or a Whipple's procedure if invasion is 
suspected) . 
Data collection and analysis was undertaken in collaboration with Alexander 
van Roon. Statistical analyses included Kaplan-Meier survival analysis and hi-
erarchical regression analysis, performed by Paris Tekkis. consultant surgeon, 
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and Gavin Kelly, biostatistician at Cancer Research UK. Analysis for genotype 
correlations was performed by grouping the germline mutation by remaining 
20AAR in the germline, as described in Chapter 6. 
5.4 Results 
There were 767 individual endoscopy records from 140 patients available for 
review. The median follow-up time after ileoanal pouch procedure was 10.3 years 
(range 0.7-24.5). Patient characteristics and operative techniques are given in 
Table 5.3. 
Male gender 76 (54 %) 
Genotypes grouped by 20AARs 
- 0 67% 
- 1 28% 
- 2 7% 
-3+ 3% 
- unknown 35% 
Age at RPC in years, median (range) 31 (9-67) 
Prior ileorectal anastomosis 63 (45 %) 
J Reservoir 78 (56 %) 
Anastomosis: handsewn with mucosectomy 69 (49 %) 
Table 5.3: Patient characteristics 
5.4.1 Incidence of Dysplasia 
For all patients over the study period, the overall risk of pouch body polyps 
was 59%. Cumulative adenoma-free survival was calculated using Kaplan-Meier 
survival analysis (see Figure 5.2). The median adenoma-free survival in the 
pre-pouch ileum (PPI) , pouch body, and anal transitional zone (ATZ) was 10.1 
7.2 and 8.1 years respectively, with 83%, 18% and 41% of patients relnaining 
polyp-free at each site at 20 years. 
CHAPTER 5. 
8 
Kaptan-Meier survival estimates, by Zone 
10 
..... 
ci 
o 
10 Media polyp-
o free survival: 7.2 yrs 
10 
N 
o 
o 
o 
ci 
Log rank test, p <: 0.001 
o 5 
10.1 yrs 83% 
B.1 yrs 
41% 
8% 
10 15 20 
PPI 
ATZ 
Body 
25 
anaJy9s time (years after pouch surgery) 
Zone=PPI Zone=Bcdy I 
Zone=ATZ 
94 
Figure 5.2: Kaplan-Meier curve showing cumulative polyp-free survival 
PPI: pre-pouch ileum, ATZ: anal transition zone , body: ileoanal pouch body 
Seventy-six patients had more than 10 years follow up. In these 76 patients , 
there were approximately equal distributions of patients with no polyps (36%), 
fewer than 10 (35%) and more than 10 polyps (29%). 
Figure 5.3 shows the pattern of pouch adenoma development for 17 patients who 
had more than 10 polyps and 6 endoscopies, suggesting that for some patients , 
there is an inflection point after which pouch adenomas exponentially increase. 
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Figure 5.3: Pattern of pouch adenoma development 
A: Polypectomy B: Pouch excision 
5.4.2 Cancer Risk in the Ileoanal Pouch 
-- -
20 
Moderate or severe dysplasia was detected in 19% of pouch body polyps, with a 
maximum size of 40mm. In contrast, moderate or severe dysplasia was present 
in 11% of polyps arising in the pre-pouch ileum, and 29% of polyps in the 
anal transition zone. There was no statistical correlation between patient age or 
pouch age and the development of moderate or severe dysplasia, and one patient 
developed moderate dysplasia at the age of 20 years. The presence of moderate 
or severe dysplasia was not significantly correlated with overall polyp burden. 
Three patients developed large tubulovillous adenomas with moderate dysplasia 
after 7, 11 and 19 years respectively, and one had uncontrolled pouch body 
polyposis with severe dysplasia after 19 years. A further patient developed an 
adenocarcinoma in the anal transition zone. These five patients required pouch 
excision, indicating an overall risk for excision of 3.6% in this cohort . 
--< 
25 
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5.4.3 Risk factors for Pouch Neoplasia 
Polyp-free survival, average polyp number and maximal polyp number was not 
affected by gender, operative factors, genotype, or pre-operative colonic polyp 
density. There were 17 families where more than one family member was in-
cluded in the cohort. While the average maximum polyp number for all patients 
in this study was 10, there was one notable family with four members who had 
an average of 40 pouch adenomas, perhaps suggesting either a common environ-
mental trigger or an inherited modifier gene. 
Statistically significant associations were found for patient age and time since 
pouch surgery. Using logistic regression, for each year increasing in pouch age, 
there were on average 0.79 extra polyps detected. For each year increasing in 
patient age, 0.13 extra polyps were detected, showing that the age of the pouch 
has relatively more effect on pouch polyp burden than patient age. 
Duodenal polyposis as expressed by Spigelman stage, was found to be signifi-
cantly correlated with number of pouch adenomas. This association is shown 
in Figure 5.4. Multivariate hierarchical regression analysis was performed for 
number of pouch polyps versus Spigelman stage and age, and for number of 
pouch polyps versus Spigelman stage and time since pouch formation. Details 
are shown in Tables 5.4 and 5.5. Spigelman stage III and IV were independently 
associated with greater pouch polyp numbers after the effect of increased follow-
up time was taken into account. Similarly, when patient age was accounted for, 
Spigelman stage IV was independently correlated with increased numbers of 
pouch body polyps. 
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Figure 5.4: Number of pouch polyps related to Spigelman stage and time of 
follow up 
Spigelman Stage Regression 95% Confidence p value 
Coefficient Interval 
I 0.07 - 0.24 - 0.38 0.658 
II 0.2 - 0.10 - 0.50 0.190 
III 0.4 0.03 - 0.78 0.037 
IV l.3 0.65 - l.94 0.000 
Age (years) 
31-40 0.16 - 0.14 - 0.45 0.295 
41-50 0.58 0.24 - 0.92 0.001 
51-60 1.40 0.97 - l.84 0.000 
61-70 l.46 0.83 - 2.08 0.000 
71-80 2.62 l.14 - 4.10 0.001 
Table 5.4: Multivariate hierarchical regression analysis: number of pouch polyps 
vs. S pigelman stage and age 
rho = 0.550. Independent variables: Spigelman stage, age. Dependent 
variable: number of pouch polyps 
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Spigelman Stage Regression 95 % Confidence p value 
Coefficient Interval 
I 0.00 -0.29 - 0.29 0.997 
II 0.09 -0.19 - 0.38 0.515 
III 0.25 -0.11 - 0.61 0.174 
IV 1.16 0.55 - 1.77 <0.001 
Follow-up time 
(years) 
5-10 0.25 0.25 0.004 
11-15 0.63 0.63 <0.001 
16-20 1.54 1.54 <0.001 
21-25 3.05 3.05 <0.001 
Table 5.5: Multivariate hierarchical regression analysis: number of pouch polyps 
vs. Spigelman stage and follow-up time 
rho = 0.560. Independent variables: Spigelman stage, follow-up time after 
ileoanal pouch procedure. Dependent variable: number of pouch polyps 
5.5 Discussion 
This longitudinal retrospective study was of patients at a single institution. 
Although endoscopic reports of polyps were carefully checked against pathol-
ogy results from representative biopsies, overall polyp numbers were counted or 
estimated by many individual endoscopists of varying levels of expertise. In ad-
dition, some experienced endoscopists performed polypectomies. However, since 
every patient was scoped by a number of different endoscopists, no systematic 
bias was introduced into the results. 
This study has shown that the majority of FAP patients develop benign neo-
plasms in the pouch body in the long term. Malignant transformation is rare in 
pouch body polyps, and there were no instances of pouch body malignancy in 
this cohort, although pouch body cancers have been reported in published liter-
ature [Church, 2005]. The 3.6% overall risk of pouch excision in this cohort was 
due to benign but high-risk neoplasia of the pouch body in four of fi\'e patients, 
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rather than of the anal transition zone. This overall risk is much lower than 
that of rectal excision after ileorectal anastomosis, but it is a significant if rare 
long-term complication of the ileoanal pouch: all pouch excision patients have 
had an end ileostomy, avoiding the risk of repeated high-risk neoplasia in a new 
pouch after a redo pouch procedure. 
Therefore, neoplasia arising in residual large bowel mucosa was responsible for 
a single pouch excision in this cohort, and the median polyp-free survival was 
longer in the anal transition zone than in the pouch body. However, moderate 
or severe dysplasia was noted in nearly one third of polyps arising in the anal 
transition zone, compared to 19% of pouch body polyps. Therefore although the 
at-risk surface area of residual large bowel mucosa is very small, a polyp arising 
in this area may be more likely to progress to greater dysplasia or invasion. This 
apparent disparity in aggressiveness between adenomas arising in small versus 
large bowel mucosa will be investigated further in Chapter 7. 
Ideally, pouch surveillance should be tailored to individual risk factors. However, 
this study found that pouch body polyposis could not be predicted by gender, 
genotype, or operative factors. Since this study found instances of moderate 
or severe dysplastic pouch polyps diagnosed in patients of young age, in newly-
created pouches, and in those with a low overall polyp burden, yearly endoscopic 
surveillance for all patients is clinically justified. This study is also the first 
to show that many patients have years of minimal pouch polyposis. with an 
unexpected inflection point after which polyp numbers rise rapidly, shown in 
Figure 5.3. This evidence justifies the same intensity of surveillance even in 
patients with insignificant pouch polyposis after many years. 
While there is no evidence for genotype-phenotype correlation, further research 
into the worst affected families may suggest the presence of other modifier genes 
or environmental exacerbators. These results also show a link between Spigelnlan 
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stages III and IV and pouch polyp burden, a finding which is suggested in only 
one previous study. This may indicate shared aetiological factors implicated in 
small bowel polyposis, which have yet to be identified. 
Chapter 6 
Somatic APe Inactivation in 
Ileoanal Pouch Polyps 
6.1 Introduction 
The previous chapter has demonstrated that pouch body polyposis is a signifi-
cant clinical problem in patients with FAP: 64% of patients have adenomas in 
the ileoanal pouch after 10 years. Polyposis of jejunum and ileum is uncommon 
in FAP (see Section 1.3). In addition, a prospectively-performed study showed 
that the prevalence of macroscopic adenomas in the terminal ileum prior to 
colectomy is close to zero [Groves et al., 2005]. Therefore, there is a striking 
rise in polyp burden when ileum is fashioned into a reservoir as in the ileoanal 
pouch procedure. 
Reasons for the post-operative development of ileoanal pouch polyps remain 
poorly understood. Since pouch body polyposis appears unrelated to genotype 
and colonic polyp burden, but seems associated with the pouch and patient 
age (see Chapter 5), this epidemiological evidence strongly suggests t ha t pouch 
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polyp development may be influenced by local environmental factors. 
This study aimed to investigate this phenomenon further by studying the ge-
netic events initiating ileal pouch adenoma formation. In FAP adenomas of the 
colon and upper gastrointestinal tract, previously published studies have found 
a close relationship between germline and somatic APe mutations, as discussed 
in Section 1.3. The relationship is determined by "just right'~ beta-catenin sig-
nalling in tumour cells, with respect to the remaining 20-amino acid beta-catenin 
binding/degradation repeats (20AARs) in the mutant APC protein (see 1.2.2.3). 
However, the relationship varies, with upper gastrointestinal polyps typically re-
taining three to four 20AARs and colonic polyps retaining one or two. If the 
optimal level of beta-catenin signalling is determined in part by the origin of the 
tissue (i.e. small or large bowel), ileoanal pouch polyps would be expected to 
show a mutational spectrum similar to polyps from the duodenum rather than 
the colon. This study aimed to investigate whether there is any evidence that 
altered mucosal environment influences the expected pattern of APe mutation. 
6.2 Study Population 
FAP patients with an ileoanal pouch were identified from the St Mark's Hos-
pital Polyposis Registry. All patients were undergoing yearly surveillance pou-
choscopy at which biopsies had been taken. Patients with polyps arising near 
the pouch-anal anastomosis were excluded to avoid polyps arising in rectal cuff 
mucosa. The germ line APe mutation was known for each case. Clinical and en-
doscopy records of each patient were reviewed and, where pathology blocks from 
more than one endoscopy episode were used, the clinical information presented 
(Table 6.1) is for the later episode. One hundred and fifty-one pouch adenOInas 
were screened from 46 patients (42 kindred). 
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I Clinical characteristics I Number of Patients (%) I 
Gender: 
Male 29 (63) 
Female 17 (37) 
Age of patient at endoscopy in years: 
<20 3 (6) 
21-30 4 (9) 
31-40 17 (37) 
41-50 16 (35) 
>50 6 (13) 
Age of pouch in years: 
<5 14 (30) 
6-10 12 (26) 
11-15 15 (33) 
>15 5 (11) 
Prior IRA 
Yes 24 (52) 
No 22 (48) 
Germline mutation: 
o 20AAR 27 (59) 
1 20AAR (including 1309 mutation) 7 (15) 
220AARs 9 (20) 
3 or more 20AARs 3 (6) 
Polyp position in pouch: 
Upper pouch 12 (26) 
Mid 15 (33) 
Throughout 12 (26) 
Lower 7 (15) 
Anal Transition Zone o (excluded from study) 
Polyp number at latest biopsy: 
<5 15 (32) 
6-15 17 (37) 
16-30 9 (20) 
31-50 4 (9) 
>50 1 (2) 
Maximum polyp size in mm: 
<5 43 (93) 
5-30 1 (2) 
>30 2 (5) 
Greatest polyp dysplasia: 
Mild 34 (74) 
Moderate 12 (26) 
Severe 0 
Table 6.1: Clinical features of patients included in the stud~' 
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6.3 Methods 
Formalin-fixed, paraffin-embedded polypectomy (N=141) or fresh-frozen polyp 
biopsy specimens (N = 10) were retrieved from histopathology archives and a 
total of 151 polyps, all of which contained at least 75% neoplastic tissue, were 
identified on R&E stained sections by a consultant gastrointestinal histopatholo-
gist (Dr T. Gunther). All polyps were mildly or moderately dysplastic adenomas 
and most were small (mode 1-2mm, range 1-40mm). Matched normal tissue was 
taken either from R&E-confirmed normal biopsies from elsewhere in the gut, or 
from adjacent mucosa. 
Methods are described in Chapter 3. Briefly, LOR analysis was performed us-
ing 5 polymorphic markers flanking APe (see Section 3.16). Multiple markers 
were used to maximise informative results, and to allow comparison between 
markers for confirmation of results. In order to assess the mechanism of LOR, 
polyps with LOR were analysed, together with matched normal controls, using 
real-time quantitative PCR to assess APe dosage. APe mutation detection 
was performed by direct bi-directional sequencing of exon 15, including the mu-
tation cluster region. For paraffin-derived samples, 12 primer pairs were used 
to sequence the gene from co dons 1214 to 1610, while 11 pairs were used for 
fresh-frozen polyp DNA to sequence codons 647 to 1720 (see Section 3.16). 
For analysis of somatic mutations, polyps were excluded from the study if they 
came from the same specimen block and showed the same second hit, since the 
appearance of two discrete lesions may have been created artefactually by cross-
section of the lesion in processing. Thus, all polyps included were confirmed 
as independent, either by being from different biopsy episodes or by showing 
different mutational changes. Although this strategy may well have led to some 
genuinely independent mutations being excluded, thus reducing the power of the 
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study, it was a conservative strategy to avoid introducing any systematic bias 
into the analysis. 
The number of 20AARs retained in the germline and somatic mutant alleles 
was calculated using the following codon positions: the first 20AAR between 
1266 and 1285; the second between 1379 and 1398; and the third between 1495 
and 1514. Where a mutation occurred within a 20AAR, then that AAR was 
counted as lost. Because LOR occurred through mitotic recombination rather 
than deletion (as demonstrated by RT -qPCR results), the resultant number of 
20AARs in such polyps was calculated as twice that present in the germ line 
allele. 
Proportions were compared using Fisher's exact test. Logistic regression anal-
ysis was performed to establish the relationship between polyp count, germline 
mutation position and clinical variables. 
6.4 Results 
6.4.1 Clinical Characteristics 
Clinical characteristics of the patients included in this study are given in Table 
6.1 above. Multiple logistic regression analysis was performed to examine the 
data for evidence of a relationship between pouch polyp count and the position 
of the germline mutation, age, previous ileorectal anastomosis prior to restora-
tive proctocolectomy, or time elapsed since pouch creation. No statistically 
significant correlations were found. 
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6.4.2 Loss of Heterozygosity at APe 
Evidence of inactivation of the wild-type allele, either by LOR or truncating 
mutation, was demonstrated in 51 of 151 polyps (34%), from 28 patients (24 
families). LOR analysis was successful in 127 of 151 of polyps (84%). There was 
no evidence of LOR in normal tissue when patients with the same constitutional 
genotypes were compared. 
Table 6.2 shows the frequency of somatic mutation by LOR according to the 
number of 20AARs remaining in the germline mutant APe allele. There was a 
significant non-random distribution of LOR overall (P < 0.001), resulting from 
an over-representation of LOR in patients whose germline mutation left a single 
20AAR in the APC protein. Comparing polyps from such patients with those 
from patients with germline mutations before the first 20AAR or after the second 
20AAR showed an even stronger association (P < 0.001). 
I Number of 20AARs in germline mutant allele I 0 1 I 2 I 3 I 
Number of polyps with LOR 4 9 1 0 
Number of polyps with no LOR 80 7 22 4 
Table 6.2: LOR according to number of 20AARs in germline mutant APe allele. 
N umbers of adenomas in each category are shown. 
6.4.3 Copy Number Analysis 
Four polyps with LOR were assessed using real-time quantitative PCR for APe 
dosage and all were found to have normal copy number (2 -b.b.CT Inore than 
1.06 for all), in accordance with previous data [Crabtree et al., 2003]. There was 
insufficient DNA available to undertake such analysis for the remaining polyps. 
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6.4.4 Thuncating Mutations 
Truncating somatic APC mutations were found in 37/151 polyps (25%). Of the 
truncating mutations detected, 35 were frameshifts and 2 were nonsense changes 
(Table 6.3). This bias towards frameshifts is in accordance with previous studies 
[Crabtree et al., 2003], both because they are far easier to detect in very small 
archival samples, and are also about twice as common as nonsense changes at 
APC. 
Table 6.3 below shows polyps where loss or mutation of the wild-type allele was 
demonstrated. 
20AAR 20AAR Type of 
in so-m Patient Germline mutation Polyp Somatic Somatic 
matic germline ID ID muta- mutation( s) 
allele allele 
tion(s) 
1 Ex5 codon 213 C>T 0 1.1 1556FS 4722insA 3 
1.2 1556FS 4722insA 3 
1.3 LOH 0 
2 Ex10 codon 445 del A 0 2.1 1557FS 4724insC 3 
3 Ex10 codon 452 ins GT 0 3.1 1464FS 4449delAG 2 
4 Ex10 codon 457 C>A 0 4.1 1464FS 4449delAG 2 
4.2 1309FS 3983delAAAG ~1 
5 Ex14 codon585 del C 0 5.1 1464FS 4449delAG 2 
5.2 1464FS 4449delAG 2 
5.3 1339FS 4016delG 1 
6 Ex15 codon 666 del 11bp 0 6.1 K1462X 4441A>T 2 
7 Ex15 codon 666 dell 1 bp 0 7.1 LOH 0 
7.2 S1407X 4275delAG 2 
8 Ex15 codon 685 del 11bp 0 8.1 1557FS 4724insC 3 
8.2 1557FS 4724insC 3 
8.3 1557FS 4724insC 3 
9 Ex15 codon 935 del ACAA 0 9.1 1464FS 4449delAG 2 
10 Ex15 codon 936 del TTAC 0 10.1 1459FS 4432delAC 2 
11 Ex15 codon1061 del ACAAA 0 11.1 1501FS 4558insT 2 
12 Ex15 codon1061 del ACAAA 0 12.1 1403FS 4263delCAGC 2 
12.2 1403FS 4263delCAGC 2 
12.3 1506FS 4573delT 2 
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20AAR 20AAR 
m 
Type of 
Patient Germline mutation Polyp Somatic Somatic 
mso-
lD germline lD mutation(s) matic muta-
allele allele 
tion(s) 
13 Ex15 codonl061 del ACAAA 0 13.1 1464FS 4449delAG 2 
13.2 1464FS 4449delAG 2 
14 Ex15 codonl061 del ACAAA 0 14.1 1496FS 4545delT 2 
14.2 LOH 0 
15 Ex15 codon 1062 del AA 0 15.1 LOH 0 
16 Ex15 codonl068 del TCAA 0 16.1 1464FS 4449delAG 2 
17 Ex15 codon 1242 del A 0 17.1 1464FS 4449delAG 2 
17.2 1425FS 1431insGA 2 
17.3 1464FS 4449delAG 2 
18 Ex15 codon 1261 del A 0 18.1 1464FS 4449delAG 2 
19 Ex15 codon1295 del 10bp 1 19.1 LOH 1 
19.2 LOH 1 
20 Ex15 codon1309 del 5bp 1 20.1 1464FS 4449delAG 1 
21 Ex15 codon1309 del 5bp 1 21.1 LOH 1 
22 Ex15 codon 1309 del 5bp 1 22.1 LOH 1 
22.2 LOH 1 
22.3 LOH 1 
23 Ex15 codon1309 del 5bp 1 23.1 LOH 1 
23.2 LOH 1 
23.3 LOH 1 
24 Ex15 codon 1392 C>G 2 24.1 1557FS 4724insC 3 
25 Ex15 codon1450 C>T 2 25.1 1337FS 4067insCT 1 
25.2 1337FS 4067insCT 1 
25.3 1371FS 4167delAG 1 
26 Ex15 codon1450 C>T 2 26.1 LOH 2 
26.2 1556FS 4726insCT 3 
27 Ex15 codon 1450 C>T 2 27.1 1528FS 4640delT 2 
28 Ex15 codon1464 del GA 2 28.1 1556FS 4724insA 3 
28.2 650FS 1951insGA 0 
Table 6.3: Polyps where loss or mutation of the wild-type allele was demon-
strated. 
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6.4.5 Association between Germline and Somatic Muta-
tions 
Pouch polyps with identified "second hits" were grouped by the number of 
20AARs in the mutant germline and somatic alleles respectively, including those 
cases in which mutation had occurred by LOH . Overall, the pairing of "first hits" 
and "second hits" differed significantly from random combination, with a strong 
tendency for polyps to acquire a total of two 20AARs (31/51, 61%) or three 
20AARs (9/51, 17%) (p<O.OOl, Fisher's exact test). There was no significant 
correlation between resultant 20AARs and pouch age, patient age, or previous 
IRA. 
I Number of 20AAR in somatic mutant allele I 0 I 1 I 2 I 3 I 
N umber of 20AAR in germline mutant allele 
0 4 2 20 6 
1 0 10 0 0 
2 1 3 2 3 
3 0 0 0 0 
Table 6.4: Relationship between 20AAR in germline mutant and somatic mutant 
alleles 
6.5 Discussion 
The post-operative development of ileoanal pouch adenomas is an interesting 
phenomenon, and investigation of this subject may indicate functional or en-
vironmental triggers of tumorigenesis. This study did not attempt to discover 
the primary influences of pouch tumorigenesis, but instead sought evidence that 
the genetic events underlying this initiation could be influenced by environ-
mental factors. Ideally, this study should have compared true ileal adenomas 
arising prior to colectomy, with those arising in the ileoanal pouch. However, as 
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discussed in the introduction of this chapter, macroscopic ileal adenomas are ex-
tremely rare. A review of histology reports of over 150 colectomies performed at 
St Mark's (where fastidious pathologists sampled macroscopically normal ter-
minal ileum attached to the resected colon), also failed to yield microscopic 
adenoma specimens which could have been used as material for analysis. Thus 
our comparison had to be with other upper gastrointestinal and duodenal polyps 
instead. 
Despite this limitation, this study has demonstrated that the "just right" model 
of beta-catenin signalling applies to pouch polyps in a tissue-specific fashion, as 
it does to other tumours in FAP. As in the colorectum, LOH was significantly 
more likely to occur in pouch polyps from FAP patients with a germline mutation 
encoding a protein with a single 20AAR (see Table 6.4). LOH occurred without 
copy number changes in those polyps studied. Thus, pouch polyps are genetically 
more similar to colorectal than upper-gastrointestinal adenomas. However, these 
data show that pouch polyps are not genetically identical to colorectal adenomas, 
based on the inclusion of truncating APe mutations into the analysis. 
Table 6.5 and Figure 6.1 compares published data on colorectal, upper-
gastrointestinal and desmoid tumours. Both pouch and colonic polyps usually 
acquire a total of two 20AARs as a result of their "second hits". However, pouch 
polyps differ from colonic polyps (p<O.OOI, Fisher's exact test) in that very 
few pouch polyps have one remaining repeat, but a substantial minority do have 
three remaining 20AARs. Upper-gastrointestinal polyps show a strong tendency 
towards 3 or 4 remaining repeats, significantly more than pouch polyps (p<O.OOl. 
Fisher's exact test). Thus the mutational pattern seen in pouch polyps has been 
modified from that which is typical of upper-gastrointestinal polyps, but remains 
intermediate between upper-gastrointestinal and colorectal polyps. In fact, the 
mutation spectrum in pouch polyps most strongly resembles that in desmoid 
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tumours (p=0.41, Fisher's exact test), although there is no evident functional 
or environmental explanation for this observation, which may simply result from 
chance coincidence of the optimal beta-catenin signalling in each tissue. 
In summary, this study has demonstrated that polyp development occurs via 
mutational changes more typical of colorectal polyps, providing the first molecu-
lar evidence that environment influences adenoma development in FAP pouches. 
Overall, these results also provide further evidence for the rationale behind pouch 
surveillance, since pouch mucosa can produce polyps genetically akin to those 
of rectal mucosa in terms of initiating genetic events. 
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20 AARs remaining 0 1 2 
after "2nd hit" 
3 4 5+ Average Std Dev 
Colorectum 4 16 66 1 2 0 1.8 0.6 
Upper GI 1 2 3 11 10 3 3.2 1.2 
Pouch (this study) 4 2 30 9 2 3 2.2 1.1 
Desmoid 0 2 16 6 3 1 2.5 0.9 
Table 6.5: Total 20AARs remaining in proteins encoded by the two mutant APe 
alleles in FAP adenomas from colorectum, duodenum and ileoanal pouch and in 
FAP desmoids , from this study and published data. 
LOR is scored as by mitotic recombination in each case, except for desmoids. 
N umbers of adenomas in each category are shown. Data are from the following 
original reports and/ or reviews: Crabtree et al. [2003] , Abraham et al. [2002] , 
Groves et al. [2002a], Andersen et al. [1999], Gallinger et al. [1995], Bapat et al. 
[1993] (combined as Upper GI), Latchford et al. [2007]. Samples with truncat-
ing mutations were included only if between 1214 and 1610, since this was the 
minimum region screened for mutations in all studies. (One polyp from Table 
6.4 was thus excluded.) 
Remaining 20AAR by Tissue Origin 
100%~--~ .. .r-------
90% +---
80% +--
70% +---
60% +---
50% +---
40% +---
30% +---
20% +--. 
1 0 % +------: 
0% +---
Colorectum Upper Gl Pouch Desmola 
Figure 6.1: Remaining 20AARs in varying tissue types (data shown in table 6.5) 
Chapter 7 
Adenoma Histogenesis in Ileoanal 
Pouch versus Rectulll 
7.1 Introduction 
The ileoanal pouch procedure became widely used in FAP after it was recognised 
that nearly a third of patients eventually developed rectal malignancy after ileo-
rectal anastomosis [Nugent et al., 1993b]. However as shown in Chapter 5, it has 
become evident that the ileoanal pouch also develops adenomas, although pouch 
cancer remains rare. There is no data concerning the individual risk of cancer 
from a single polyp of large bowel versus small bowel origin. However, we may 
hypothesise that large bowel adenomas are more aggressive and likely to progress 
to cancer. There are two main foundations for this hypothesis. Firstly, the clin-
ical experience of the long-term follow up of patients with ileoanal pouch is that 
unresected polyps in the anal cuff progress more frequently to invasion, and fre-
quently recur following repeated polypectomy. This is supported by worldwide 
literature reporting cancer of the anal cuff and canal more frequently than true 
pouch body cancers worldwide Church [2005], Ooi et al. [2003]. Secondly, rectal 
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cancers are seen in patients with sparse polyps in their rectum; compared to 
the rarity of pouch cancer even in those with dense pouch polyposis, as seen in 
Chapter 5. Since the genetic events triggering adenoma initiation are similar 
between rectal and pouch polyps (Chapter 6), it suggests that the subsequent 
process of tumorigenesis may differ to account for this disparity in the natural 
history of neoplasms at these sites. 
In both locations, neoplasms form when clonal outgrowths develop from mutated 
stem cells situated near the bottom of intestinal crypts. In normal mucosa, 
stem cells proliferate to form enterocytes that gradually mature as they move 
towards the mucosal surface or villus (see Section 1.2.1). Once a threshold 
level of proliferating cells is reached, crypts can undergo fission. Although crypt 
fission is proposed to be the basis of intestinal development in infancy [Cummins 
et al., 2008], it is also the mechanism by which a mutated clone of stem cells 
expands in the gastrointestinal tract [Yen and Wright, 2006, Greaves et al., 2006, 
Leedham et al., 2005, Boman et al., 2004]. 
Proliferation in the cryptal niche is maintained and modulated by cell signalling 
between mucosal epithelium and underlying mesodermal cells. The most im-
portant signalling pathway is Wnt signalling, which controls cell proliferation, 
differentiation, and apoptosis along the crypt-villus axis [Yen and Wright, 2006]. 
APe is a key mediator of this pathway and is heterozygously mutated in the 
germ line of patients with FAP. 
Mesodermal cells, which are specific to the tissue of origin, thus control mucosal 
cellular proliferation and cryptal fission. However, environmental factors also in-
fluence cryptal proliferation. Mouse studies have suggested that intestinal stem 
cells respond to segmental bowel resection by undergoing fission [Dekaney et al. ~ 
2007]. Intestinal cell proliferation and crypt fission differ in orally or parenterally 
fed mice, and observed effects vary according to gut locality [FitzGerald et al., 
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2005]. In humans, diet (as reflected by obesity) and gastric bypass may increase 
colonic epithelial cell proliferation and crypt fission [Sainsbury et al., 2008]. 
Therefore, although Chapter 6 demonstrated that ileoanal pouch adenoma ini-
tiation is similar to that of colorectal polyps [Will et al., 2008b], the interplay 
between gut origin and environment may affect crypt proliferation and fission; 
and therefore adenoma progression. This may account for the difference in ma-
lignant potential of pouch and rectal adenomas. In order to investigate the 
disparity, this chapter examines the histogenesis of these lesions in terms of cell 
proliferation, crypt morphology and fission, and immunohistochemical charac-
teristics. 
7.2 Study Population and Methods 
For cryptal dissection, fresh polyps and biopsies of normal mucosa were ob-
tained during surveillance endoscopy from 10 patients with FAP after written 
informed consent. Patient details are given in Table 7.1. Flexible sigmoidoscopy 
of the rectum or pouch was performed shortly after a phosphate enema by a 
single experienced endoscopist (Ripple Man). Adenomas were 2-3mm in size 
and surveyed using magnifying narrow-band imaging for mucosal pit patterns in 
keeping with mild dysplasia [East et al., 2008]. There were 8 pouch body and 
7 rectal adenomas. Normal mucosa was surveyed by chromendoscopy before 
biopsy. Seven samples of normal supra-anastomotic ileum (proximal either to 
the ileoanal pouch or rectum), 6 of normal pouch mucosa and 6 of normal rec-
tal mucosa were collected. The tissues were stored immediately in Clark's fluid 
and crypt dissection [Wong et al., 2002] was performed as described in Chapter 
3. For each biopsy, 100 crypts were counted under x10 magnification and the 
number of crypts undergoing fission recorded. Under x40 magnification. mitotic 
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figures were counted for 20 micro dissected crypts. Outlines of 10 crypts were 
drawn with a Leitz drawing tube under x16 magnification, to calculate cryptal 
area. 
For immunohistochemistry, 29 formalin-fixed, wax-embedded archival samples 
were obtained from 14 mutation-positive FAP patients, details given in Table 
7.3. All adenomas were mildly dysplastic and 2-3mm in size. There were 9 
polyps from pouch body, 10 from the rectum (with matched normal biopsies 
on the same tissue blocks) and 10 microscopically normal biopsies from the 
supra-anastomotic ileum. Immunohistochemistry was performed for TP53, beta-
catenin and lysozyme, as described in Chapter 3. Immunohistochemistry was 
attempted for caspase-3, but this was unsuccessful, as discussed below in Section 
7.4. Immunohistochemistry scoring was performed by a histopathologist (Dr 
Maesha Deheragoda), by assessing positivity per 1000 cells in longitudinally 
orientated crypts. 
Statistical analysis was performed using GraphPad Prism software. Results are 
given as group means (SEM). Statistical techniques used to calculate p values 
included two-tailed t-tests and logistic regression. 
I Patient Identifier I Germline Mutation I IRA/Pouch I 
1 ex 13 cd 553 C>T IRA 
2 ex 15 cd 1190 C>A IRA 
3 ex 15 cd 1062 del AA IRA 
4 ex 15 cd 1309 5bp del IRA 
5 ex 4 dupl Pouch 
6 ex 15 cd 1061 del ACAAA Pouch 
7 ex 11-13 del Pouch 
8 ex 15 cd 1926 del A ins CT Pouch 
9 ex 10 cd 444 del A Pouch 
10 unknown Pouch 
Table 7.1: Patients included in cryptal dissection study 
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1 Site I Patient identifiers I Number of specimens I 
Pre-anastomotic ileum - normal mucosa 3, 8, 9 7 
Pouch body 
- normal mucosa 6, 7, 8, 9, 10 6 
- polyps 5, 6 8 
Rectum 
- normal mucosa 1, 3, 4 6 
- polyps 1,2 7 
Table 7.2: Samples for cryptal dissection 
Site Number of Germline mutations Number of 
patients polyps 
Ileum above 5 Ex 5 cd 213 10 
IRA 
Ex 14 cd 635 
Ex 15 cd 1198 
Ex 7 3' del 
Ex 15 cd 1083 
Pouch 5 Ex14 cd 585 9 
Ex13 cd 564 
Ex15 cd1309 
Ex 10 cd 1333 
Ex 15 cd 1061 
Rectum 4 Ex 6 cd 216 10 
Ex 13-15 del 
Ex 4 dupl 
Ex 15 cd 1061 
Table 7.3: Patient characteristics for immunohistochemistry samples 
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7.3 Results 
7.3.1 Crypt Morphology 
Crypt morphology is shown in Figures 7.1 and 7.2. Normal crypts were all cylin-
drical in shape, but their area differed significantly according to their location. 
Crypts from the supra-anastomotic ileum were smaller than those from the rec-
tum (areas 0.09 (0.01) and 0.53 (0.06) mm2 respectively), as shown in Figure 
7.3, graph 1. Interestingly, crypts from normal pouch body were significantly 
larger than those of supra-anastomotic ileum (0.17 (0.01), p<O.OOl), and thus 
were intermediate in area between normal ileal and rectal crypts. Adenomatous 
crypts arising in the pouch were similar in area to those arising in rectum (means 
0.68 and 0.67 respectively), but the shapes of the crypts were different. While 
most crypts from rectal adenomas were markedly elongated, pouch adenomas 
were broader with more asymmetrical and superficial budding (Figure 7.3, graph 
1 b ). In the rectum, there was little difference in cryptal area between normal 
and adenomatous crypts (0.53 (0.06) versus 0.68 (0.09), p=0.23). 
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Ileum 
Normal 
Pouch 
Normal Adenoma 
Rectum 
Normal Adenoma 
Figure 7.1: Morphology of representative crypts from ileum, pouch and rectum 
Ten crypts from each area were drawn under x16 magnification onto A4 paper 
before being scanned. Normal rectal crypts are longer and wider than those 
from the pouch and the ileum. However , adenomatous crypts from the pouch 
were wider with frequent fission causing irregular shapes. 
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Figure 7.2: Photograph of representative dissected crypts from pouch and rectal 
adenomas 
Pouch crypts shown above, rectal crypts are below. Crypts photographed 
under x20 magnification. (In analysing the crypts for mitotic figures , the crypt 
remain three-dimensional structures , and the focus of the microscope is 
continually adjusted to rake through the depth of the crypt. Photographs of 
the crypts therefore look as though they are out of focus .) 
7.3.2 Crypt Proliferation 
Data for cryptal mitoses are shown in Figure 7.3 , graph 2. Fewer than ten 
mitoses per crypt were observed in normal mucosa at all sites: means (SEM) 
for ileum, pouch and rectum were 3.27 (0.15) , 6.04 (0.73) and 6.76 (0.51) re-
spectively. Normal pouch mucosa had significantly more mitoses per crypt than 
normal ileum (p= 0.002) , and did not differ significantly from normal rectal mu-
cosa (p = 0.4). Cryptal mitoses were higher in pouch adenomas compared to 
rectal adenomas: 23.14 (1.25) versus 16.78 (1.48) , p= 0.005. For all samples , mi-
toses per crypt were directly proportional to cryptal area (r2= 0.46 p< O.OOOl) , 
shown in graph 2b. 
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Cryptal fission data are shown in graph 3. In normal tissue, crypt fission indices 
(proportion of crypts in fission) for normal pouch and rectal mucosa were similar 
(5.4 (1.04) and 4.4 (0.56) respectively). However, the crypt fission index for 
supra-anastomotic ileum was 9.4 (0.8), statistically greater than those of pouch 
and rectum (p=O.Ol and p=0.0006 respectively). The crypt fission index was 
23.4 (2.5) in pouch adenomas: substantially higher than in rectal adenomas, 
at 7.5 (1.8) (p<O.OOl). In the pouch, there was a strong correlation between 
cryptal area and fission (p=0.03, r2 =0.32), shown in graph 3b. There was no 
significant relationship for ileal ( p=O. 78) or rectal crypts (p=O. 79). 
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Figure 7.3: Results of crypt dissection 
Means and standard deviations indicated in graphs 1-3. 
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7.3.3 Immunohistochemistry 
In normal mucosa, expression of nuclear beta-catenin and TP53 was less than 
1 %. There was no significant difference in nuclear beta-catenin expression be-
tween pouch and rectal adenomas, shown in Figure 7.4 (p= O.l). However , TP53 
expression was significantly greater in rectal adenomas (p= O.OOl). Pouch polyps 
retained lysozyme expression, which was also present in normal ileal mucosa but 
absent from rectal tissues (see Figure 7.5). 
Beta-Catenin Expression 
• 
I 
• 
••• 
• 
TP53 Expression 
A 
A 
I 
AA 
Figure 7.4: Immunohistochemistry results 
• • 
•• 
* • 
Figure 7.5: Lysozyme expression retained in pouch polyps 
Rectal polyp shown on left , pouch polyp shown on right. 
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7.4 Discussion 
The ileal environment is altered when it is fashioned into a replacement rectal 
reservoir, when there is faecal stasis in the pouch. This is likely to change the 
time the mucosa is in contact with bile acids, and also change the bacterial 
colonization (see Section 1.5.1). Although true metaplasia does not occur in the 
pouch [Fruin et al., 2003], these results confirm that pouch mucosa undergoes 
morphological changes that are presumably adaptive: crypts enlarge to resemble 
those from the rectum, which have previously been shown to be deeper than 
those of the more proximal colon [Brunsgaard, 1997]. However, ileal mucosal 
function (as assessed by lysozyme expression) remains present in the ileoanal 
pouch. 
Baseline rates of crypt mitoses in normal tissue were similar to those found 
in previous studies [Wasan et al., 1998]. As in this study, previous studies 
have similarly found that crypt mitoses were proportional to crypt area [Wong 
et al., 2002], probably because the stem cell number is proportional to the size 
of the crypt. However, a similarly proportional relationship was not seen for 
crypt fission, in contrast to other colon-confined studies [Wong et al., 2002]. In 
general, it is thought that crypts divide once stem cell numbers exceed a certain 
threshold, so larger crypts are more likely to be undergoing fission. While the 
ileoanal pouch showed a proportional relationship between crypt area and fission, 
this was not the case for the ileum or rectum. This finding suggests that the 
threshold for crypt fission varies by gut location. Since in the rectum the area 
of adenomatous and normal crypts was similar, fission may be initiated only 
after a significant increase in cryptal area. Although macroscopically the pouch 
and rectal polyps were all <3mm in size, the pouch adenomatous crypts were 
seen to have already undergone a large change in area from their normal state. 
This may have initiated their greatly increased and asymmetrical fission. \ Ye 
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speculate that a directly proportional relationship between CFI and area in rectal 
adenomas may therefore be observed only for larger, more progressed lesions. 
Diminutive pouch adenomas appear already to be in a state of crypt proliferation 
and fission, while similar rectal polyps appear to have fewer mitoses and signif-
icantly less crypt fission. Possibly counter-regulatory apoptotic processes are 
therefore activated earlier in pouch adenomas, accounting for their lack of ma-
lignant progression. Interestingly, abnormal TP 53 expression was significantly 
raised in rectal polyps. Increased nuclear TP 53 expression was found to be cor-
related with TP53 mutation in 68% of colorectal tumours Soong et al. [1996]: 
mutated TP53 is unable to activate genes responsible for cell cycle arrest and 
repair, or apoptosis [Conlin et al., 2005] (see Section 1.2.2). In contrast, pouch 
and rectal polyps showed similar nuclear beta-catenin expression, indicative of 
similar Wnt pathway activation. 
It would have been interesting to investigate whether pouch and rectal polyps 
differ in terms of apoptotic activity. Attempts to investigate this by caspase-3 
immunohistochemistry staining were unsuccessful as varying results were ob-
tained on repeated staining. For this antibody, the small size of the polyps 
seemed to produce staining by edge-artifact despite attempts at altering stain-
ing conditions. However, an alternative would be to use the more expensive 
method of TUNEL (Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick 
End Labeling). 
In conclusion, this study has shown that aggressiveness of rectal adenomas is 
not due to increased crypt proliferation, fission, or increased Wnt pathway ac-
tivation. While ileoanal pouch polyps may resemble those from rectum on a 
molecular level [Will et al., 2008b], this study has demonstrated that tissue 
origin appears to influence subsequent adenoma histogenesis and thus possibly 
malignant potential. 
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Chapter 8 
PMS2 and a New Cancer 
Phenotype 
The onset of colorectal cancer at a young age is strongly predictive of an un-
derlying genetic susceptibility, as discussed in Chapter 1. Accurate diagnosis 
of the underlying condition has important implications for patient management, 
prognosis, and family surveillance. In addition, unusual presentations have often 
provided insights into disease pathogenesis and gene function [Solomon et al., 
1987, Bodmer et al., 1987]. In this chapter [Will et al., 2007a], clinical and molec-
ular features are investigated in a patient presenting with an unusual phenotype 
primarily consisting of multiple colorectal cancers and adenomas. 
8.1 Clinical History 
A 23 year old man developed rectal bleeding and subsequently underwent pan-
proctocolectomy: there were 10 separate carcinomas with 35 adenomatous 
polyps in the colectomy specimen (see Figure 8.1). In view of the young age of 
presentation, he was referred to a familial colorectal cancer clinic. 
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Figure 8.1: Colectomy specimen (courtesy Dr J. Chin-Aleong) 
Further assessment of the patient and family therefore took place after he had 
recovered from colectomy. He had severe intellectual disability and was the 
oldest child of parents who were first cousins, and of Indian origin. He was 
noted to have short, upward-slanted palpebral fissures , microcephaly with a 
markedly flattened occiput, and a prominent supraorbital ridge. He had cafe-
au-Iait pigmentation of scalp and trunk, was discoordinated in movement and 
never developed speech. 
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Figure 8.2: Dysmorphic features in proband 
From left to right: upward-slanting palpebral fissures , fiat occiput , large 
cafe-au-Iait macules on left anterior abdominal wall. Photographs taken by 
author with parents' permission. Black bars placed for patient confidentiality. 
His parents and three younger brothers were phenotypically normal ; no other 
significant family history was available, although a vague suggestion was made 
by his parents of three other children with intellectual disability (see pedigree 
in Figure 8.3), one of whom had died. 
Figure 8.3: Family pedigree 
Family members screened by colonoscopy are shown in dark grey; arrow 
indicates proband. 
At the age of 25 the patient had a CT scan of his head performed after a 
fall: microcephaly and absence of the corpus callosum were noted , but th re 
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was no cerebral malignancy (see Figure 8.7). Later that year, he developed 
persistent vomiting. Upper gastrointestinal endoscopy, biopsy and subsequent 
abdominal CT imaging revealed an unresectable duodenal adenocarcinoma that 
was palliatively stented. He died shortly after this diagnosis. His parents and 
younger brothers underwent colonoscopy to screen for polyps. No other family 
members screened had colonic adenomas or carcinoma. 
8.2 Materials and Methods 
Parents and family members gave written informed consent for laboratory ge-
netic testing of their own blood, for testing of the patient's blood and tumour 
specimens. Routine diagnostic molecular testing in NBS laboratories had failed 
to identify a germline APe, MYH, MLHl or MSH2 mutation. 
Details of DNA extraction, karyotype analysis, aCGH and peR analysis are 
given in Chapter 3. Thirteen formalin-fixed, paraffin-embedded samples from 
10 distinct colonic cancers, one duodenal cancer biopsy and 9 adenomas were 
retrieved from histopathology archives. Immunohistochemistry of tumours and 
surrounding normal tissue was performed for PMS2 and beta-catenin as de-
scribed in Chapter 3, by L. Carvajal and G. Polanco. Luis Carvajal designed 
PMS2 primers with Ian Tomlinson, and performed the germline DNA analysis of 
the proband and relatives. Karyotyping was performed with Patricia Gorman. 
Deletional analysis was performed as follows. Primers were chosen to flank the 
suspected area of deletion identified on aCGH. In a patient without a deletion. 
they would hybridize too far apart on the template DNA to allow PCR amplifi-
cation. However, in a patient with a homozygous or heterozygous deletion, they 
would hybridize more closely and a PCR product could be obtained. Sequential 
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primer pairs were selected such that the region of deletion could be progressively 
narrowed and thus accurately determined. 
Tumour samples were screened for microsatellite instability (MSI) and screened 
for mutations in KRAS2 (codon 12 and 13), BRAF (around codon 600 hotspot), 
AXIN2 (exon 7), and beta catenin (CTNNBl exon 3) by direct sequencing. The 
APC gene was screened in tumours for mutations between co dons 1200 and 1600 
using direct sequencing. Short oligonucleotide tracts in APC (GT repeat in exon 
10, two GA repeats in exon 15), TCF4 (exon 1, A9 repeat), AXINl (exon 7, 
C6 repeat) and TGFBR2 (exon 3, A8 repeat) [Grady et al., 2006] were screened 
for insertions and deletions using fluorescent genescan analysis. 
8.3 Results 
8.3.1 Germline Analysis 
The proband's karyotype was normal in terms of chromosomal number and 
banding patterns, as shown in Figure 8.4. 
The patient's constitutional DNA was analysed by aCGH, which demonstrated 
a decreased signal at BAC clones mapping to 3.3Mb and 5.7Mb on chromosome 
7p. For one of the clones, the dosage in our patient's DNA fell below the 50% 
expected for a single-copy deletion (see arrow on Figure 8.5), suggesting possible 
deletion of both alleles at the locus. 
Dr L. Carmona then attempted to amplify across the putative deletion and de-
signed multiple primer pairs for this purpose as described above. The deleted 
region was found to be 400kb in size, spanning base pairs 5,597,458 - 5,998,620 
(UCSC Genome browser 2006 build). This deletion involved four genes. P1US2 
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Image obtained by Patricia Gorman. 
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(exons 9-15) , oncomodulin, TRIAD3 and FSCN1. peR confirmed that the dele-
tion involved both copies of chromosome 7, and demonstrated that the proband's 
parents both carried the same change in the heterozygote state, and that two of 
his three brothers were also heterozygotes. 
8.3.2 Tumorigenic Mutations Downstream of PMS2 
PMS2 protein expression was lost in all samples of normal tissue and tumours 
from the proband. Microsatellite instability in BAT25 and BAT26 was present in 
5 cancers and 3 adenomas, while 8 cancers showed band shift for D5S346, shown 
in Figure 8.6 below. There was no microsatellite instability in morphologically 
normal tissue from the large bowel. 
Figure 8.6: D5S346 analysis showing microsatellite instability in cancer 
D5S346 is 3' of APe. Results from tumour tissue shown above. Results from 
proband's normal tissue shown below, for comparison. 
Mutational analysis of genes involved in colorectal tumorigenesis revealed that 7 
cancers harboured KRAS2 mutation (all G> A; G13D) , while single base inser-
tion or deletion in the A8 tract of TGFBR2 was found in 5 MSI positive cancers. 
No mutations were found in APC, BRAF, AXIN2 or beta-catenin. The short 
mononucleotide repeat tracts in TCF4 and AXINl and the dinucleotide repeat 
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tracts in APe, were normal in all tumours. Immunohistochemistry of beta-
catenin showed nuclear expression in 9 of 10 cancers and 5 of the 9 adenomas , 
while normal tissue showed membranous or cytoplasmic staining only. 
8.4 Discussion 
In this patient, a homozygous deletion involving PMS2 caused a phenotype of 
multiple colorectal adenomas and carcinomas and a duodenal carcinoma. Large 
germ line deletions of PMS2 have not previously been reported. Moreover, most 
individuals with bi-allelic P MS2 mutations have had childhood haematological 
malignancies and/or brain tumours [Vos et al., 2006, de Vos et al., 2005], nei-
ther of which was present in our patient. Multiple colorectal polyps, colorectal 
carcinoma, cafe-au-lait spots, and brain malignancies are described features of 
Thrcot's syndrome [Murphy et al., 2005], and a small number of PMS2 mutant 
homozygotes with colorectal tumour(s) have been reported [Tan et al., 2008, 
Jackson et al., 2008]. However, the large number of gastrointestinal malignan-
cies found at a young age in our patient has not previously been recorded in 
carriers of mono-allelic or bi-allelic MMR mutations or in patients with FAP or 
MAP. 
Recently, new methods of mutation detection [Clendenning et al., 2006] have 
allowed improved analysis of PMS2 in patients fulfilling Bethesda criteria (see 
Chapter 1). It is now estimated that heterozygotes have an approximately five 
times increased risk of colorectal cancer above that of the general population 
[Senter et al., 2008]; while a particular exon 11 mutation was found to be enriched 
in patients with Scandinavian and British ancestry [Clendenning et al., 2008]. 
Thus it now seems that P MS2 mutation is far more prevalent than previously 
thought, but that the gene has lower penetrance for colorectal cancer than other 
CHAPTER 8. 135 
mismatch repair genes, hampering its diagnosis. 
There has been very little study [Rosa et al., 2000] of the molecular pathways in 
colorectal tumours from carriers of bi-allelic MMR mutations. A comparison of 
Mlhi- versus Pms2-deficient mice [Yao et al., 1999] showed that the latter dis-
played a tendency towards mutation at dinucleotide rather than mononucleotide 
repeats. This finding is borne out here, as there was slightly greater instabil-
ity in the cancers at the dinucleotide repeat D5S346 rather than BAT25 and 
BAT26. However, not all our patient's tumours showed MSI, suggesting that 
the mutator phenotype caused by P MS2 deficiency is mild. MSI was also absent 
in the normal tissue that we studied. 
Mutation of TGFBR2 was found in 5 cancers. Moreover, seven cancers carried 
KRAS2 mutations, but no somatic mutations were found in APC, beta-catenin, 
AXINi, AXIN2 or TCF4. By contrast, in colorectal tumours from Lynch syn-
drome cases (mono-allelic MMR mutants), APC and beta-catenin mutations 
are relatively common. However, we found nuclear expression of beta-catenin, 
and hence evidence of Wnt pathway activation in our patient's tumours, without 
these concomitant mutations. Thus it is possible that the pathway of colorectal 
tumorigenesis in carriers of bi-allelic P MS2 mutations differs from those found 
in Lynch syndrome, FAP, MAP and most sporadic colorectal cancers. It is also 
possible that the tumours did harbour these mutations, but not in the regions 
that were screened here. If fresh frozen tissue had been available, more of the 
APC gene could readily have been sequenced. 
It is not clear whether homozygous deletion of FSCNi, TRIAD3, and oncomod-
ulin affected the patient's phenotype. Little is yet known about the function of 
TRIAD3 and oncomodulin. Importantly, FSCNi has previously been studied 
in the context of colorectal cancer. It is an actin cross-linking protein involved 
in cell-surface projections [Arcangelis et al., 2004][Yamashiro et aL 1998]. It has 
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been proposed [Jawhari et al., 2003, Vignjevic et al., 2007] that its upregulation 
is a significant component in the acquisition of invasiveness in colonic carcinoma. 
This patient appears to disprove this hypothesis. 
Our patient could not be distinguished on clinical grounds from cases with at-
tenuated FAP or MAP, although his numerous, synchronous gastrointestinal 
malignancies were not typical of any of the known Mendelian syndromes. His 
absence of childhood brain tumour and haematological malignancy distinguished 
him from other homozygote or compound heterozygote P MS2 mutation carriers. 
This case report shows that PMS2 mutations - and perhaps other homozygous 
MMR mutations - should be considered as the underlying cause of any patient 
who presents with early-onset, multiple tumours of the gastrointestinal tract in 
the absence of other "syndromic" malignancies. 
8.5 The Role of FSCN in the Neurological Phe-
notype 
8.5.1 Introduction 
The patient investigated in this chapter had a CT scan showing absent corpus 
callosum, cerebellar and white matter changes (see Figure 8.7). These features 
are not expected with homozygous P MS2 mutation, suggesting that one of the 
other deleted genes may have caused this phenotype. While little information 
about oncomodulin and TRIAD3 is available in the scientific literature, it is 
known that FSCN plays a role in brain development in rats [Sasaki et al., 1996b]' 
drosophila [Kraft et al., 2006], and mouse [Arcangelis et al., 2004] in dendrite 
outgrowth and neurite trajectory. 
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Figure 8.7: CT scan of brain of proband, showing absent corpus callosum and 
white matter changes 
Note enlarged ventricles and irregular absence of brain tissue at midline , by 
comparison with normal brain scan at comparable level shown on right. 
In participation with Professor S. Sisodiya at The National Hospital for Neurol-
ogy and Neurosurgery, parents and family members agreed to participate in ge-
netic and neurological research. Both parents were hemizygous for the deletion; 
and MRI brain showed one parent to have frontal lobe white matter changes, 
while the other had cerebellar abnormalities on the scan, though both parents 
were clinically normal. The corpus callosum was present in both parents. 
Based on this evidence, we postulated that FSCN deletion may have accounted 
for the neurological phenotype in the proband and parents. In order to inves-
tigate this possibility, Professor Sisodiya located 16 samples of germline DNA 
from California and the UK, donated for genetics research from patients with a 
similar neurological phenotype. We hoped to find mutation of the FSCN gene 
in an unrelated sample, to show a causative link between the genetic mutation 
and the specific brain abnormality. 
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8.5.2 Study Population 
Sixteen patients were included in this study. All patients had absent corpus cal-
losum, as well as associated abnormalities in rhomencephalon, prosencephalon, 
cerebellum (cerebellar vermis and lobar hypoplasia with or without Dandy-
Walker complex), polymicrogyria, and bilateral frontal polymicrogyria. 
8.5.3 Methods 
All samples were screened for FSCN mutation using PCR amplification of FSCN 
exons 1 to 5. (FSCN is in a highly-duplicated area on chromosome 7; primer 
pairs were carefully designed (Ian Tomlinson) for unique amplification). DNA 
was limited from these samples, thus O.625ng DNA was used in each PCR reac-
tion, with LC Green dye to allow analysis using LightScanner technology. Can-
didates were then sequenced bidirectionally. Ten of these samples (for which 
there was sufficient remaining DNA) were also analysed on a 500kb Affymetrix 
array by Kimberley Howarth. 
8.5.4 Results 
Thirteen possible candidates were identified by the LightScanner. However, all 
candidates were found to be normal on sequencing analysis. No mutations were 
thus found in FSCN in any of the new samples. Affymetrix array did not show 
a large area of gain or deletion in any patient, nor any consistent areas of dosage 
change between samples. 
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8.5.5 Discussion 
We have found no conclusive evidence that FSCN deletion contributed to the 
neurological phenotype in our patient. Possible reasons may include the follow-
ing: firstly, the brain anomalies used to identify the DNA samples for testing 
may be polygenic and multifactorial; thus FSCN may contribute to the pheno-
type in the proband but not in the unrelated patients. Secondly, the proband 
may have inherited another (unidentified) homozygous mutation from his con-
sanguineous parents, in addition to the large deletion we have identified. Lastly, 
FSCN may not be involved in the proband's neurological phenotype; or TRIAD3 
or oncomodulin may have been the causative mutations. 
8.6 The Role of PMS2 in Related Colorectal 
Phenotypes 
8.6.1 Introduction and Aims 
PMS2 is identified as the causative mutation in fewer than 5% of Lynch syn-
drome cases (see Section 1.4). However, as mentioned above, it is a difficult gene 
to analyse. The proband patient in the study above had early-onset colorectal 
cancer, was of Asian descent, and had multiple adenomas. We aimed to investi-
gate whether germline P MS2 mutation could be causative in other patients with 
multiple adenomas without an identified mutation in APC, MYH, or common 
MMR genes (MLH-l, MSH-2 and MSH-6) . Secondly, we identified other pa-
tients with cryptogenic early-onset colorectal cancer, both Asian and Caucasian. 
and investigated whether P MS2 mutation could have resulted in their cancers. 
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8.6.2 Study Population 
Archival tissue blocks were located from the St Mark's Hospital Polyposis Reg-
istry, the CORGI tissue consortium [Kemp et al., 2006] and the Royal London 
Hospital (with individual written patient consent) for the following: 21 patients 
with multiple (>5) colorectal adenomas without a history of colorectal cancer; 
38 patients who had colorectal cancer under age 45, 6 patients of Asian descent 
with colorectal cancer under age 25, and 1 Caucasian with mild neurological 
impairment and colon cancer under age 45. All multiple adenoma patients had 
undergone screening for APC, MYH, MLH-l, MSH-2 and MSH-6. Mismatch 
repair expression for MLH-l, MSH-2 and MSH-6 was normal in the patients 
with young-onset colorectal cancer. 
8.6.3 Methods 
Immunohistochemistry for P MS2 expreSSIOn was performed as described in 
Chapter 3. Gene sequencing for PMS2 and FSCN was performed for a sin-
gle patient (see below). PMS2 was screened between exons 6 to 15 only (exons 
1 to 5 were homologous with other chromosomal regions). 
8.6.4 Results 
PMS2 expression was present in all samples from patients with the multiple 
adenoma phenotype. Two patients with young-onset colorectal cancer showed 
loss of P MS2 mutation in tumour tissue only. One of these patients was Asian 
and also had ovarian cancer, the other was a patient with mild neurological 
impairment. Germline DNA was available for this latter patient. Sequencing of 
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PMS2 and FSCN showed no abnormalities in the germ line DNA, but tumour 
DNA showed a frameshift in intron 7. 
8.6.5 Discussion 
P MS2 seems unlikely to be involved in the patients with multiple adenomas 
as all of this cohort had normal immunohistochemistry. P MS2 mutation may 
be causative in a subset of patients with young-onset colorectal cancer, but 
at the time of this research, a robust method of sequencing all of PMS2 had 
not been devised. This would now be possible with the availability of new 
techniques involving long-range PCR amplification combines with nested PCR. 
These findings are in agreement with new research confirming PMS2 as an 
important (and often unrecognised) cause of Lynch syndrome. Routine testing 
for P MS2 should be included in mismatch repair gene screen for patients with 
young-onset colorectal cancer [Senter et al., 2008]. 
Part III 
Adenoma Initiation and 
Progression in Sporadic Colorectal 
Adenomas 
1--12 
Chapter 9 
Crypt-by-Crypt Analysis of 
Carcinomas arising in Adenomas 
9.1 Introduction 
In colorectal cancer, much is understood at the histopathological level about 
the stepwise progression from a benign adenoma to cancer. Although we know 
which main molecular alterations occur along the adenoma-carcinoma sequence 
[Jones et al., 2008, Fearon and Vogelstein, 1990] less is known about how they 
propagate in order to drive neoplastic progression. 
Applying the sequential histopathological model of colorectal tumorigenesis to 
molecular events would imply that all cancerous cells in a lesion should have 
common advantageous mutations as the "fittest" cell divides and out-competes 
its neighbours, spreading through a crypt "bottom up" [Preston et al.; 2003] and 
then populating the growing lesion in waves of expansion. 
In oesophageal cancer, this mode of dysplastic spread known as the "selecti\'e 
sweep" [Maley et al., 2004] (see Figure 9.1), was cast into doubt by a recent study 
14:3 
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where mutational analysis of single crypts demonstrated mosaic competitive 
clonal colonization and co-existence of multiple independent clones [Leedham 
et al., 2008]. Similar clonal heterogeneity in colorectal adenomas is suggested 
by studies employing fluorescent in-situ hybridization [Bomme et al., 2001]' al-
though no colorectal cryptal comparison studies have yet been performed. 
,--' pi 
Figure 9.1: Selective sweep model of tumour progression. Figure reproduced 
from Maley et al. [2004] 
This model implies that when a clone of cells with a more advantageous 
mutation appears, it expands due to natural selection until fixation occurs -
clones lacking that mutation are subsumed. 
Sporadic colorectal adenomas have been studied at the whole-lesion level to 
identify genes commonly mutated in tumours. As discussed in Section l.2.2 , the 
results are often conflicting. This may be due to heterogeneity of early cancer 
precursors, but also reflects that, while commonly mutated genes important 
for tumorigenesis ("gatekeepers", "caretakers" and "landscapers" [Michor et al., 
2004]) have successfully been identified, confusion remains in classifying them 
as causal, permissive, or neutral "hitchhiker" mutations [Maley et al., 2004]. At 
very least , the linear model of a simple, stepwise adenoma-carcinoma sequence 
needs further development. 
Instead of analysing whole lesions as representative of a single state of dysplasia 
or cancer, this study aimed to investigate the process of neoplastic progression on 
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a finer level by analysing and comparing multiple individual crypts in adjacent 
zones of adenoma and carcinoma. Thus, multiple crypts were screened for some 
of the most common genetic alterations in colorectal cancer: point mutations 
in APC, KRAS2 and TP53, loss of heterozygosity (LOH) in 5q (APe) , 17p 
(TP53) and 18q (SMAD4 and DCC), aneuploidy and microsatellite instability 
(MSI). In so doing, this study aimed to determine the pattern of clonal spread 
in colorectal tumorigenesis and to infer the possible order of mutational events 
in the transformation from adenoma to carcinoma. 
9.2 Materials and Methods 
Eleven formalin-fixed, paraffin-embedded samples of adjacent colorectal carci-
noma and adenoma were identified from archival sporadic carcinoma cases. H&E 
slides of the samples were reviewed and marked by a consultant gastrointestinal 
histopathologist (Dr Jo-Anne Chin-Aleong); an example is shown in Figure 9.2. 
Figure 9.2: Representative H&E slide, histology marked by Dr J. Chin-Aleong 
l=invasive area, 2=high grade adenoma. 
I screened 5 samples in collaboration with Enric Domingo, while 6 samples were 
screened by Simon Leedham (indicated by "SL" sample numbers given in results). 
Clinicopathological details of tumours (where known) are given in Table 9.1. 
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I Sample identifier I Gender I Age I Dukes' stage I Grade of dysplasia analysed I 
1 F 34 C low 
2 F 54 B low 
3 F 61 A low 
4 M 77 B high 
5 F 69 A high 
SL1 M 55 A moderate 
SL2 M 64 A moderate and high 
Table 9.1: Clinicopathological details of tumours where known 
Firstly, needle dissection was used to prepare representative samples of adenoma 
and carcinoma. Needle-dissected material was used for ploidy analysis and DNA 
was extracted for initial gene screening as described in Chapter 3. Secondly~ 
laser capture microdissection was performed. Between 3 and 11 crypts each 
from adenomatous and carcinomatous areas were dissected and also crypts from 
normal areas where present and/or normal stromal tissue. 
Needle-dissected DNA was screened for mutations in the mutation cluster region 
of APC (codons 1100 -1560 in exon 15), in TP53 (exons 5-8) and KRAS2 (exon 
1). Microsatellite markers D5S346 and D5S299 were used to assess LOR in 5q 
near APC, D17S786 and D17S1832 in 17p near TP53 and D18S46 and D18S69 
in 18q21 near the SMAD4/DCC locus. Alterations detected in any needle-
dissected section were subsequently analysed in the all the microdissected crypts 
from the same sample. In addition, the MSI status of each crypt was assessed 
using BAT26. 
Ploidy analysis was performed using an automated image-based cytometry tech-
nique as described in Section 3.15. Individual cryptal ploidy analysis was not 
possible as the technique requires> 1000 nuclei for adequate quality of results. 
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9.3 Results 
9.3.1 Individual Cryptal Results 
Results of analysis for each pair are summarised in Figures below. 
(2 Low Grade Dysplasia (5 crypts) Cancer (5 crypts) 
APe ND wt wt 
5q LOH wt wt wt wt wt wt wt 
TP53 wt wt wt wt wt wt wt nfa 
17p LOH wt wt wt wt wt wt wt LOH LOH LOH nfa LOH 
18q LOH wt wt wt wt wt wt wt LOH LOH LOH nfa LOH 
KRAS2 wt wt seq 35 g>a wt seq 35 g>a wt wt wt wt wt G12D G12D 1. Normal 
Ploidy ND Diploid 
2. Dysplasia 
3. Cancer 
Bat26 MSS MSS 
Sample 1. No APe mutation was ident ified within the region screened. How-
ever , the cancer contains crypts with and without 5q LOH. It is possible t hat the 
cancer arose from the cryptal clone with 5q LOH and the single cancerous crypt 
without LOH is a spurious result. TP53 mutation, 17p LOH and 18q LOH was 
here present in the cancer only. However , t he KRAS2 mutation detected in 4 of 
5 adenomatous crypts was not seen in t he cancer , implying wither that a clone 
without this mutation developed into t he cancer, or that t he KRAS2 mutation 
occurred after cancer clone divergence , and hence after TP53 mutation and 18q 
LOR. Aneuploidy was detected in the cancerous area only. 
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APC 
5q LOH n/a n/a n/a 
TP53 n/a wt wt 
17p LOH n/a n/a n/a 
18q LOH wt wt 
KRAS2 wt wt mul mul seq 359>1 G12V in all 1. Normal 
2. Dysplasia 
Ploidy n/a Diploid Diploid 3.Cancer 
Bat26 MSS MSS 
Sample 2. The same APe mutation (exon 15 codon 1487 del 10bp) and KRAS2 
mutations were seen in both adenoma and cancer. Interestingly, a single crypt 
showed microsatellite instability, which was "carried through" to the cancer. 
Low Grade Dysplasia (5 crypts) Cancer (5 crypts) 
APC NO wt wt 
5qLOH n/a n/a wt wt wt wt wt 
TP53 wt n/a wt wt wt wt wt 
17p LOH wt wt LOH LOH LOH LOH wt 
18q LOH n/a n/a n/a LOH LOH wt LOH 
KRAS2 NO wt wt 1.Normal 2. Dysplasia 
3. Cancer 
Ploidy NO 
Bat26 MSS 
Sample 3. While an AP e mutation was not identified in the screened region, 
5q LOH was detected in the cancerous crypts . These also showed 17p LOH. 
However, both t he adenoma and the cancer showed evidence of polyclonali ty 
wit h respect to 18q, implying that this change occurred after divergence of the 
malignant clone. Aneuploidy was present in both adenoma and cancer. 
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(2 High Grade Dysplasia (5 crypts) Cancer (5 crypts) 
APC n/a wt wt 
5q LOH n/a 
TP53 wt 
17p LOH wt wt 
18q LOH wt n/a LOHA1 n/a n/a LOHA1 
KRAS2 n/a n/a mut wt n/a wt 1. Normal 
2. Dysplasia 
Ploidy NO Diploid 3. Cancer 
Bat26 MSS MSS MSS 
Sample 4. LOR at 5q was detected in adenoma and cancer; although an APC 
point mutation was not identified. The cancer was wild-type for TP53 and 17p 
LOR. The KRAS2 mutation present in the adenoma is "carried through" to the 
cancer. Aneuploidy was detected only in the cancer. 
(0 High Grade Dysplasia (5 crypts) Cancer (5 crypts) 
APC NO wt wt 
5q LOH ND wt 
TP53 ND wt 
17p LOH ND wt 
18q LOH ND 
KRAS2 ND wt mut seq 85 g>c G12R in all 1. Normal - not present 2. Dysplasia 
Ploidy NO Diploid Diploid 
3. Cancer 
Bat26 ND MSS MSS 
Sample 5. In this sample, the APC mutation was not detected within the region 
screened , and there was no evidence of 5q LOR. The cancer showed no changes 
apart from LOR at 18q which was in a different allele from that seen in the ad -
noma. This may imply that 18q LOR occurred independently in adenomatou 
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and cancerous areas, after divergence of the cancer from adenoma had occurred. 
The adenomatous crypts had wild-type KRAS2, the G12R mutation matching 
those present in all crypts of the cancer, and a different G12D mutation. 
(3 Low Grade Dysplasia (11 crypts) 
APe wt 
5q LOH nla nla nla 
TP53 wt R273H in all R273H in all 
17p LOH LOH LOH in all LOH in 3 
18q LOH wt LOH LOH in all 
KRAS2 wt wt 1.Normal wt 2. Dysplasia 
3.Cancer 
Ploidy Diploid Diploid 
8at26 MSS MSS 
Sample 6 (SL1). Mutation in both APe and TP53 is seen in all crypts of the 
adenoma. Only some crypts showed 18q LOR, but this was seen in all cancerous 
crypts, implying that a malignancy arose in a clone with this loss , and that 18q 
LOR occurred after TP53 mutation. 17p LOR was not detected in all cancerous 
crypts. Aneuploidy was detected in the cancer only. 
5q LOH wt nla nla nla 
TP53 wt wt R213Q in all R213Q in all 
17p LOH nla nla nla nla 
18q LOH wt wt LOH A1 in all 
KRAS2 wt wt G12V G13D in all 
Ploidy Diploid Diploid Diploid Diploid 
8at26 MSS MSS MSS MSS 
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Sample 7 (SL2). As in the previous sample, both APe and TP53 mutations 
were present in all crypts of the high grade adenoma; but here, this mutation 
was not present in moderately dysplastic area. 18q LOR was detected in both 
high grade adenoma and cancer, but a different allele was lost suggesting that 
the change occurred after divergence of the malignant clone, and thus after TP53 
mutation. A different KRAS2 mutation was detected in the high grade adenoma 
from the cancer, again suggesting that these events occurred independently after 
the cancerous clone was established. 
Cancer (7 crypts) 
APe wt 
5q LOH wt wt 
TP53 wt E171X in all E171X in all 
17p LOH n/a n/a n/a 
18q LOH wt LOH A2. in all LOH A2. in all 
KRAS2 wt wt wt 
l .Normal 
Ploidy Diploid Diploid 2. Dysplasia 
3. Cancer 
Bat26 MSS MSS 
Sample 8 (SL3). The cancer shows LOR at 5q but is wild-type for the APe 
mutation seen in the adenoma. This may indicate that there was an APe 
mutation in a region of the gene not screened, and that there are three "hits" in 
this lesion. TP53 is again seen in all crypts from the adenoma, as is LOR at 
18q. Aneuploidy is seen in the cancer only. 
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5q LOH n/a n/a n/a 
TP53 wt wt wt 
17pLOH wt LOH in all LOH in all 
18q LOH wt lOH A2. in all lOH A2. in all 
KRAS2 wt wt wt 
Ploidy Diploid Diploid l . Normal 2. Dysplasia 
3. Cancer 
Bat26 MSS MSS 4. Hyperplastic area 
Sample 9 (8L4). Both adenoma and cancer have wild-type TP53, but there was 
LOH at 17p and 18q detected in all crypts of the adenoma, implying that these 
changes occurred early in adenomatous progression to have become fixed in all 
crypts. Aneuploidy was detected only in the cancer. 
5q LOH n/a n/a n/a n/a 
TP53 wt wt wi wi 
17p LOH wi wi LOH in all LOH in all 
18q LOH wi wi wi wi 
KRAS2 wi G12V G12Vin all G12V in all 
Ploidy Diploid Diploid Diploid Diploid 
Bat26 n/a nla nla nla 
Sample 10 (SL5). While the same APC and KRAS2 mutations were evident 
in all crypts from both moderately and highly dysplastic areas and the cancer 
17p LOH was not evident in the moderately dysplastic region, suggesting that 
this loss occurred after APC and KRAS2 mutations. 
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5q LOH n/a n/a n/a n/a 
TP53 wt wt ins Ain all ins A in all 
18q LOH n/a n/a n/a n/a 
KRAS2 wt wt wt wt 
Ploidy Diploid Diploid Diploid Diploid 
Bat26 MSS MSS MSS MSS 
Sample 11 (SL6). Similarly to Sample 10, the TP53 mutation probably occurred 
after APe mutation and only in the highly dysplastic adenomatous area. Be-
cause all highly dysplastic crypts share this mutation, it presumably occurred 
early in the change to high grade dysplasia. 
9.3.2 Pairings and Frequencies Summary 
A summary of the results for all adenoma-carcinoma pairs is given in Table 
9.2 below, which notes the pairings and the frequencies of identified genetic 
alterations. 
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Altered in Altered in Altered in Wild-type Wild-type 
adenoma adenoma carCInoma and and 
only and only altered altered 
carCInoma clones in clones in 
same same 
adenoma carCInoma 
KRAS2 3 4 1 3 0 
APe 15q 1 6 2 2 1 
LOR 
TP53/17p 0 8 2 1 1 
LOR 
18q LOR 3 6 2 4 2 
Aneuploidy 0 1 5 nla nla 
MSI 0 1 0 1 0 
Table 9.2: Frequencies of alterations (mutation or LOR) by pairs 
Where 2 different mutations are present in the same gene, or different alleles 
are lost, they are counted independently. 
9.4 Discussion 
This study was of only 11 carcinomas arising in adenomas, and therefore its 
aim is to describe whether the findings here concur or disagree with hypotheses 
about the adenoma-carcinoma sequence. Many more numbers, combined with 
statistical analysis and phylogenetic modelling, would be required to draw firm 
conclusions about the predicted sequence of mutational events. 
Another caveat is that this study rests on the supposition that the cancer arose 
out of a clone present in its adjacent cancer. While this is a logical supposition, 
it is also theoretically possible that a cancer grows and destroys the tissue which 
gave rise to it; and thus inferring an order of events by looking at an adenoma 
and cancer "pair" is not valid. The same argument holds good for assuming that 
moderate dysplasia occurred "before" high grade dysplasia. A final criticism to 
address is that this study (and all studies based on analysing "adenomas" versus 
"cancers"), can only define a cancer as a lesion breaching the lamina propria. 
CHAPTER 9. 155 
This histological way-point may misclassify a cancerous clone of cells, by chance 
captured on the tissue block before they had time to breach the lamina propria. 
Thus there is difficulty in analysing the neoplastic process using a histologically-
defined state. 
However, in this descriptive study the results for adenomas and carcinomas taken 
independently are in broad agreement with the sequence of alterations found 
previously in studies employing whole-lesion analysis. Alterations in APC were 
found to occur early as identified mutations were present in all crypts of the 
adenomas. Aneuploidy was found in 55% (6 out of 11) of the samples, while 
10% (1 out of 10) had MSI, frequencies expected in sporadic tumours. The other 
alterations analysed have results broadly consistent with current models of the 
neoplastic sequence: KRAS2 was mutated in both adenoma and carcinoma, 
TP53 in carcinoma and high grade dysplasia but not in low grade, and the 
frequencies of LOH were higher in carcinomas than in adenomas. 
Cryptal and pairwise analysis of results has allowed us to infer a likely sequence 
of genetic events in our samples. All bar one of the sample pairs analysed showed 
shared alterations between the adenoma and the carcinoma, showing that the 
carcinoma arose from the dysplasia. The only exception was Sample 1, which had 
4 out of 5 crypts with a KRAS2 mutation not present in the carcinoma although 
one of these crypts also had LO H in 5q detected in the paired carcinoma. These 
results suggest that the carcinoma may have arisen from another crypt in the 
adenoma not analysed. 
The earliest alteration detected in our samples was APC, as detected mutations 
were consistently found in all dysplastic crypts and fixed in the carcinomas, 
which agrees with its putative role as an initiating alteration in colorectal neo-
plasia. However, 5q LOH was present only in some crypts in the adenoma while 
it was usually fixed in the carcinomas, suggesting that this alteration is a late 
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event in neoplastic progression. Sample 8 had an APe mutation in the adenoma 
not present in the carcinoma, but 5q LOR was found only in the carcinoma. This 
suggests that the mutated allele was lost in the cancer. 
Unexpectedly, 2 of 6 samples with KRAS2 mutations showed the alteration in 
the adenoma but not in the carcinoma, implying that the mutations in these 
samples did not give rise to the carcinoma. For example, in Sample 1 the 
wild-type clone (rather than the crypts with mutated KRAS2) gave rise to the 
cancer (which acquired additional changes in TP53, 17p and 18q, and became 
aneuploid). Also, in sample SL2, the KRAS2 mutation identified in the cancer 
was different from that present in the paired dysplasia. This pattern of KRAS2 
mutation would be similar to that expected of a neutral or hitchhiker mutation, 
and casts doubt on a role central to neoplastic progression. 
Similar results were found regarding 18q LOR as Sample 7 had lost a different 
allele in the adenoma and the carcinoma. Moreover, two other samples were 
heterogeneous for 18q LOR in both adenoma and carcinoma. Nonetheless, since 
5 samples had this alteration in all the crypts, 18q LOR may be important for 
carcinogenesis. It has to be noted that it is still unclear what gene is targeted 
by this alteration: if it is more than one, the cryptal pattern of this alteration 
could be difficult to assess. 
Alteration of TP53 either by point mutation or 17p LOR, despite being de-
scribed as a late event in neoplastic progression and one that heralds malignant 
invasion, was most frequently identified in both adenoma and cancer, although 
it was never identified in the adenoma alone. In addition, in most cases these 
alterations were found in all the crypts analysed, indicating that enough time 
had elapsed for the mutation to become fixed. Since all adenomas here neces-
sarily are those giving rise to a cancer, this suggests that TP53 may be either a 
marker of invasive potential, or since alteration was identified in all but 1 sam-
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pie, a prerequisite for malignant progression. These results therefore suggest 
that TP53 alteration occurs earlier in the adenoma-carcinoma sequence than 
previously postulated, even before KRAS2. 
Aneuploidy occurred in 6 samples, 5 of which were in the cancer alone. While 
ploidy assessment was of the whole lesion rather than individual crypts, it is 
interesting that aneuploidy was not detected in more adenomas. This suggests 
that aneuploidy occurs late in the adenoma-carcinoma sequence. While previous 
studies have shown that loss of TP53 resulted in whole-chromosome gain and 
loss in Ape-mutant mice [Alberici et al., 2007], and that elimination of tetraploid 
cells is TP53-dependent [Margolis, 2005], here there was no correlation between 
TP53 alteration and aneuploidy. Instead, these findings may be interpreted 
as lending weight to the argument that CIN is unlikely to be present as an 
early event, since aneuploidy would then likely be present in a larger number of 
adenomas. However, the development of microsatellite instability did correspond 
to malignant progression in Sample 2, where a single adenomatous crypt showed 
instability, "carried through" to the cancer. 
Most sample pairs revealed a mutational pattern "carried through" to the cancer, 
by having at least one adenomatous crypt showing an exact subset of alterations 
found in its paired cancer - presumably, the most advantageous combination. 
This argues in favour of a progression model in which adenomas show differ-
ent independent clones, one of which will finally progress to a carcinoma that 
then accumulates subsequent additional changes. Cryptal heterogeneity is main-
tained even in cancers, although to a lesser extent than adenomas. It is likely 
that mutations occurring later in neoplastic progression - perhaps involved in 
angiogenesis or metastasis - would be better markers to assess clonality of the 
carcinomas. However it is notable that, apart from MIN and KRAS2 mutation. 
all of the alterations studied were mosaic and heterogeneous in both adenomas 
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and cancers. This finding indicates that a "selective sweep" model of tumorige-
nesis, where a single successful clone out-competes and replaces all others, may 
not necessarily apply in colorectal neoplasia. 
In summary, these results suggest that TP53 may be altered before KRAS2 in 
the adenoma-carcinoma sequence and that KRAS2 and 18q LOH may not be 
a prerequisite for malignant transformation. In addition, these findings support 
a multi-pathway model for adenoma formation from which a single clone will 
progress to cancer. In different adenomas, the specific pattern of mutations 
may be unpredictable, with the overall mutational interaction determining the 
malignant potential of a specific cell or clone. Adenomas have considerable 
heterogeneity at the cryptallevel, showing that while a single clone may progress 
to invasiveness, subsequent growth of the lesion re-establishes genetic diversity in 
the cancer, as well as its preceding adenoma. These findings may have important 
implications for future cancer therapeutics. 
Chapter 10 
Ploidy and Genome-Wide LOH 
Analysis of Carcinomas Arising in 
Adenomas 
10.1 Introduction 
Most sporadically-occurring colorectal cancers have alterations of chromosomal 
number and structure known as aneuploidy [Lengauer et al., 1997] . Aneuploid 
tumours are characterized by frequent copy number gains and deletions, thus 
resulting in loss of heterozygosity of oncogenes and tumour suppressor genes 
[Ando et al., 2005, Cianchi et al., 1999, Meling et al., 1993, Offerhaus et al.. 
1992] . 
It is not yet clear at what point aneuploidy occurs in the adenoma-carcinoma 
sequence. Although using flow cytometry, aneuploidy was detected in fewer than 
ten percent of colorectal adenomas [Quirke et al., 1986], aneuploidy has been 
variously proposed to initiate tumorigenesis [Nowak et al., 2002. Shih et al.. 
159 
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2001], appear in early adenomas [Alberici et al., 2007, Cardoso et al., 2006] or 
to take place during the adenoma-carcinoma transition [Hermsen et al.: 2002, 
Sieber et al., 2002a]. 
The process by which aneuploidy develops also remains a matter for specula-
tion, as discussed in Section 1.2.2.1. While it is accepted that cell cycle defects 
causing chromosomal missegregation lead to aneuploidy, there are two com-
peting models of how this might occur. The first model is that of a stepwise 
accrual of mutations with slow incremental increase in chromosomal content. 
For example, APC inactivation may induce chromosomal instability [Hadjihan-
nas and Behrens, 2006] , by disruption of kinetochore-microtubule interaction 
[Dikovskaya et al., 2007] and compromise of the mitotic spindle checkpoint and 
spindle anchoring [Caldwell et al., 2007]. However, there is also some evidence 
that aneuploidy in cancers can arise via a state of tetraploidy [Ganem et al., 
2007], due to chromosomal non-disjunction in late mitosis. Tetraploid cells are 
stable and can divide; but their progeny is often highly aneuploid due to ran-
dom chromosomal missegregation caused by multipolar spindles [Margolis, 2005]. 
Cellular division of tetraploid cells may require inactivation of TP53-dependent 
checkpoint. In this model, a sudden increase in chromosomal content to 4N 
(twice normal) may be followed by a gradual decrease in chromosomal content 
[Storchova and Pellman, 2004]. 
Apart from the timing and mechanism of aneuploidy, its role as a cause or conse-
quence of neoplastic progression is still under debate [Rajagopalan and Lengauer, 
2004], as is the requirement for underlying chromosomal instability to "drive" 
aneuploidy [Tomlinson and Bodmer, 1999, Nowak et al., 2002]. Therefore. many 
aspects of the nature and role of cellular aneuploidy in tumorigenesis remain to 
be elucidated. 
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10.2 Aims 
The aim of this study was to investigate the phenomenon of ploidy change in 
contiguous carcinomas arising in adenomas, which provide useful tissue pairs in 
which to study chromosomal and molecular changes in the context of adenoma-
. . 
carCInoma progreSSIOn. 
Firstly, this study aimed to ascertain whether ploidy change was evident at 
early or late stages of tumorigenesis. Secondly, it aimed to characterise the ane-
uploidy, and determine whether there was evidence for a tetraploid intermediate 
state. Thirdly, it investigated how large scale chromosomal change (as detected 
by image cytometry) correlated with sub-chromosomal loss of heterozygosity 
(detected by genome-wide analysis and verified by locus-specific LOR analysis 
at 17p, 18q and 5q), and whether there was evidence of intra tumour clonal 
variation. Lastly, the study aimed to investigate whether cytometry results 
correlated well with evidence of Wnt pathway dysregulation (as ascertained by 
beta-catenin immunohistochemistry). 
10.3 Methods 
10.3.1 Patient Samples 
Seventy-one archival paraffin-embedded tissue sanlples from 64 different tu-
mours showing adjacent but discrete colorectal carcinoma and adenoma were 
identified (10.1). Sample preparation, laboratory work and data analysis was 
performed in collaboration with Dr Enric Domingo. Case selection was per-
formed as follows. Twenty-eight of the tumours were selected from the CoRGI 
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study cohort (see Chapter 8), which excluded tumours showing microsatellite in-
stability (MSI) [Kemp et al., 2006]; the histopathology reports of the remaining 
patients were reviewed to exclude those with multiple adenomas or MSI-H his-
tological features [Umar et al., 2004]. This was done to avoid including tumours 
with confirmed or likely MSI. 
Sample Gender Age Dysplasia Dukes LN Inv Vasc Inv Differentiation Site 
1 F 34 Low A NA NA NA NA 
2 M 57 Low C Yes NA Poor Descending 
3 M 65 Low A No No Moderate Rectum 
45# , F 78 Low B No No Moderate Caecum 
6 M 65 Low A No No NA Ascending 
724# , F 34 Low C Yes Yes Moderate Descending 
853# , F 60 Mixed C Yes No Moderate Rectum 
9 M 76 Low A No No NA Sigmoid 
10 M 55 Low A No No Moderate Sigmoid 
11 M 64 Low A No No Poor Rectum 
12 M 76 Low A No No Moderate Sigmoid 
13 M 76 Low A No No Moderate Sigmoid 
14 M 72 Low A No No Moderate Rectum 
15 F 76 Low A No No Moderate Rectum 
16 F 68 Low A No No Moderate Rectum 
17, M 60 Low A No No NA NA 
19, 
31# 
18,40# F 54 Low B No No Moderate Ascending 
20 M 37 Low A No No NA Rectum 
21,22# M 68 Low D Yes Yes Moderate Caecum 
23* F 34 Low C Yes No Moderate Rectum 
25 F 54 Low D Yes Yes NA Caecum 
26 M 77 High B NA No NA Rectum 
27 M 55 Low A No No Moderate Caecum 
28 M 50 High A No No Well Rectum 
29 M 46 High A No No Moderate Rectum 
30 F 56 High C Yes No Moderate Ascending 
32 F 61 Mixed A No No Moderate Ascending 
33 F 61 Low A No No Moderate Rectum 
34 F 69 High A No No Moderate Descending 
35 M 66 Low A No No NA Rectum 
36 F 57 Low B No No Moderate Caecum 
37 M 73 Low A No No Moderate Rectum 
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Sample Gender Age Dysplasia Dukes LN Inv I Vasc Inv Differentiation Site 
38 F 87 Low A No No Well Caecum 
39 M 64 Low A No No Moderate Rectum 
41 M 37 Low A NA NA NA NA 
43 M 50 Low A No No NA Descending 
44 F 47 High A No No Moderate Rectum 
45 F 55 Low B No No Moderate Rectum 
46 F 55 Low A No No Moderate Rectum 
48 M 61 Mixed C Yes No Moderate Rectum 
50 M 59 Low A No No Moderate NA 
52 F 39 Low A No No NA Ascending 
56 M 59 Low A No No Moderate Rectum 
57 F 62 Low A No No Poor Rectum 
58 F 83 Low A No No Moderate Ascending 
59 M 87 Low A No No Moderate NA 
63 M 69 Mixed NA No No Well Sigmoid 
64 M 42 Low A No No NA Sigmoid 
65 M 60 Low A No No Moderate Sigmoid 
66 F 56 Low A No No Moderate Sigmoid 
67 F 80 Low A No Yes Moderate Rectum 
68 F 69 Low A No No Moderate Rectum 
69 F 66 Low A No No Moderate Sigmoid 
70 M 84 Low A No No Moderate Rectum 
71 M 74 Low A No No Moderate Sigmoid 
72 M 67 Mixed A No No Moderate Sigmoid 
73 M 83 Low A No No Moderate Sigmoid 
74 M 80 Low A No No Well Sigmoid 
75 M 71 Low A No No Moderate Sigmoid 
76 F 33 Low A No No Moderate Sigmoid 
77 M 55 Low A Yes No Moderate Sigmoid 
78 NA NA Low A NA NA NA NA 
79 NA NA Low A NA NA NA NA 
80 NA NA Low A NA NA NA NA 
Table 10.1: Clinical data of tumours included in this study 
*Samples 1 and 23 correspond to two different tumours from the same patient. 
# Different blocks analysed from the same tumour (see Table 10.3) 
LN Inv: Lymph Node Invasion; Vasc Inv: Vascular Invasion; NA: Not 
Available 
Most adenomas were of low grade, while most cancers were Dukes A and showed 
moderate differentiation. Haematoxylin and eosin (H&E) slides were reviewed 
I 
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for accurate identification of adenomatous and carcinomatous areas by a consul-
tant histopathologist, Dr Jo-Anne ChinAleong. DNA from adenoma, carcinoma 
and normal tissue if present was extracted from samples after needle dissection 
as described in Chapter 3. 
10.3.2 Image Cytometry 
Ploidy analysis was performed with the assistance of Mr Dahmane Oukrif, using 
an automated image based cytometry technique (Fairfield Imaging, Nottingham, 
UK) as described in Chapter 3. Forty-one pairs of adjacent adenoma and carci-
noma were analysed: those samples with sufficient material for needle-dissection 
were selected. Only high quality samples with more than 500 scanned nuclei from 
epithelial cells were included, median 1126 (range 692-1560) scanned nuclei per 
sample. After integrated optical density histograms were generated, aneuploidy 
was defined as present if 20% or more of the nuclei were in the >2.5C fraction, 
where 2C is defined as expected chromosomal content for a normal diploid cell. 
10.3.3 Individual SNP and Microsatellite Instability Anal-
. 
YSIS 
PCR for LOR and microsatellite instability analysis was performed as described 
in Chapter 3. Depending on DNA availability, up to 3 microsatellites in 5q near 
APC (D5S346, D5S1965 and D5S299) and up to 5 microsatellites in 18q21 near 
SMAD4 and DCC (D18S46, D18S1110, D18S35, D18S69 and D18S1407) were 
analysed. For microsatellite instability analysis, BAT26 microsatellite marker 
was used. 
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10.3.4 Immunohistochemistry 
Immunohistochemistry was performed for MLR1 and beta-catenin, as described 
in Chapter 3. MLR1 expression was scored by the author as positive or negative. 
Beta-catenin expression was evaluated by a pathologist, Dr Jo-Anne ChinAleong 
and the author, by scoring five high power fields (x40 magnification), to take 
into account any heterogeneous expression patterns within tumours. Scores were 
1 (0-25% expression), 2 (25-50%),3 (50-75%) or 4 (75-100%) and the sum gave 
a total number from 5 (weak nuclear expression) to 20 (high expression). For 
validation, nine samples were blindly scored on two occasions, obtaining the 
same overall results. 
10.3.5 Genome-wide SNP Array 
Thirty-five adenoma and carcinoma pairs were analysed for genome-wide LOR; 
cost constraints limited the number of samples analysed. The Illumina Sentrix 
Beadarray human linkage mapping panel (version IVb) was used as previously 
described in Chapter 3, with the help of Angela Jones for the GoldenGate work-
flow. Image data was analysed using BeadStudio 3, and LOR was counted as 
present when at least 10 consecutive markers displayed homozygous patterns. 
A representative image showing 5q LOR, generated by BeadStudio, is shown in 
Figure 10.1. 
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Figure 10.1: Genome-wide LOR analysis: example of LOR in 5q in a carcinoma 
(sample 21) 
10.3.5.1 Determination of Minimal LOR Regions (MLRs) 
Computational analysis of the data gained from genome-wide SNP array was 
performed with the help of a biostatistician, Dr Trevor Graham, as follows. 
Since in a single sample, a particular loss may be targeted to remove a copy 
of a tumour suppressor gene, but may also remove other "bystander" genes, 
the shared regions of loss between samples are of particular interest. These 
shared regions of loss are here dubbed "minimal loss regions" (MLRs). For each 
sample, the observed loss was checked against all other similar samples (adenoma 
or cancer). If another sample also had loss overlapping this region, the MLR 
was defined as the region of loss common to both. This process was repeated 
iteratively. The size and location of the MLRs, numbers of samples showing the 
loss, and the frequency observed in adenomas versus cancers were then analysed. 
10.4 Results 
10.4.1 MSI Testing 
Twenty-eight out of 64 tumours were part of the CoRGI study and were pre-
viously screened for the absence of MSI (Kemp et al. , 2006). In addition, the 
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expression of MLH1 was confirmed by immunohistochemistry in 58 tumours. 
All were positive, apart from three with poor quality staining. The remaining 
eight tumours, not from the CoRGI study, were analysed separately in the ade-
noma and the carcinoma for MSI, and all were microsatellite stable. In this way 
the study population was shown to be broadly representative of sporadically 
occurnng cancers. 
10.4.2 Ploidy Analysis 
Image cytometry was performed for 41 different pairs of adjacent adenoma and 
carcinoma. An example is shown in Figure 10.2. 
Figure 10.2: Representative example of image cytometry (sample 64) 
On the left is shown a diploid adenoma, and on the right is shown its paired 
aneuploid carcinoma. Green columns represent epithelial nuclei and light blue 
dark blue and red represent other cell types (plasma cells, fibroblasts or 
lymphocytes - excluded from the analysis). The yellow line is the defined 2C 
fraction. 
Firstly, samples were categorised as diploid or aneuploid USIng a numerical 
threshold as described above. Twenty-two percent (9 out of 41) of the ade-
nomas and 49% (20 out of 41) of the carcinomas were aneuploid (Fisher ' exact 
test p < 0.025). In 38% (12 out of 32) of the diploid adenomas , the corresponding 
carcinoma was aneuploid, while in 89% (8 out of 9) of the aneuploid adenoma 
the corresponding carcinoma was also aneuploid (Figure 10.3). 
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Figure 10.3: Ploidy change from adenoma to carcinoma in 41 sample pairs 
Uncategorised numerical ploidy results (using percentage of cells >2.5C) were 
then analysed further, in order to characterise ploidy in greater detail. As ex-
pected, adenomas had lower percentages of > 2.5C nuclei (median 11.46, range 
2.4 - 63.75) than carcinomas (median 19.44, range 4.44 - 83.08); p= 0.0002 (paired 
T-test). This data is shown below in Figure 10.4. 
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Figure 10.4: Adenomas and carCInomas compared by percentage of cells In 
> 2.5C fraction 
In fact when numerical results were analysed, there was no sharp distinction b -
tween the diploid and aneuploid phenotypes, shown below in Figure 10.5, graph 
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A. Instead, a gradual distribution was seen. When pairs where compared, most 
of the adenomas showing high frequencies of >2.5C nuclei had similar patterns 
in their corresponding carcinoma, while predominantly diploid adenomas could 
have a carcinoma with either a high or low frequency of > 2.5C nuclei (Figure 
10.5, graphs B and C). 
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Figure 10.5: Percentage of cells in the >2.5C fraction . . 
A (Top). Adenomas (light grey bars) and carcinomas (black bars) In sIngle 
plot. 
B. Adenomas on top in increasing order with their corresponding paired 
carcinomas in the same position at the bottom. . 
C. Carcinomas at the bottom in increasing order with their correspondIng 
paired adenomas in the same position on top. 
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Aneuploid peaks were evenly distributed in both adenomas and carcinomas be-
tween 2.6C and 3.8C (Figure 10.6) so no purely tetraploid tumours were de-
tected. 
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Figure 10.6: Peak positions in adenomas and carcinomas determined by image 
cytometry 
In aneuploid samples showing multiple peaks >2.5C, the highest aneuploid 
peak was recorded. 
10.4.3 Genome-wide LOH Analysis 
10.4.3.1 Observed Regions of Loss in Adenoma-Carcinoma Pairs 
Thirty-five adenoma and carcinoma pairs were analysed for genome-wide LOR. 
Data from samples showing poor quality were excluded, leaving results from 31 
pairs of adenoma and carcinoma, and 3 unpaired adenomas (data shown in Table 
10.2). Two of the paired samples had no alterations detected in either dysplastic 
or invasive tissue. Table 10.2 below shows the regions of LOR detected in each 
sample, allowing comparison between the paired adenoma and carcinoma. 
I Sample I Chr I LOR Adenoma (region in Mb) I LOR Carcinoma (region in l\Ib) I 
I 1 1 10 1 86-l27 1- 1 r 2 2 - 0-66 
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! Sample! Chr I LOR Adenoma (region in Mb) I LOR Carcinoma (region in ;\Ib) I 
2 4 - 54-95, 112-142, 182-187 
2 8 - 0-65 
2 10 - 92-123 
2 12 17-26, 36-44, 54-64, 77-96 -
2 14 - O-tel 
2 15 - 0-74 
3 6 - 21-37 
5 2 O-tel -
5 4 - 39-85 
5 15 48-tel 62-74 
6 - - -
8 8 - O-tel 
8 18 - O-tel 
9 6 - 127-tel 
9 11 - 83-tel 
9 17 - 0-22 47-61 , 
9 18 - 11-53 
9 20 - 10-18 
10 1 0-31 -
10 3 166-tel 158-tel 
10 8 - O-tel 
10 11 92-109 -
10 12 0-12 -
10 17 - 0-22 
10 18 21 tel -
11 1 o 31 15-29 
11 2 - 25-52 
11 5 - 66-114 
11 6 16 44 -
11 11 O-tel 
11 15 67-79 6779 
11 17 - 22-57 
11 20 - 29 57 
11 22 39 tel 39 tel 
12 1 3-32 -
12 5 69-tel O-tel 
12 20 21-54 
12 21 19 25 -
12 22 O-tel -
13 1 213-234 
13 2 18-32, 180-201 
13 5 79-tel 
13 6 - 115-135 
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! Sample! Chr I LOR Adenoma (region in Mb) I LOR Carcinoma (region in Mb) I 
13 8 - 23-138 
13 9 - 114-tel 
13 12 79-93 
-
13 16 58-70 
-
14 1 - 219-242 
14 5 101-tel 107-tel 
14 10 - 81-112 
14 11 - O-tel 
14 15 44-51 -
15 3 - O-tel 
15 5 18-29 50-tel 
15 7 52-79 23-34 
15 8 - 47-tel 
15 10 - 51-tel 
15 11 - 53-tel 
15 12 - 66-tel 
15 14 - O-tel 
15 20 - 10-27 
15 22 - O-tel 
16 1 - 20-35, 70-99 
16 9 68-107 -
18 3 O-tel O-tel 
18 5 62-79, 102-tel -
18 16 65-73 64-73 
19 1 1-36 0-36 
19 1 93-121 
19 1 219 tel 237-tel 
19 6 o 55 0-56 
19 18 o tel O-tel 
19 20 o 26 0-27 
19 20 32-49 
19 21 o tel o tel 
19 22 O-tel O-tel 
20 --
21 3 41 66 
21 4 o tel 
21 5 62-tel 87-tel 
21 8 - O-tel 
21 9 041 
21 10 - 104-117 
21 12 0-27 0-29 
21 15 - 53-76 
21 17 - 0-29 
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r Sample I Chr I LOR Adenoma (region in Mb) I LOR Carcinoma (region in Mb) I 
21 18 - 34-55, 58-69 
21 19 43-52 7-17 
21 20 - O-tel 
21 22 - O-tel 
23 1 - O-tel 
23 5 - O-tel 
23 6 - O-tel 
23 10 95-111 O-tel 
23 11 0-32 
-
23 12 - 20-tel 
23 14 - O-tel 
23 17 - O-tel 
23 18 - O-tel 
23 20 - O-tel 
23 22 - O-tel 
24 3 - O-tel 
24 5 - 89-166 
24 8 - 77-114 
24 12 - 90-117 
24 13 - O-tel 
24 14 - O-tel 
24 16 - 15-54 
24 17 O-tel O-tel 
24 20 28-tel O-tel 
24 21 26-tel O-tel 
25 1 - 0-34 
25 3 - 067 
25 14 64-87 6487 
25 16 - 67-tel 
25 17 o 22 
25 18 - 25-tel 
26 1 0-68 -
26 5 73-tel 87 tel 
26 6 16-38 
26 9 - 3-13 
26 10 112-tel 113-tel 
26 18 o tel -
26 20 0-27 0-27 
26 20 - 50-59 
26 22 o tel O-tel 
27 2 0-28 
27 5 76 tel 69 tel 
28 4 85 tel 85-tel 
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r Sample I Chr I LOR Adenoma (region in Mb) I LOR Carcinoma (region in ~Ib) I 
28 17 - 0-11, 15-tel 
29 2 O-tel 
-
29 5 78-tel 
-
29 12 O-tel 
-
30 7 0-34 0-33 
30 8 - 0-26 
30 11 - 72-102 
30 19 - 0-18 
30 20 0-27 
-
32 1 0-31 0-30 
32 5 O-tel 71-tel 
32 17 - 0-26 
32 18 - 9-tel 
32 22 - O-tel 
33 1 0-42 0-42 
33 1 169-202 -
33 4 40-56 29-55 
33 5 O-tel O-tel 
33 14 O-tel O-tel 
33 15 0-88 0-88 
33 17 - 0-22 
33 18 O-tel O-tel 
33 20 O-tel O-tel 
34 1 0-37 0-36 
35 11 - 57-tel 
35 12 0-18 0-18 
35 17 51-tel 25-tel 
36 4 50-tel 51-tel 
36 5 o tel O-tel 
36 8 - O-tel 
36 11 o tel 54-tel 
36 14 18 45 0-40 
36 15 0-82 O-tel 
36 17 O-tel 0-24, 37-69 
36 18 O-tel 
36 19 0-13 0-13 
37 2 101 220 ND 
37 3 18 27 ND 
37 5 100-121 ND 
37 7 84-90, 110 121 ND 
37 12 15-25 ND 
38 5 99-tel ND 
38 6 21 36, 101-108, 157-tel ND 
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I Sample I Chr I LOH Adenoma (region in Mb) I LOH Carcinoma (region in l\Ib) I 
39 
39 
39 
39 
11 72-93 ND 
14 36-46 ND 
15 67-79 ND 
16 45-56 ND 
Table 10.2: Regions showing LOH in Megabases (Mb) 
Chr: chromosome; tel: telomere; ND: Not determined 
There were fewer individual instances of LO H in adenomas than in carcinomas 
(Figure 10.7 A), with 96 LOH changes detected in 34 adenomas and 149 LOR 
changes in 31 carcinomas, giving a mean of 2.8 (SD 2.3) alterations for adenomas, 
and 4.6 (SD 3.8) alterations for carcinomas. Most of the alterations found in the 
carcinomas were not present in the adenomas and some alterations were found 
in both tissues, either with the same boundaries or with partial overlap (Figure 
10.7B and Table 10.2). However, some of the alterations found in the adenomas 
were not detected in their corresponding carcinoma. 
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Figure 10.7: Number of LOR changes in 31 paired adenomas and carcinomas 
A (top): Overall instances of LOR detected 
B (below): Correspondence of LOR instances between 31 paired adenomas 
and carcinomas. 
To ascertain whether coexistence of different clonal cell populations within the 
same lesion could explain why some adenoma alterations are not present or 
overlapped only partially with their paired carcinomas, in 5 samples further 
dysplastic and invasive tissue was analysed from the same lesion , but from a 
different site (extracted from a different archival block) , data shown in Table 
10.3. Although some of the alterations previously identified were again seen in 
the new site, in either adenoma or carcinoma, some of the alterations differed. 
Samples Chr LOR Adenomas (region in Mb) LOH Carcinomas (region in f.. lb) 
5'4 2 O-tel . - - -, , , 
5'4 4 - - 39-85 . -, , ,
5'4 , 15 48-tel ; - 62-74 ; -
5'4 16 - - - . 44-82 , , ,
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Samples Chr LOR Adenomas (region in Mb) LOR Carcinomas (region in Mb) 
!5;4 
5·4 , 
19 . 17 . 31 1 0-36 . 0-36 . 0-36 0-36 . 14-30· -, , , , , , 
19 . 17 . 31 1 - - - 93- 121 ; - ; -, , , , 
19 . 17 . 31 1 219-tel ; 219-tel ; 212-tel 237-tel ; 212-227 ; -, ,
19 . 17 . 31 4 - . 29-50 . -
- - -
, , , , , , 
19 . 17 . 31 6 0-55 . 0-38 . 0-57 0-56 . 0-55 . -, , , , , , 
19 . 17 . 31 8 
- ; - ; 95-106 + 108-118 
- - -
, ,
, , 
19 . 17 . 31 12 - . 90-103 . -
- , - -
, , , , , 
19 . 17 . 31 17 - . 30-79 . -
- , - , -
, , , ,
19 . 17 . 31 18 0-tel ; 0-tel ; 0-tel O-tel . - . -, , , , 
19 . 17 . 31 , , 20 0-26 . 0-54 . 0-27 , , 0-27 + 32-49 ; 0-21 ; -
19 . 17 . 31 21 O-tel ; O-tel ; O-tel O-tel . O-tel . -, , , , 
19 . 17 . 31 , , 22 0-tel ; 0-tel ; 0-tel O-tel ; - : -
24 ·7 , 3 O-tel . -, 0-tel ; 0-tel 
24 ·7 , 5 - . 114-139 , 89-166 ; 122-164 
24 ·7 , 8 - . 77-113 , 77-114 ; 1-26 + 77-114 
24 ·7 , 10 - . 0-60 , - . 0-57 ,
24 . 7 12 - - 90-117 . -, , ,
24 ·7 13 - - O-tel ; O-tel , , 
24 ·7 , 14 - . O-tel , O-tel ; O-tel 
24 ·7 16 - - 15-54 . -, , ,
24 . 7 , 17 O-tel ; O-tel 0-tel ; 0-tel 
24 ·7 , 18 - . O-tel , - . O-tel ,
24 ·7 , 20 28-tel ; 0-tel 0-tel ; 0-tel 
24 . 7 , 21 26-tel ; 0-tel 0-tel ; 0-tel 
18 ; 40 1 - . 210-233 , ND 
18 ; 40 3 0-tel ; 0-tel ND 
18 ; 40 5 62-79 + 102-tel ; - ND 
18 ; 40 16 65-73 ; - ND 
18 ; 40 18 - . 0-32 , ND 
18 ; 40 19 - . 0-11 , ND 
21 ; 22 3 ND 41 66 ; 
21 ; 22 4 ND O-tel ; -
21 ; 22 5 ND 87 tel; 76 tel 
21 ; 22 8 ND O-tel ; 0-36 
21 ; 22 9 ND o 41 ; -
21 ; 22 10 ND 104 117 ; -
21 ; 22 12 ND 0-29 : -
21 ; 22 15 ND 53-76 ; O-tel 
21 ; 22 17 ND o 29 ; 0-28 
21 ; 22 18 ND 34 55 + 58-69 ; 0-9 + 18-tel 
21 ; 22 19 ND 7-17 : 
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I Samples ! Chr I LOR Adenomas (region in Mb) I LOR Carcinomas (region in 1rJb) I 
I 21 ; 22 120 1 ND 1 O-tel ; O-tel 1 
I 21 ; 22 
Table 10.3: LOR detected in different samples from the same tumour, in 
Megabases 
The first sample in each tumour pair/triplet has already been included in 
Table 10.2. 
Mb: Megabase; Chr: Chromosome; tel: telomere; ND: Not Determined; - No 
alteration found. 
10.4.3.2 Validation of LOR Results Using Microsatellite Markers 
The genome-wide LOR results were validated using individual polymorphic mi-
crosatellite markers, used to analyse 7 paired samples for LOR at 5q (near APC) 
shown in Table 10.4. All alterations found in 5q using microsatellite markers, 
concurred with results from the genome-wide analysis. Furthermore, 20 paired 
samples were analysed for LOR at 18q21 (near SMAD4 and DCC), shown in 
Table 10.5. All the LOR alterations detected in the genome-wide analysis were 
confirmed, although 6 samples showed new LOR alterations in some of the mark-
ers in 18q21. 
I Sample I Genescan 5q Ad ! Genescan 5q Car ! 
21 LOR (1/1) LOR (1/1) 
25 None (0/1) None (0/1) 
26 LOR (1/1) LOR (1/1) 
33 LOR (1/1) LOR (1/1) 
34 None (0/1) None (0/1) 
36 LOR (1/1) LOR (1/1) 
38 LOR (1/1) ND 
Table 10.4: Genescan results from informative markers at 5q (APC) 
In brackets: number of samples showing LOR/informative markers analysed. 
All the alterations found concurred with the genome-wide analysis. 
ND: Not determined 
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! Sample I Genescan 18q21 Ad I Genescan 18q21 Ca r 
1 None (0/1) None (0/2) 
2 LOH (1/3) LOH (2/3) 
3 None (0/2) None (0/2) 
6 None (0/2) None (0/2) 
7 LOH (1/1) LOH (1/1) 
8 LOH (1/1) LOH (1/1) 
13 LOH (1/3) LOH (2/3) 
16 LOH (1/3) LOH (1/3) 
18 None (0/3) None (0/3) 
19 LOH (3/3) LOH (3/3) 
21 None (0/2) LOH (2/2) 
25 None (0/4) LOH (3/4) 
27 None (0/3) None (0/3) 
28 None (0/4) None (0/4) 
29 None (0/2) LOH (1/2) 
32 None (0/2) LOH (2/2) 
33 LOH (3/3) LOH (3/3) 
34 None (0/4) LOH (1/4) 
35 None (0/3) None (0/3) 
36 None (0/5) LOH (3/3) 
Table 10.5: Genescan results from informative markers at 18q21 (SMAD4 and 
DCC) 
In brackets: number of samples showing LOH/informative markers analysed. 
All the alterations found concurred with the genome-wide analysis, except 
those highlighted in red. 
10.4.3.3 Computational Analysis of LOH Results 
Computational analysis of the genome-wide LOH data, allowed identification 
of areas of LOH common between multiple samples (minimal loss regions. or 
"MLRs") (Table 10.6). While identified regions were large, they were in accor-
dance with expected results, showing LOH at 5q, 17p and 18q corresponding to 
APC, TP53 and SMAD4/DCC loci. Interestingly, some MLRs were identified in 
the adenoma only: chromosome 12 LOH was identified solely in the adenoma in 
5 sample pairs. However, most MLRs were altered only in the carcinoma or in 
both tissues, for example chromosome 8 where all eight alterations detected oc-
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curred in the carcinoma only, and chromosome 5 where 8 paired samples showed 
LOR. No clear indication was found that any two MLRs tended to occur together 
in tumours (data not shown). 
Chr Start (Mb) End (Mb) Length (Mb) Adenoma Carcinoma Both 
only (N) only (N) 
1 15 30 15 3 3 5 
1 213 246 33 0 3 1 
2 18 32 14 2 4 0 
3 0 200 200 0 3 2 
4 51 191 140 0 2 2 
5 89 166 77 2 5 8 
6 0 56 56 2 2 1 
8 0 138 138 0 8 0 
10 0 135 135 1 4 2 
11 72 134 62 2 5 1 
12 0 132 132 5 3 1 
14 0 106 106 0 4 3 
15 67 74 7 0 1 4 
16 64 89 25 1 1 1 
17 0 29 29 0 9 2 
17 37 61 24 0 4 3 
18 25 76 51 2 6 2 
20 10 27 17 1 5 3 
20 29 57 28 0 5 2 
21 0 47 47 1 0 2 
22 0 50 50 1 3 3 
Table 10.6: Genome-wide LOR analysis: frequency table of minimal loss regions 
(MLR's). 
Mb: megabase; Chr: Chromosome 
10.4.4 Ploidy and LOH Association 
LOR in some particular chromosomal regions (APe, TP53 and 18q) has been 
associated with aneuploidy. Therefore 46 paired samples were anal~'sed for LOR 
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at these loci using microsatellite markers, and results correlated with the cat-
egorical ploidy results obtained previously (diploid or aneuploid). Results are 
shown in Table 10.7. 
Statistical analysis shown in Table 10.7, demonstrated an association between 
aneuploidy and LOR at 17p (TP53) and 18q21 (SMAD4 and DCC): where 
diploid samples had significantly less LOR. This association was found in the 
carcinomas but not in the adenomas. Interestingly, there was no similar associ-
ation for LOR at 5q (APe). 
The association between ploidy and LOR detected by genome-wide analysis was 
assessed, by comparing the percentage of nuclei in the >2.5C fraction, and LOR 
as the sum of all single LOR lengths in one sample. Results are shown in Figure 
10.8. Analysis by linear regression showed that for the 24 adenomas, p=0.027 
(r2=0.21), while for carcinomas a stronger association was found, p=O.0003, 
(r2=O.5). 
APC wt (adenoma and carcinoma) APC LOH TP53 wt TP53 LOH 18q21 wt 18q21 
LOH 
Diploid 19 (14+5) 11 (5+6) 30 0 28 2 (2+0) 
(19+11) (17+11) 
Aneuploid 11 (4+7) 5 (1+4) 9 (4+5) 7 (1+6) 10 (4+6) 6 (1+5) 
X2 Ns (Ns+Ns) p<O.OOl p<O.05 
(Ns+p<O.02E) (Ns+p<O.05) 
--
Table 10.7: The relationship between aneuploidy and LOH at 5q (APe), 17p (TP53) and 18q (SMAD4) 
wt: wild type; Ns: not significant 
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Figure 10.8: Association between LOR and ploidy in adenomas and carcinomas 
10.4.5 Beta-catenin Immunostaining and Association with 
Ploidy 
Nuclear beta-catenin expression was assessed in 57 paired samples. As expected, 
carcinomas showed more nuclear expression of beta-catenin (median 5, range 5-
20) than adenomas (median 5, range 5-15), p=0.0012, rs 0.37 Wilcoxon signed 
rank test (Figure 10.9, top). Thirty-six paired adenomas and carcinomas were 
also analysed by image cytometry. For these 72 adenomas and carcinomas com-
bined, beta-catenin score was associated with ploidy (percentage of cells > 2.5C); 
p= O.Ol, r2 = 0.1 using linear regression (Figure 10.9, bottom). 
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8eta-Catenin Score in Adenomas and Carcinomas 
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Figure 10.9: Beta-catenin immunostaining results 
Top: Beta-catenin scores for 67 pairs of adenomas and carcinomas 
Bottom: Relationship between beta-catenin score and ploidy for 72 adenomas 
and carcinomas 
10.5 Discussion 
Carcinomas arising in adenomas provide useful paired tissue to compare cellular 
and molecular alterations in the context of the adenoma-carcinoma sequence. 
This technique provides a new alternative to traditional studies comparing fre-
quencies of alterations using unpaired pooled samples of adenomas and carcino-
mas. Interpretation of this study assumes that the carcinomatous tissue arose 
from a sub-clone of the adenomatous tissue. There are some important caveat . 
Firstly, it is possible that the carcinomatous clone might engulf all of the adeno-
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matous clone that actually gave rise to it, and may not be as close in phylogenetic 
terms as its spatial localization suggests. Secondly, the observed histological 
state of dysplasia versus malignancy (based on breaching of the basement mem-
brane) may not actually reflect the state of the molecular process in a particular 
region of tissue - a limitation affecting all studies of the adenoma-carcinoma 
sequence. Thirdly, all the adenomas studied here had associated cancerous pro-
gression, while studies using pooled adenomas include adenomas that might not 
progress to malignancy, as is the case in 95% of colorectal adenomas [Hermsen 
et al., 2002]. Nevertheless, paired tissue allows close comparison of results and 
facilitates inferences regarding clonal selection of observed alterations. 
10.5.1 Aneuploidy 
Image cytometry of adenomatous and carcinomatous regIOns provided high-
quality results, free of contamination by non-epithelial cells. In agreement with 
previous studies using flow cytometry [Suzuki et al., 1995], aneuploidy in the 
adenoma predicted aneuploidy in the paired cancer. In more than a third of 
diploid adenomas, the paired cancer was aneuploid. These results may lend 
weight to the hypothesis that aneuploidy occurs later in the adenoma-carcinoma 
sequence, and is not usually the event initiating dysplasia. It is also possible 
that adenomas are polyclonal with respect to ploidy, and that aneuploid clones 
may be more likely to progress to invasion. Future studies, capable of detecting 
ploidy in individual dysplastic and cancerous crypts, would be needed to test 
this hypothesis. 
This study is the first to represent detailed quantitative data. in terms of the 
degree of aneuploidy (the percentage of nuclei in the >2.5C fraction) and the ex-
act peak position noted in the lesions. These results show that the proportion of 
aneuploid cells in an adenoma is maintained or increased in its paired carcinOIna. 
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Similarly, the aneuploid peak position remained stable between the paired ade-
nomas and carcinomas, suggesting little alteration in degree of aneuploidy after 
malignancy occurs. 
While tetraploidisation has been proposed as the possible event initiating ane-
uploidy [Storchova and Pellman, 2004], these results do not support this hy-
pothesis, as no pure tetraploid peaks were found in any of the adenomas or 
carcinomas. However, tetraploidy leading to aneuploidy could be a very tran-
sient event, undetectable using this method. 
10.5.2 Loss of Heterozygosity 
Nearly all samples showed alterations on genome-wide LOH analysis. The two 
samples without changes may have had bi-allelic mutations of APe or other 
genes, or have had epigenetic instability not detected in this study. For the 
other samples, LOH alterations were more frequent in carcinomas, and most 
alterations were present only in the carcinoma or in both adenoma and carci-
noma. There were some LOH alterations in the adenomas not found in their 
corresponding carcinoma, implying that these changes occurred after divergence 
of a malignant clone. Interestingly, by performing genome-wide analysis on 
tissue taken from different areas of the same lesion, different alterations were 
identified, showing that in some lesions there was significant heterogeneity in 
LOH observed between different areas of the adenoma and carcinoma. 
Results obtained on genome-wide LOH analysis were validated by using indiyid-
ual polymorphic markers, and all of the LOH detected by genome wide analysis 
was confirmed. However, some additional regions of loss were identified in 18q 
in a subset of the markers, suggesting that LOR in these samples spanned a 
short region not detectable by genome-wide screening. 
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Through computational analysis of data from genome wide analysis: regions of 
loss common between samples were identified. The MLRs identified conformed 
to expected losses in terms of position and frequency; for example: the most fre-
quently detected MLR corresponded to the APe locus. This MLR was usually 
identified in both paired adenoma and carcinoma, suggesting that this was an 
early tumorigenic alteration. Moreover, LOH in 17p (TP53) and 18q (SMAD4) 
was detected with a high frequency in carcinomas but a low frequency in adeno-
mas, suggesting that these were late events in the adenoma-carcinoma sequence, 
results correlating with the accepted model of colorectal carcinogenesis [Fearon 
and Vogelstein, 1990, Kinzler and Vogelstein, 1996]. 
Aneuploidy and LOH were quantitatively associated. Thus, tumours showing 
high levels of LOH in the genome were aneuploid, regardless of whether the lesion 
was an adenoma or carcinoma. However, some tumours with little LOR were 
also aneuploid, probably due to copy number gain without LOR. This suggests 
that large-scale chromosomal gains can precede LOR. 
Aneuploidy was found to be associated with LOH in 17p (TP53) and 18q 
(SMAD4) as previously described [Ando et al., 2005, Cianchi et al., 1999, Meling 
et al., 1993], and in agreement with the hypothesis that TP53 has an important 
role in the acquisition of aneuploidy [Fukasawa et al., 1996, Haruki et al., 2001]. 
Interestingly, an association with aneuploidy was not found with LOR at the 
APe locus. This result argues against a direct role for APe in the development 
of the aneuploid phenotype; although other undetected alterations may have 
been present, such as APe promoter methylation or mutations in other Wnt 
signalling genes. 
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10.5.3 Beta-catenin Immunohistochemistry 
To investigate the relationship between wnt pathway dysregulation and aneu-
ploidy, beta-catenin immunohistochemistry was performed. Abnormal nuclear 
localisation of beta-catenin was more frequently found in carcinomas. There was 
an association between aneuploidy (percentage of cells in a >2.5C fraction) and 
nuclear positivity, confirming a link between wnt dysregulation and aneuploidy. 
However, the causal chain of events remains to be elucidated. 
10.5.4 Conclusion 
In conclusion, by using comparative analysis of contiguous adenomas and car-
cinomas, this study has more accurately characterised the phenomenon of ane-
uploidy in colorectal tumorigenesis. Rather than categorising tumours as aneu-
ploid or diploid, quantitative analysis was made possible by using percentage of 
nuclei >2.5C, and measured peak position. Overall, these results may support 
the hypothesis that aneuploidy occurs late in the adenoma-carcinoma sequence, 
and no evidence of tetraploidisation was found. LOH results support an associ-
ation between aneuploidy and alterations at TP53 and SMAD4, but not APe. 
However, aneuploidy was associated with wnt pathway dysregulation in terms 
of nuclear beta-catenin localisation. Further studies are necessary to identify 
the causal sequence of events. 
Chapter 11 
SUIllIllary and General Discussion 
11.1 Introduction 
As readily identifiable cancer precursors, adenomas in the gastrointestinal tract 
facilitate study of the initiation and progression of neoplasia in the gut. Their 
number, distribution and age of onset help to define clinical phenotypes impor-
tant in patient diagnosis and management. Whether adenomas occur in the 
context of sporadic or inherited phenotypes, there is considerable overlap in 
underlying molecular events of the adenoma-carcinoma sequence responsible for 
neoplastic progression. While the main genetic events in the sequence have been 
identified[Fearon and Vogelstein, 1990], many details remain to be elucidated 
regarding their initiation, propagation, associated genetic and pathological fea-
tures and their interaction with local environmental and constitutional factors , 
in specific clinical contexts. 
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11.2 Part I: Locoregional Variation in Adenoma 
Initiation and Progression 
Bi-allelic APe inactivation is a key initiating event in tumorigenesis. Germline 
APe mutations cause familial adenomatous polyposis, where somatic inactiya-
tion of APe in colonic mucosa results in a classical phenotype of thousands of 
polyps. 
The spectrum of somatic mutations observed in FAP adenomas is determined 
by a non-random association with the germline mutation, previously defined for 
the duodenum [Groves et al., 2002a] and the colon [Crabtree et al., 2003]. In 
the duodenum, the resultant APC protein retains 3-4 20-amino acid repeats, 
while 1-2 repeats tend to remain in the colorectum. It is postulated that in 
the duodenum and colon respectively, the remaining beta-catenin binding and 
degradation sites confer the optimum advantage for a mutated clone to undergo 
neoplastic expansion (the "just-right" hypothesis [Albuquerque et al., 2002]). It 
would therefore appear that that the optimum level of Wnt signalling varies by 
gut location. 
Locoregional variation in adenomas is a notable feature of the FAP phenotype: 
the small bowel mucosa distal to the duodenum is usually free of polyps, despite 
the ubiquitous expression of APC in the gut. This observation lends weight 
to the hypothesis that somatic inactivation of APe, and possibly subsequent 
downstream genetic events, are influenced by unidentified factors in the local 
lumenal environment or mucosal tissue. 
This dissertation examined the relationship between gut location and somatic 
mutations of APe. Data presented here show that even within the colorectum. 
the optimum level of Wnt signalling required for clonal adYRntage nla~' yar~' 
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along its length. In patients with a 1309 germline mutation, the second hit pref-
erentially seen in the colorectum - loss of heterozygosity of APe - occurred at 
a far higher frequency distally. This may represent the first molecular explana-
tion of the clinical finding that patients with 1309 germline mutation have worse 
rectal polyposis than individuals with other germline mutations, often necessi-
tating restorative proctocolectomy rather than ileorectal anastomosis. Exactly 
how colonic location affects the frequency of LO H in the colon remains unclear, 
although a link with alterations in cell proliferation was demonstrated. Future 
studies are needed to refine whether a colonic gradient in Wnt signalling is per-
haps inherent in the colonic tissue, or due to environmental factors. 
This dissertation has further explored the influence of local mucosal factors on 
somatic APe mutation, by investigating the phenomenon of adenoma develop-
ment in the ileoanal pouch. The ileoanal pouch is a surgically created "hybrid" 
area which is constructed from small bowel, and yet functions as replacement 
rectal reservoir. Long-term longitudinal follow-up data presented here suggests 
that polyposis of the ileoanal pouch increases with time and age, and that the 
severity of duodenal polyposis may correlate with pouch body polyposis. This 
finding may suggest that common modifiers - genetic or environmental - may 
influence the propensity of the small bowel to develop adenomas. 
Data from this dissertation also revealed that the spectrum of somatic APe 
mutations found in ileoanal pouch polyps differs from that seen in duodenal 
mucosa, resembling that of the colorectum. This work established that the "just 
right" model of beta-catenin signalling also applies to pouch polyps. As in the 
colorectum, LOH was significantly more likely to occur in pouch polyps from 
FAP patients with a germline mutation encoding a protein with a single 20A;\R, 
and, as in the colorectum, LOH occurred without copy number alteration. These 
findings may suggest that some environmental factor. as yet unidentified, pro-
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vokes adenoma development in the ileum, which is usually free of adenomas 
prior to colectomy. 
Despite sometimes heavy ileoanal pouch polyp burden, cancer in the pouch re-
mains rare. Worldwide, the risk of cancer developing in retained large bowel 
mucosa at the rectal cuff or anal transition zone, remains a greater risk than 
pouch body cancer [Church, 2005]. While data comparing the risk of cancer 
from a single adenoma of the pouch versus that arising in the rectum are not 
available, it remains a possibility that rectal polyps may differ in their subse-
quent histogenesis, and thus be more aggressive than polyps arising in the pouch 
body. Histological comparison of adenomas from rectum and pouch, indicated 
that crypt proliferation and fission was increased in pouch polyps. However, 
nuclear TP53 expression was higher in rectal polyps, suggesting that mutations 
downstream of APe may account for the disparity in cancer incidence at these 
sites. 
Future studies into genetic changes and environmental alterations may one day 
indicate how adenoma initiation and progression might be modulated using phar-
macotherapy. Further lines of enquiry could include using expression arrays to 
compare normal ileal mucosa prior to colectomy versus ileoanal pouch mucosa, 
and pouch mucosa versus rectal mucosa in patients with an IRA. Another line 
of enquiry would be to perform further analysis on the long-term follow-up data, 
to ascertain whether there is any relationship between improved pouch function 
and pouch polyposis, which may indicate that prolonged faecal stasis may pre-
cipitate pouch adenomas. Prospective studies to study the relationships between 
pouch microfiora, diet or bile acids may account for some of the differences in 
pouch body polyposis observed between individuals. Family studies may identify 
genetic modifiers of small bowel polyposis in FAP. 
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11.3 Part II: Neoplastic Initiation and Progres-
sion in aNew Colorectal Cancer and Intel-
lectual Disability Phenotype 
The phenotype of multiple colorectal polyps combined with intellectual disabil-
ity led to the initial discovery of the APC gene on chromosome 5q, and indicates 
the important role of clinical phenotype in indicating specific gene malfunction 
[Bodmer et al., 1987]. This dissertation presented the genetic investigation of 
a patient with early-onset colorectal cancer, multiple colorectal adenomas, in-
tellectual disability, brain abnormality, and cutaneous pigmentation. A novel 
homozygous deletion involving P MS2 and FSCN genes was identified. 
Bi-allelic mismatch repair mutations are a recognised cause of Turcot's syn-
drome, thus accounting for the colorectal cancer, multiple adenomas, duodenal 
cancer and cafe-au-lait pigmentation [de Vos et al., 2005]. However, the associ-
ated dysmorphic features and cerebellar and corpus callosum defects seen in this 
patient have not been described previously. It is possible that the specific novel 
deletion of PMS2 accounted for all of the features noted, or that FSCN gene 
was also implicated in the neurological phenotype. This dissertation did not find 
evidence that FSCN mutation is a cause of related neurological phenotypes, and 
nor was P MS2 mutation identified as a cause of multiple adenomas in patients 
without identified APC or mismatch repair mutations, in the absence of other 
phenotypic features. 
A necessary role for fascin in the development of neoplastic invasion, while sug-
gested by previous studies [Jawhari et al., 2003, Li et aL 2008. Tong et al.. 
2005, Vignjevic et al., 2007], was cast into doubt since this patient developed 
numerous malignancies despite constitutional absence of FSCN. Bi-allelic PJIS.l 
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mutation was demonstrated to have resulted in Wnt pathwa d 1 t' , Y ysregu a IOn In 
the proband's colorectal tumours; but further downstream alterations in \Vnt 
pathway genes were not identified. However, mutations commonly occurring in 
MMR-deficient cancers including TGFBR!! and KRAS2, were confirmed. 
11.4 Part III: Investigating Neoplastic Progres-
sion in Sporadic Carcinomas arising in Ade-
nomas 
The current model of the adenoma-carcinoma sequence postulates initiating and 
downstream mutations which result in increasing levels of mucosal dysplasia, 
culminating in invasion. Previous studies comparing mutational frequencies in 
pooled samples (for example, mildly-dysplastic adenomas with unmatched colo-
rectal cancers) have produced a short-list of genes frequently altered in colo-
rectal tumorigenesis [Fearon and Vogelstein, 1990]. However, the functional 
significance of such alterations - as causative, permissive or neutral mutations -
remains unclear. 
This dissertation presented data from crypt-by-crypt mutational analysis of car-
cinomas arising in adenomas, a technique which allowed comparison between 
the adenomatous precursor and the resultant cancer. Inferences were possible 
concerning the order in which the mutational changes occurred, and the clonal 
advantage they conferred which resulted in their selection and fixation in the 
cancer. These data confirmed the hypothesis that APe mutation occurs early in 
tumorigenesis, but KRAS2 mutation was not found to confer obvious clonal ad-
vantage. The results also suggested that TP53 mutation occurred earlier in the 
adenoma-carcinoma sequence than suggested by the accepted model. Nearly' all 
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mutations studied were found to be heterogeneous in the adenoma and cancer. 
This genetic diversity seen within the same lesion has important implications 
for future cancer therapeutics. 
Finally, this work studied ploidy alteration and loss of heterozygosity in 
adenoma-carcinoma pairs. Ploidy change is a very frequent finding in colorectal 
tumours; although it is debatable whether the phenomenon is due to underlying 
chromosomal instability in all cases. The process by which aneuploidy develops 
is also debatable. In this dissertation, ploidy change was accurately charac-
terised in the adenomas and carcinomas by defining the peak position and the 
numbers of cells observed in the >2.5C fraction, rather than applying simple cat-
egories of "diploid" or "aneuploid". This study found no experimental evidence 
for an intermediate tetraploid state, and the aneuploid peaks were instead very 
evenly distributed, and the peak position was maintained between adenoma and 
carcinoma pairs. In general, more aneuploidy was seen in carcinomas arguing 
against ploidy change as being an early or initiating event in tumorigenesis as 
has previously been suggested. Genome-wide loss of heterozygosity analysis re-
vealed a close association between LOR and aneuploidy. Specific LOR markers 
confirmed a link between LOR at 17p and 18q, however no association was found 
with LOR at 5q, despite the postulated role of APe inactivation in the devel-
opment of aneuploidy. Wnt pathway dysregulation, however, was found to be 
associated with the degree of aneuploidy. 
Ongoing work is evolving with improved software to analyse copy number change 
as well as LOR in the adenoma-carcinoma pairs, to asees the role of gene dosage 
in malignant transformation and the development of aneuploidy. Thus far, how-
ever correlation between chromosomal gains detected using the GoldenGate , 
system, and that detected on the same samples using array CGH: have been 
inconsistent. 
CHAPTER 11. 196 
11.5 Conclusion 
This dissertation has described investigation into many aspects of neoplastic 
initiation and progression in both inherited and sporadic contexts. In order 
to investigate locoregional variation in adenoma initiation and progression, this 
thesis has refined the two-hit hypothesis in the colorectum, ascertained "just 
right" signalling for adenomas of the ileoanal pouch, and investigated the natu-
ral history and histogenesis of ileoanal pouch adenomas. In the context of mis-
match repair deficiency, a novel bi-allelic germline mutation involving P MS2 was 
identified, and a new colorectal cancer phenotype was described. Finally, the 
adenoma-carcinoma sequence was investigated in the context of sporadically-
occurring cancers arising in adenomas, where heterogeneity of mutations was 
confirmed within small areas of lesions on a crypt-by-crypt basis, allowing mod-
ification of the proposed mutational sequence of events for individual lesions 
studied. The phenomenon of aneuploidy in neoplasia was further characterised, 
and its association with loss of heterozygosity and Wnt pathway dysregulation 
investigated. 
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